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SUMMARY 
 
During the second cell fate choice in the mammalian embryo, two 
lineages are specified, the extraembryonic primitive endoderm (PrE), which 
will give rise to the yolk sac, and the pluripotent epiblast (EPI), which will go 
on to form the embryo proper. This lineage choice takes place in the inner cell 
mass (ICM) of the blastocyst stage embryo. Cells of the ICM are initially 
totipotent and express markers for both, PrE and EPI, but gradually 
downregulate one or the other until their expression becomes mutually 
exclusive and the two lineages are committed. In this work computational 
analysis of cells in the ICM showed that the distribution of emerging EPI and 
PrE cells is stochastic and independent from each other.  
The earliest markers for which the gradual segregation of the two 
lineages can be observed are the transcription factors NANOG, which 
becomes EPI-specific, and GATA6, which marks the PrE. NANOG is known 
to be involved in the maintenance of pluripotency in embryonic stem cells and 
in its absence the embryo fails to form the EPI lineage. The present work 
demonstrated that GATA6 is the master regulator of the PrE lineage. Embryos 
lacking GATA6 did not upregulate any successive PrE markers and failed to 
specify the PrE. Instead, all cells of the ICM expressed NANOG. In wildtype 
context the downregulation of NANOG in PrE-biased cells is mediated by FGF 
signaling. This process was revealed to be GATA6 dependent, thereby 
shedding light on a novel element of the network governing the second cell 
fate decision. GATA6 was also shown to act in a dosage dependent manner, 
with Gata6 heterozygous embryos exhibiting not only reduced numbers of PrE 
cells, but also slowed lineage commitment, suggesting relative levels of 
NANOG and GATA6 may govern the segregation of EPI and PrE. 
Stem cells can be derived from both lineages, with embryonic stem 
(ES) cells representing the EPI and extraembryonic endoderm stem (XEN) 
cells the PrE. This work demonstrated efficient protocols for the derivation of 
Summary 
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either cell type, thereby facilitating the study of the properties of the two 
lineages.  
Beyond the involvement of transcription factors and signaling 
pathways, epigenetic gene regulation is thought to be involved in the 
maintenance and loss of pluripotency. DNA methylation and demethylation 
are such mechanisms. While DNA methylation is important for the silencing of 
genes e.g. during differentiation, DNA demethylation takes place in the 
preimplantation embryo to remove such repressive marks. In this work, ES 
cells were derived from blastocysts lacking the DNA demethylation promoting 
deaminase AID. These ES cells exhibited lower derivation efficiencies, 
pointing to the possible involvement of DNA demethylation for the 
establishment of the pluripotent epiblast lineage. Furthermore, fibroblasts 
lacking AID were reprogrammed and it was revealed that the resulting 
induced pluripotent stem (iPS) cells failed to maintain their pluripotent state. 
In conclusion, the present work provides insights into the establishment 
of pluripotency in vivo and in vitro by revealing new mechanisms for the 
lineage choice between EPI and PrE as well as the potential involvement of 
epigenetic regulation. 
  
Zusammenfassung 
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ZUSAMMENFASSUNG 
Während der zweiten Zellschicksalsentscheidung im Säugetierembryo 
werden zwei Zelllinien gebildet, das extraembryonische primitive Endoderm 
(PrE), das sich später zum Dottersack entwickelt, und der pluripotente 
Epiblast (EPI), aus dem der Embryo hervorgeht. Diese Entscheidung findet in 
der inneren Zellmasse (ICM) der Blastozyste statt. Die Zellen der ICM sind 
zunächst totipotent und exprimieren Marker für PrE und EPI, regulieren 
jedoch jeweils einen Marker graduell herunter bis sich ihre Expression 
gegenseitig ausschließt und die Zelllinien differenziert sind. In der 
vorliegenden Arbeit konnte mit Hilfe von Computer unterstützten 
Berechnungen gezeigt werden, dass die Verteilung der beiden neu 
entstehenden Zelltypen stochastisch, und ihre Lokalisation nicht von einander 
abhängig ist. 
Die frühesten Marker, durch die die graduelle Segregation der beiden 
Abstammungslinien beobachtet werden kann, sind die Transkriptionsfaktoren 
NANOG, der EPI-spezifisch wird, und GATA6, der PrE-spezifisch wird. 
NANOG ist durch seine Beteiligung an der Aufrechterhaltung der Pluripotenz 
in embryonalen Stammzellen bekannt und in seiner Abwesenheit im Embryo 
kann die EPI-Linie nicht gebildet werden. Die vorliegende Arbeit konnte 
zeigen, dass GATA6 der Hauptregulator der PrE-Linie ist. Embryonen ohne 
GATA6 aktivieren keine nachfolgenden PrE-Marker und können kein PrE 
bilden. Stattdessen exprimieren alle ICM-Zellen in diesen Embryonen 
NANOG. NANOG wird gewöhnlich in PrE-Vorläuferzellen durch den FGF 
Signalweg herunterreguliert. Diese Arbeit hat erstmals gezeigt, dass die FGF-
vermittelte Repression von NANOG jedoch GATA6 abhängig ist und zeigt 
damit einen neuen Mechanismus auf, der die zweite 
Zellschicksalsentscheidung reguliert. Es wurde weiterhin gezeigt, dass 
GATA6 in einer Dosis-abhängigen Weise fungiert. In Gata6 heterozygoten 
Embryonen war nicht nur die Anzahl von PrE-Zellen reduziert, sondern auch 
die Differenzierung dieser Zellen verlangsamt. Dies deutet darauf hin, dass 
Zusammenfassung 
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relative Level von NANOG und GATA6 die Segregation von EPI und PrE 
regulieren könnten. 
Von beiden Abstammungslinien, EPI und PrE, können Stammzellen 
gewonnen werden und diese dienen als Zellkultur-Modell für die beiden 
Linien. Embryonale Stammzellen (ES-Zellen) repräsentieren den 
pluripotenten Epiblasten während sogenannte extraembryonale Endoderm-
Stammzellen (XEN-Zellen) das primitive Endoderm repräsentieren. In der 
vorliegende Arbeit konnten effiziente Protokolle entwickelt werden um beide 
Stammzelltypen zu gewinnen, wodurch die Studie der Eigenschaften der 
beiden Linien erleichtert wird. 
Abgesehen von der Beteiligung von Transkriptionsfaktoren und 
Signalwegen, spielt die epigenetische Genregulation eine wichtige Rolle in 
der Aufrechterhaltung und dem Verlust von Pluripotenz. DNA-Methylierung 
und Demethylierung sind solche Mechanismen. Während DNA-Methylierung 
wichtig für die Stilllegung von Genen, z.B. während der Differenzierung ist, 
findet während der Präimplantationsentwicklung DNA-Demethylierung statt, 
um solche repressiven Markierungen zu entfernen. In dieser Arbeit wurden 
ES-Zellen von Blastozysten gewonnen, denen die Deaminase AID fehlt, 
welche DNA-Demethylierung fördert. Solche ES Zellen konnten mit 
verringerter Effizienz gewonnen werden, was darauf hindeutet, dass DNA-
Demethylierung in der Etablierung der pluripotenten EPI-Linie eine Rolle 
spielt. Darüber hinaus wurden Fibroblasten ohne AID zu induzierten 
pluripotenten Stammzellen (iPS-Zellen) reprogrammiert. Solche iPS-Zellen 
konnten ihren pluripotenten Status nicht aufrechterhalten. 
Zusammenfassend gibt die vorliegende Arbeit Einblick in die 
Etablierung der Pluripotenz in vivo und in vitro, durch die Aufdeckung neuer 
Mechanismen für die Zellschicksalsentscheidung zwischen EPI und PrE, 
sowie der Beteiligung von epigenetischer Regulation. 
1.  Introduction 
 5 
1.  INTRODUCTION 
1.1. PREIMPLANTATION MOUSE DEVELOPMENT: AN OVERVIEW 
The field of developmental biology aspires to understand the 
mechanisms that allow a single cell, the fertilized egg, to develop into a 
complex functioning organism, comprising a multitude of cells, tissues and 
organs that all have to interact proficiently on several levels. The process of 
development is therefore tightly regulated and timed. In mammals, where 
embryonic development takes place in utero, the initial days after fertilization 
are dedicated to laying the groundwork for implantation through formation of 
extraembryonic tissues that enable the absorption of maternal nutrients and 
by poising the embryonic lineage for the subsequent differentiation of the 
embryonic tissues. 
In the mouse, preimplantation development spans the first five days 
after fertilization and is devoted to the specification of the first three lineages: 
the extraembryonic trophectoderm (TE) and primitive endoderm (PrE) 
lineages and the pluripotent epiblast (EPI) (Figure 1). During the first two 
days, from the fertilized egg, or zygote, to the 8-cell stage, cells (also called 
blastomeres) undergo a series of synchronous cleavage divisions, with all 
blastomeres remaining totipotent – i.e. retaining the potential to develop into 
all extraembryonic as well as embryonic cell types, reflected by their ability to 
give rise to each of the first 3 lineages (Hillman et al., 1972; Tarkowski and 
Wróblewska, 1967). At the 8-cell stage (~E2.5-2.75) the process of 
compaction begins. During this time blastomeres adhere tightly to each other 
via the interaction of extracellular E-Cadherin domains, which form adherens 
junctions (Ducibella and Anderson, 2003; Fierro-González et al., 2013; Hyafil 
et al., 1980; Johnson and Ziomek, 1981a; Larue et al., 1994; Pauken and 
Capco, 1999; Reeve and Ziomek, 1981). The compacted embryo now 
resembles a mulberry in shape and has therefore been named morula (from 
Latin morum). Due to the process of compaction, cells generated during the 
following cell division cycles acquire inside or outside positions. Cells 
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localized on the inside are called the inner cell mass (ICM) and initially (~ until 
the 6th cleavage division) retain the developmental potential of early 
blastomeres (Handyside, 1978; Rossant and Lis, 2003; Suwinska et al., 
2008). Outside cells undergo polarization and epithelialization and thereby 
start the differentiation into TE, which will give rise to the ectoplacental cone 
and the chorion, the embryonic contribution to the placenta (Johnson and 
Ziomek, 1981b). 
 
FIGURE 1. Preimplantation development. Preimplantation development is devoted to the 
zygote-to-embryo-transition, which is marked by a series of cell divisions leading to the 
formation of the blastocyst. During this time two consecutive cell fate decisions take place to 
specify the three lineages the implanting blastocyst is comprised of: the extraembryonic 
trophectoderm (green) and primitive endoderm (blue) lineages and the pluripotent epiblast 
(red). Modified from (Schrode et al., 2013). 
 
Following compaction and epithelialization of outside cells, these TE 
cells start pumping ions into the intercellular space, thereby creating a fluid 
filled cavity called the blastocyst cavity (reviewed in (Watson et al., 2004)). 
Cavitation and growth of the embryo through two rounds of symmetric and 
asymmetric divisions concurrently leads to the formation the early blastocyst 
(~32 cells) (Motosugi et al., 2005; Smith and McLaren, 1977). A second extra-
embryonic lineage now arises within the ICM, the primitive endoderm (also 
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referred to as hypoblast), which will give rise to the endoderm of the visceral 
and parietal yolk sacs and also possibly contribute cellular descendants to the 
gut endoderm (Kwon et al., 2008; Viotti et al., 2014). PrE cells form an 
epithelium lining the blastocyst cavity along the surface of the remaining 
inside cells, which are now referred to as the epiblast. Epithelial cells of the 
extraembryonic TE and the PrE now encompass the pluripotent EPI, which 
will ultimately give rise to the embryo proper, and all somatic cells. Having 
reached this stage between embryonic day 4 and 5 (~ 150-200 cells) the 
embryo is now ready to implant into the maternal uterine wall. 
 
1.2. LEAVING BEHIND TOTIPOTENCY: THE FIRST CELL FATE 
DECISION 
From fertilization to the 8-cell stage all blastomeres retain totipotency 
and importantly, they coexpress transcription factors that are needed for both 
following lineage decisions (Figure 3). At the late 8-cell stage (~ E2.75) the 
embryo compacts and increases E-Cadherin dependent cell-cell contacts, 
laying the groundwork for the first cell fate decision, which is highly influenced 
by spatial information (Johnson et al., 1986). Initial studies demonstrated that 
TE/ICM specification takes place according to an outside or inside position at 
the late morula stage (“inside-outside model”) (Balakier and Pedersen, 2003; 
Tarkowski and Wróblewska, 1967). Additionally polarity was linked to the first 
cell fate decision (Johnson and Ziomek, 1981a). While cells positioned on the 
inside of the compact morula, now called inner cell mass (ICM), remain apolar 
and totipotent (Rossant, 1975; Spindle, 2005), cells on the outside acquire 
apical-basal polarity and become biased towards the extraembryonic TE. 
Polarization of these cells takes places through asymmetric localization of 
polarity proteins, such as the complex formed by the serine/threonine atypical 
protein kinase C (aPKC) and the adapter proteins PAR3 and PAR6 (aPKC-
PAR complex) as well as the cytoplasmic peripheral membrane protein Ezrin 
(EZR) (Dard et al., 2009; Louvet et al., 1996; Pauken and Capco, 2000; 
Plusa, 2005; Vinot et al., 2005). Following compaction, two rounds of 
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asymmetric cell divisions take place, eventually leading to the formation of the 
blastocyst.  
Specification of the trophectoderm is thought to be regulated by a set 
of master regulators, including the transcriptional enhancer factor family 
member TEAD4, the caudal-related transcription factor CDX2 and the product 
of the T-box gene EOMES (Ciruna and Rossant, 1999; Hancock et al., 1999; 
Nishioka et al., 2008; Russ et al., 2000; Strumpf, 2005; Yagi et al., 2007). Of 
these transcription factors, deletion of Tead4 shows the earliest defect with a 
failure to specify the TE and the blastocyst cavity (Nishioka et al., 2008; Yagi 
et al., 2007). This places TEAD4 at the top of the hierarchy, and it has been 
shown to initiate the TE program by activating the downstream lineage 
specific markers Cdx2 and Gata3 (Figure 3) (Nishioka et al., 2009; Ralston et 
al., 2010). Tead4 is a component of the Hippo signaling pathway and is 
expressed in both inside and outside cells. The lineage specific activity of the 
Hippo signaling pathway stems from the nuclear localization of TEAD’s 
binding partner and transcriptional co-activator YAP1 in outside cells. By 
contrast, in apolar inside cells, Hippo signaling through the kinase LATS1/2 
phosphorylates YAP1, which inhibits its translocation to the nucleus and leads 
to its degradation, thereby preventing TEAD4 activity in the ICM (Nishioka et 
al., 2009; Ralston et al., 2010). Recent studies have linked this differential 
activity in inside and outside cells with cell polarity, implicating the Hippo 
pathway components Angiomotin (Amot) and Neurofibromatosis (Nf2) 
(Cockburn et al., 2013; Hirate et al., 2013; Leung and Zernicka-Goetz, 2013). 
AMOT is thought to form an adherens junction-associated complex with NF2 
and LATS and cooperatively promote phosphorylation of YAP, leading to ICM 
identity. In outside cells, YAP phosphorylation would be prevented due to the 
sequestration of AMOT to their apical domain. 
Regulation of Cdx2 expression by the TEAD4-YAP nuclear complex in 
outside cells is accompanied by the concomitant downregulation of the 
transcription factor Pou5f1 (Oct4), possibly through direct repression, since in 
the absence of Oct4 most ICM cells differentiate into TE cells (Nichols et al., 
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1998; Niwa et al., 2005). Reversely, in the absence of Cdx2, outer cells fail to 
form TE and to downregulate Oct4 and Nanog, suggesting CDX2 represses 
Oct4 and Nanog in TE cells (Niwa et al., 2005; Strumpf, 2005). In the ICM 
OCT4 in cooperation with the transcription factor SOX2 is thought to activate 
expression of the FGF signaling ligand Fgf4 and the homeobox transcription 
factor Nanog as has been shown in ES cells (Ambrosetti et al., 2000; Basilico 
et al., 1997; Boyer et al., 2005). FGF4, secreted by ICM and later EPI cells, is 
an important paracrine factor, acting through the MEK/ERK signaling pathway 
to promote proliferation of the TE, which expresses the FGF receptor FGFR2 
(Tanaka et al., 1998). On the other hand, CDX2 binds to an FGF4-responsive 
enhancer in the promoter of the growth factor gene Bmp4, which led to BMP4 
secretion by TS cells (Murohashi et al., 2009). In combination with the finding 
that ES cell maintenance requires BMP4 (Kodaira et al., 2006; Qi et al., 2004; 
Ying et al., 2003) it could be inferred that TE cells secret BMP4, which may be 
important for ICM growth. A recent study inhibiting components of the BMP 
pathway suggested a role for BMP signaling in the formation of the PrE 
(Graham et al., 2014). 
Specification of the trophectoderm is a gradual process with TE cells 
remaining somewhat plastic and becoming only fully committed by the mid to 
late blastocyst stage, accompanying the second cell fate decision (Anani et 
al., 2014; Rossant and Vijh, 1980; Watanabe et al., 2014). 
1.3. ESTABLISHING THE PLURIPOTENT LINEAGE: THE SECOND 
CELL FATE DECISION 
Pluripotent embryonic stem (ES) cells (Evans and Kaufman, 1981) hold 
great potential for regenerative medicine and have therefore been the subject 
of extensive research, most of it focusing on their ability to differentiate into all 
cell types of the body. To fully understand the potential they hold however, it 
is important to understand pluripotency in the context of their in vivo 
counterpart, the pluripotent EPI (Boroviak et al., 2014; Brook and Gardner, 
1997). As discussed above the EPI arises during the second cell fate 
decision, taking place within the ICM of the blastocyst stage embryo.  
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Immunohistochemistry using antibodies directed against proteins, 
which represent lineage specific markers and live imaging using a PrE 
specific reporter, PdgfraH2B-GFP (Hamilton et al., 2003), led to a three-phase 
model of lineage specification in the ICM (Figure 1 and 3) (Chazaud et al., 
2006; Plusa et al., 2008). This model posits that the ICM of the early 
blastocyst (16-32 cells) comprises a homogenous cell population of bipotent 
cells, which coexpress markers for both EPI and PrE lineages. In a seemingly 
stochastic fashion, ICM cells then begin up- and downregulating lineage 
specific markers, leading to a mixed population of PrE and EPI biased cells 
after the mid blastocyst stage (>64 cells) (Figure 1 and 3). EPI and PrE 
biased cells at this stage are arranged in a salt and pepper distribution within 
the ICM and are marked by mutually exclusive expression of lineage specific 
transcription factors. These cells subsequently begin the process of sorting to 
their final adjacent layers and gain apical-basal polarity, which leads to the 
epithelialized PrE lining the blastocyst cavity by the late blastocyst stage (> 
100 cells) (Figure 1) (Gerbe et al., 2008; Meilhac et al., 2009; Saiz et al., 
2013). Sorting of PrE cells has been shown to involve a variety of different cell 
behaviors, including PrE cells relocating to the surface of the ICM, changing 
their lineage bias or undergoing apoptosis if neither occurs in time (Plusa et 
al., 2008). 
While much is known about the cellular processes taking place during 
the second cell fate decision, there are still many open questions surrounding 
the gene regulatory network that governs it. 
TRANSCRIPTION FACTORS  
Two transcription factors, the zinc finger transcription factor GATA6 
and the homeobox protein NANOG, are the earliest markers for PrE and EPI 
biased cells, respectively, and their interplay is thought to be at the center of 
the gene regulatory network controlling ICM fate choice (Chambers et al., 
2003; Koutsourakis et al., 1999; Mitsui et al., 2003; Morrisey et al., 1998a). 
Both, Gata6 and Nanog, along with the transcription factors Oct4 and Sox2 
are co-expressed from the early morula stage onward (Figure 3) (Dietrich and 
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Hiiragi, 2007; Plusa et al., 2008). Nanog, Sox2 and Oct4 subsequently 
become restricted to the EPI lineage during the second cell fate decision 
(Avilion et al., 2003; Grabarek et al., 2012; Guo et al., 2010; Niwa et al., 2005; 
Palmieri et al., 1994; Strumpf, 2005). In contrast Gata6 becomes confined to 
the PrE lineage, which subsequently activates additional PrE specific 
transcription factors, such as Sox17 and Gata4 (Artus et al., 2011; Kurimoto, 
2006; Morris et al., 2010; Niakan et al., 2010; Plusa et al., 2008). Collectively 
these transcription factors are at the center of the second cell fate decision 
(Figure 3). 
NANOG is a homeobox transcription factor, discovered for its 
importance in the maintenance of pluripotency (Chambers et al., 2003; Mitsui 
et al., 2003; Silva et al., 2009). Ectopic expression of Nanog in ES cells 
maintains their undifferentiated state even in the absence of leukemia 
inhibitory factor (LIF, see Introduction p. 27) (Chambers et al., 2003). In vivo 
NANOG is expressed in the early morula, in the ICM of blastocyst stage 
embryos, in the EPI of E6.5 and E7.5 embryos and in embryonic germ cells 
(Chambers et al., 2003; Hart et al., 2004; Hatano et al., 2005; Mitsui et al., 
2003). During the second cell fate decision NANOG is the first transcription 
factor that becomes restricted to the EPI lineage (Guo et al., 2010). Nanog 
deficient embryos fail to specify the EPI and display pan-ICM expression of 
the PrE marker GATA6 (Frankenberg et al., 2011; Messerschmidt and 
Kemler, 2010; Mitsui et al., 2003; Silva et al., 2009). In both, ES cells as well 
as in vivo, Nanog expression is positively regulated by the transcription 
factors OCT4 and SOX2, which form a regulatory complex that binds to the 
Nanog promoter (Liang et al., 2008; Rodda, 2005; Wang et al., 2006).  
SOX2 is a member of the SRY-related HMG-box (SOX) family of 
transcription factors and is involved in the self-renewal of cells of the 
developing central nervous system (Li et al., 1998; Zappone et al., 2000). In 
ES cells Sox2 is regulated by an autoregulatory SOX2/OCT4 complex (Chew 
et al., 2005). It is involved in the regulation of other pluripotency genes like 
Oct4 and Nanog and is therefore essential for the maintenance of 
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pluripotency (Chew et al., 2005; Kuroda et al., 2005; Masui et al., 2007; 
Okumura-Nakanishi et al., 2005). In vivo, Sox2 is the earliest marker of ICM 
cells and its restriction was suggested to be regulated by HIPPO signaling 
(Avilion et al., 2003; Guo et al., 2010; Wicklow et al., 2014). During the 
second cell fate decision SOX2 becomes restricted to the EPI lineage (Avilion 
et al., 2003; Guo et al., 2010; Wicklow et al., 2014). Accordingly, embryos 
lacking Sox2 are peri-implantation lethal with a failure to form ICM (Avilion et 
al., 2003; Keramari et al., 2010) and cannot yield ES cells (Avilion et al., 
2003). It is one of the factors used to reprogram somatic cells to induced 
pluripotent stem (iPS) cells, underscoring its importance for the regulation of 
pluripotency (Takahashi and Yamanaka, 2006).  
OCT4 is a transcription factor necessary, like Sox2, to maintain 
pluripotency in ES cells and in vivo (Nichols et al., 1998; Niwa et al., 2000). In 
vivo it is expressed in germ cells, oocytes and the ICM of the morula until 
early to mid blastocyst but then becomes restricted to the EPI (Palmieri et al., 
1994; Pesce et al., 1998; Rosner et al., 1990; Schöler et al., 1990; Yeom et 
al., 1996). Homozygous null mutant embryos are peri-implantation lethal with 
a failure to specify PrE and the blastocyst eventually differentiates into 
trophectoderm (Frum et al., 2013; Le Bin et al., 2014; Nichols et al., 1998). 
OCT4 forms a trimeric complex with SOX2 to autoregulate their own 
expression as well as other pluripotency factors such as Nanog and Fgf4 
(Chew et al., 2005; Kuroda et al., 2005; Okumura-Nakanishi et al., 2005; 
Rodda, 2005; Yuan et al., 1995). In a complex with NANOG, OCT4 and SOX2 
are also thought to repress differentiation-promoting genes (Sun et al., 2006). 
GATA6 is a zinc finger transcription factor and member of the GATA 
family. In the postimplantation embryo it is involved in liver development and 
together with Gata4 in heart and pancreas development (Koutsourakis et al., 
1999; Morrisey et al., 1996; Xin et al., 2006; Xuan et al., 2012; Zhao et al., 
2005; 2008). During preimplantation development Gata6 is expressed in all 
cells in the early morula but becomes restricted to the PrE coincident with the 
second cell fate decision (Chazaud et al., 2006; Plusa et al., 2008). It is 
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thereafter involved in the formation of the extraembryonic endoderm lineages 
(Koutsourakis et al., 1999; Morrisey et al., 1998a). Accordingly, 
overexpression of Gata6 in ES cells causes their conversion to 
extraembryonic endoderm (XEN, (Kunath, 2005)) stem cells (Fujikura et al., 
2002; Shimosato et al., 2007). Embryos lacking Gata6 were initially reported 
to be early postimplantation lethal with defects in PrE derivative lineages 
(Koutsourakis et al., 1999; Morrisey et al., 1998a) as well as with an absence 
of a PrE layer as early as E4.5 (Cai et al., 2008). However, in these previous 
studies of early Gata6 null mutant embryo genotyping was performed using in 
situ hybridization or immunofluorescence on histological sections and did not 
provide robust unequivocal genotyping information as do the PCR genotyping 
methods that are used as a standard today (see (Morrisey et al., 1998a), 
Figure 5). The exact phenotype and thereby role of Gata6 during 
preimplantation development therefore remained an open question. 
SOX17 is a member of the SOX family of transcription factors and is 
involved in the development of gut endoderm, cardio-vascular and fetal (but 
not adult) hematopoietic stem cells (Francois et al., 2010; Kanai-Azuma et al., 
2002; Kim et al., 2007; Matsui, 2006). During preimplantation development 
Sox17 is expressed in the PrE (Morris et al., 2010; Niakan et al., 2010). 
Homozygous null mutants form a PrE layer but are postimplantation lethal 
with severe impairment in the formation of the definitive endoderm (Kanai-
Azuma et al., 2002; Viotti et al., 2014). However, when implantation is 
artificially delayed through experimental induction of diapause, embryos 
lacking Sox17 display defects in the epithelial integrity of the PrE (Artus et al., 
2011), suggesting it is involved in the formation of the extracellular matrix 
secreted by the PrE during preimplantation development. 
GATA4, like Gata6 is a member of the GATA transcription factor family 
and is expressed in the heart, liver, pancreas and small intestine of the 
developing embryo (Arceci et al., 1993). Gata4 and Gata6 are speculated to 
have partially redundant roles, for example in pancreas and heart 
development (Xin et al., 2006; Xuan et al., 2012; Zhao et al., 2005). During 
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preimplantation development Gata4 is activated specifically in PrE cells, and it 
is the first factor exclusively marking the PrE lineage (Kurimoto, 2006; Plusa 
et al., 2008). Gata4 null mutant embryos display postimplantation lethality with 
defects in heart development and ventral morphogenesis (Kuo et al., 1997; 
Molkentin et al., 1997; Narita et al., 1997). Nevertheless, GATA4 is capable of 
inducing extraembryonic endoderm fate and Gata6 expression when 
overexpressed in ES cells (Fujikura et al., 2002) and its interaction with 
GATA6 has been suggested to be necessary for PrE specification (Capo-
Chichi et al., 2005; Fujikura et al., 2002; Soudais et al., 1995). These results 
support the important roles of GATA4 for PrE specification while the less 
severe early defects in single knockout embryos support the hypothesized 
redundancy of GATA6 and GATA4. 
FGF SIGNALING 
As discussed above, Gata6 and Nanog are thought to be the 
transcription factors governing the events of the second cell fate decision. 
Their interplay is additionally impinged on by FGF signaling, potentially aiding 
communication between ICM cells during their lineage divergence.  
LIGANDS AND RECEPTORS 
The FGF family of growth factors encompasses 22 members, which 
signal through four ligand-dependent FGF receptor tyrosine kinases (Figure 
2). These FGF receptors gain additional ligand specificity through alternative 
splicing of the extracellular binding domain and their isoforms are tissue-
specifically regulated (reviewed in (Zhang et al., 2006)). Activation of the FGF 
signaling pathway at preimplantation stages seems to occur specifically 
through the FGF4/FGFR2 ligand/receptor complex (Arman et al., 1998; 
Feldman et al., 1995; Wilder et al., 1997) (Figure 2). 
Fgf4, like Nanog, is under the direct transcriptional control of the 
OCT4/SOX2 regulatory complex (Ambrosetti et al., 2000; Avilion et al., 2003; 
Keramari et al., 2010; Nichols et al., 1998; Yuan et al., 1995) and is 
expressed highly in all cells of the ICM from the 8-cell stage onwards (Guo et 
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al., 2010). It becomes restricted to EPI-biased cells at the beginning of their 
specification (Guo et al., 2010). Null mutants for Fgf4 fail to specify the PrE 
and display pan-ICM expression of Nanog (Kang et al., 2013; Krawchuk et al., 
2013). 
The FGF receptors FGFR1 and FGFR2 are both expressed in the ICM 
of the preimplantation embryo (Ohnishi et al., 2014), but only deletion of Fgfr2 
has been shown to be peri-implantation lethal (Arman et al., 1998). 
Furthermore, FGFR1 remains expressed in both PrE and EPI, while FGFR2 
becomes restricted to the PrE during the second cell fate decision (Guo et al., 
2010; Ohnishi et al., 2014). 
SIGNAL TRANSDUCTION 
FGF signaling is activated by the formation of an FGF ligand/FGF 
receptor (FGFR) complex, leading to dimerization of the receptor. 
Downstream signal transduction proceeds mainly through four different 
pathways, the JAK/STAT, the PLCγ, the PI3K and the ERK pathway (Figure 
2) (Dailey et al., 2005). The latter two have been found to be active during 
preimplantation development. Both are relayed through formation of a 
complex between FGFR, FRS2a, SHP2 and GRB2, which in turn activates 
AKT via PI3K and ERK via the SOS/RAS pathway (Figure 2). In ES cells the 
FGF/AKT pathway acts upstream of extracellular matrix components like 
Laminin and Collagen IV (Li et al., 2001) and therefore seems likely to be 
involved in the epithelial maturation of the PrE rather than its formation. In 
contrast, the FGF/ERK pathway has been strongly implicated in the 
segregation of the EPI and PrE lineages. Perturbation of the FGF/ERK 
pathway in preimplantation stage embryos has been shown to cause severe 
effects on PrE/EPI lineage segregation. Null mutants for the ligand Fgf4, its 
putative receptor Fgfr2, the downstream adapter Grb2 and inhibition of the 
mitogen-activated protein kinase ERK all lead to a failure to fully specify the 
PrE, which leads to an ICM comprised solely of EPI cells (Arman et al., 1998; 
Chazaud et al., 2006; Cheng et al., 1998; Feldman et al., 1995; Goldin and 
Papaioannou, 2003; Kang et al., 2013; Krawchuk et al., 2013; Nichols et al., 
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2009; Ohnishi et al., 2014; Yamanaka et al., 2010). Conversely, treatment of 
early embryos with ectopic FGF4 directs all ICM cells towards the PrE lineage 
(Yamanaka et al., 2010).  
 
 
FIGURE 2. FGF signaling pathway. FGF signaling is relayed through 4 different pathways 
(JAK/STAT; PLCγ; PI3K/AKT; MEK/ERK). In ES cells the MEK/ERK pathway downregulates 
Nanog. Refer to text for further information. Arrows: positive regulation.  
 
REGULATION OF PRE/EPI DIFFERENTIATION 
TRANSCRIPTION FACTOR INTERACTIONS 
As discussed above, many of the transcription factors as well as FGF 
signaling components that are involved in the second cell fate decision are 
coexpressed from the early morula stage onward (Dietrich and Hiiragi, 2007; 
Guo et al., 2010; Plusa et al., 2008). Lineage bias towards EPI or PrE is 
initiated around the early blastocyst stage when cells in the ICM start 
downregulating either Gata6 or Nanog, with future EPI cells downregulating 
Gata6 and future PrE cells Nanog, until they attain a mutually exclusive 
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expression pattern (Chazaud et al., 2006; Guo et al., 2010; Kurimoto, 2006; 
Plusa et al., 2008; Rossant et al., 2003).  
From this stage onwards the two factors become the first markers for 
their respective lineages and are thought to govern their maturation. Indeed, 
overexpression of Gata6 is sufficient to direct ES cells towards an 
extraembryonic endoderm like state and leads to the downregulation of 
Nanog (Fujikura et al., 2002; Shimosato et al., 2007). In ES cells NANOG has 
been shown to bind the Gata6 promoter and possibly suppress it (Mitsui et al., 
2003; Singh et al., 2007). These observations hint at a mutually repressive 
relationship between Gata6 and Nanog and it is thought that early co-
expression of the factors is maintained by a state of mutual repression until 
this balance is disturbed and lineage segregation initiated at the early 
blastocyst stage. Supporting this idea is the observation that all ICM cells of 
Nanog null mutants express GATA6 (Frankenberg et al., 2011; 
Messerschmidt and Kemler, 2010; Silva et al., 2009) while Gata6 null mutants 
display defects in PrE derivative lineages (Cai et al., 2008; Koutsourakis et al., 
1999; Morrisey et al., 1998a).  
If the two factors indeed repress each other, the question remains how 
they maintain stable expression levels until lineage segregation commences. 
As has been shown for Oct4 and Sox2 (Jaenisch and Young, 2008), positive 
autoregulation has been speculated for Gata6 (Frankenberg et al., 2011). The 
Gata6 gene has been found to have GATA binding motifs of its own and could 
therefore regulate its own expression (Molkentin, 2000). Nanog is known to be 
positively regulated by SOX2 and OCT4 as well as through positive 
autoregulation (Jaenisch and Young, 2008; Rodda, 2005; Wu et al., 2006). 
However, repression through FGF signaling (Santostefano et al., 2012), as 
well as autorepression, has also been shown for Nanog in ES cells (Fidalgo et 
al., 2012; Navarro et al., 2012). 
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FIGURE 3. Gene 
regulatory networks 
governing pre-
implantation development.   
The lineage specific 
transcription factors Cdx2 
(TE), Gata6 (PrE) and 
Nanog (EPI) are 
coexpressed at the early 
morula stage but 
subsequently segregate to 
their respective lineages. 
Cdx2 becomes exclusive to 
the TE during the first cell 
fate decision at the morula 
stage and represses Oct4 
and Nanog in TE biased 
cells. In the inner cell mass 
Nanog as well as Fgf4 are 
positively regulated by a 
OCT4/SOX2 regulatory 
complex. Additionally, Gata6 
and Nanog may 
autoregulate themselves.  
Nanog and Gata6 become 
exclusive to EPI and PrE 
respectively during the 
second cell fate decision, 
starting at the early 
blastocyst stage. In EPI 
biased cells NANOG is 
thought to repress Gata6 
and vice versa. EPI and PrE 
specification is additionally 
regulated through FGF/ERK 
signaling, with EPI cells 
secreting FGF4. This may 
lead to repression of Nanog 
through the FGFR2/ERK 
pathway in PrE biased cells. 
Further PrE specific genes, 
such as Sox17 and Gata4, 
may be regulated by GATA6 
and FGF/ERK signaling.   
Refer to text for further 
information. Green: TE. 
Blue: PrE. Red: EPI. Purple: 
bipotent ICM. Arrows: 
positive regulation. Blocked 
arrows: repression. Dashed 
arrows: speculated 
interactions. Adapted from 
(Schrode 2013). 
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INFLUENCE OF FGF SIGNALING 
Gata6 and Nanog display balanced co-expression until the early 
blastocyst stage when their divergence begins. FGF signaling is directly 
involved in this process by promoting PrE differentiation in a cell non-
autonomous fashion. This effect is thought to be caused by downregulation of 
Nanog through FGF/ERK signaling in these cells, which in case of 
NANOG/GATA6 mutual repression would lead to upregulation of Gata6. 
Indeed, work in ES cells showed that homodimerization of FGFR2, leading to 
its constitutive activation is sufficient for transcriptional downregulation of 
Nanog (Santostefano et al., 2012). 
In addition, the reciprocal expression of FGF ligand and receptor in the 
two lineages paralleling their segregation suggests the direct involvement of 
FGF4 and FGFR2 in the second cell fate decision. Moreover, Guo et al. 
showed that the inverse correlation of Fgf4 and Fgfr2 in the ICM precedes 
that of Nanog and Gata6 (Guo et al., 2010). In a recent single cell expression 
profiling study of embryos during preimplantation development, Ohnishi et al. 
further demonstrated that Fgf4 is indeed the first lineage specific factor that is 
differentially expressed in the ICM of early blastocysts and seems therefore to 
be a candidate to break homogeneity in the ICM (Ohnishi et al., 2014). These 
findings support a hypothesis where FGF4 initiates the second cell fate 
decision and provides the cue to break symmetry in the ICM. 
Interestingly, recent studies investigating Fgf4 mutant embryos, 
demonstrated a reduction of PrE cells in Fgf4 zygotic or maternal zygotic 
heterozygous embryos, respectively (Kang et al., 2013; Krawchuk et al., 
2013). Moreover, Kang et al. showed that the EPI/PrE salt and pepper 
conformation could not be rescued in Fgf4 null embryos by treatment with 
exogenous FGF4, while Krawchuck et al. occasionally saw progressive 
modulation of lineage proportions through treatment with varying FGF doses. 
This suggests that FGF4 levels have to be tightly regulated in the embryo to 
ensure the differentiation of a correct ratio of EPI and PrE cells in the ICM and 
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it raises the question of how the initially homogenous cells of the ICM are able 
to react differentially to similar levels of FGF4 in the extracellular space. 
ESTABLISHING THE INITIAL LINEGEAGE BIAS 
Though above findings point to FGF4 as the initial cue that starts the 
second cell fate decision, it is still unclear what causes Fgf4 to be expressed 
differentially in the first place.  
One model assumes a stochastic event caused by expression 
heterogeneities breaks symmetry in the ICM and causes cells to acquire a 
lineage bias – especially Nanog shows very heterogeneous expression in ICM 
cells as well as ES cells  (Chambers et al., 2007; Kalmar et al., 2009; Mitsui et 
al., 2003; Torres-Padilla and Chambers, 2014) and it has been speculated 
that NANOG acts upstream of Fgf4 (Frankenberg et al., 2011). Such 
heterogeneities could initiate a bias in cells of the ICM.  
On the other hand, a study by Morris et al. proposed that the time of 
internalization of ICM cells influences their future fate (Morris et al., 2010). 
Accordingly, cells internalized during the second wave of asymmetric divisions 
would be further along in their development and therefore express higher 
levels of FGF4’s putative receptor FGFR2, which would increase their 
susceptibility to FGF signaling and increase the potential to differentiate 
towards PrE (Morris et al., 2013). However, an independent tracing study by 
Yamanaka et al. found no such correlation (Yamanaka et al., 2010). More 
studies are therefore necessary in this area to determine the initial 
mechanism(s) that break symmetry within the ICM. 
CHANGES IN DEVELOPMENTAL PLASTICITY 
While it is still unclear how the initial lineage bias is established and 
how expression of the master regulators Gata6 and Nanog is regulated to 
govern this process, observations have been made about the events following 
the initiation of lineage specification.  
Following the initial upregulation of Fgf4 in future EPI cells, its putative 
receptor Fgfr2 is upregulated in PrE precursor cells (Guo et al., 2010; Ohnishi 
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et al., 2014). PrE biased cells sequentially downregulate the pluripotency 
markers Nanog, Sox2 and finally Oct4 and in parallel activate additional PrE 
markers, namely Sox17, Gata4 and Sox7 (Figure 3) (Artus et al., 2011; 
Frankenberg et al., 2011; Grabarek et al., 2012; Guo et al., 2010; Kurimoto, 
2006; Morris et al., 2010; Niakan et al., 2010; Plusa et al., 2008). Both 
FGF/ERK signaling, as well as GATA6, are suggested to be involved in this 
process. FGF/ERK signaling leads to the downregulation of Nanog and 
possibly upregulation of Sox17 and Gata4 (Frankenberg et al., 2011). 
Additionally, both, Sox17 and Gata4 posses GATA response elements and 
are therefore speculated to be regulated by GATA6 (Niakan et al., 2010; 
Wang and Song, 1996). However, in Nanog null mutant embryos, Gata6-
positive ICM cells do not express Sox17 and Gata4, suggesting that FGF 
signaling is indeed cooperatively involved in the activation of these genes 
(Frankenberg et al., 2011).  
Simultaneously, pluripotency markers, which were homogenously 
expressed throughout the ICM until the early blastocyst stage, are being 
restricted to future EPI cells. Sox2 is found solely in EPI cells around the mid 
blastocyst stage (Guo et al., 2010). Interestingly, Oct4, which is commonly 
regarded, and taken advantage of, as an important pluripotency marker in ES 
cells, is restricted to the EPI only by the late blastocyst stage (Grabarek et al., 
2012) once the lineages have sorted. This points to ES cells representing 
mature EPI cells, which has recently been confirmed through gene expression 
profiling and functional cell-derivation assays (Boroviak et al., 2014). Around 
the time of implantation Nanog is progressively downregulated, priming the 
EPI for the subsequent differentiation into the embryonic lineages (Chambers 
et al., 2003; Hatano et al., 2005; Medvedev et al., 2008; Mitsui et al., 2003). It 
can be readily inferred that precursors of both lineages become increasingly 
locked in their fate as the differentiation program progresses and additional 
factors are activated. By the time the PrE and EPI lineages exhibit a clear salt 
and pepper distribution in the ICM, their cell fates were thought to be fully 
committed and to have lost their initial plasticity. However, experiments 
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involving treatment of embryos with exogenous FGF4, as well as ERK 
inhibitors, for various time frames during blastocyst maturation showed that 
both cell types retain their EPI/PrE bipotency until the late blastocyst stage, if 
forced by extreme modulation of FGF signaling (Yamanaka et al., 2010). 
Similarly, isolation of lineage biased cells from various stages and 
transplantation into early embryos showed varying plasticity of ICM cells up to 
the peri-implantation stage and intriguingly a higher plasticity of PrE than EPI 
cells (Grabarek et al., 2012). This raises the question when and how exactly 
cells of the ICM commit to either lineage and loose their ability to respond to 
FGF signaling cues, i.e. their plasticity. 
Among the multitude of possible factors influencing plasticity, as well 
as fate stabilization, is epigenetic regulation. 
DNA METHYLATION STATUS 
The adult mammalian body consists of an astounding number of 
different cell types, forming complex tissues and organs that are in constant 
cross talk with each other to function correctly. The formation of the embryo 
proper entails the differentiation of the pluripotent EPI cells into a multitude of 
precursor cells and eventually differentiated somatic cell types. EPI cells are 
therefore subject to strict regulation to maintain pluripotency and 
simultaneously to be able to readily enter a primed state and initiate 
differentiation upon various cues (Chambers et al., 2003). Complex signaling 
and transcription factor cascades ensure directed differentiation of these cells 
while epigenetic modifications, such as histone marks and DNA methylation, 
secure their identity is maintained and prevent straying from their given 
differentiation path (Reik, 2007). 
DNA methylation is considered a repressive mark and is one of the 
most important epigenetic mechanisms to ensure cell identity, for example by 
silencing pluripotency genes in differentiating cells (Tsumura et al., 2006). It 
occurs through methylation of the fifth carbon of cytosine, creating 5-
methylcytosine (5mC) and mainly occurs in the context of symmetrical CpG 
sequences (Bird and Wolffe, 1999; Jones and Takai, 2001). So-called CpG 
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islands, DNA stretches with high CpG density, are often found near the 
promoter regions of genes. When these are hypomethylated it is considered a 
sign of active gene transcription (Cross and Bird, 1995; Larsen et al., 1992). 
De novo DNA methylation is mainly achieved through the DNA 
methyltransferases DNMT3a and DNMT3b. On the other hand, the 
maintenance of distinct methylation patterns in specialized cells and tissues is 
ensured through DNMT1, which recognizes hemimethylated DNA in daughter 
cells and restores the full methylation status (Bestor, 2000; Li et al., 1992; 
Margot et al., 2003; Okano et al., 1999). 
At the blastocyst stage a hypomethylated genome enables pluripotent 
EPI cells to differentiate into any cell type and acquire their respective distinct 
DNA methylation pattern (Tsumura et al., 2006) (Figure 4). This is not the 
case at the zygote stage however, since sperm cells and oocytes are highly 
(~90 % and ~40 % respectively) methylated cell types (Kobayashi et al., 
2012). As a result, global demethylation must occur after fertilization to reset 
the epigenome for the next generation (Figure 4).  
FIGURE 4. DNA methylation and demethylation during preimplantation development. 
The DNA of the fertilized oocyte, combining both parental genomes, is highly and 
asymmetrically methylated. The paternal genome is rapidly and probably actively 
demethylated shortly after fertilization. In contrast, the maternal genome is passively 
demethylated. DNA demethylation is completed by the blastocyst stage when the first cell fate 
decisions are taking place and de novo methylation of the embryonic genome is initiated. 
Adapted from (Wu and Zhang, 2014). 
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DNA methylation is considered a comparatively stable epigenetic mark 
and to date no enzyme is known to remove methyl groups directly (Cortázar 
et al., 2007). Alternatively however, methylation density can be diluted 
passively through replication in the absence of nuclear DNMT1, thereby 
causing gradual loss of the mark in daughter cells (Howell et al., 2001; Santos 
et al., 2002). This replication dependent demethylation is thought to occur in 
the maternal genome after fertilization and during preimplantation 
development (Dean et al., 2001; Howell et al., 2001; Oswald et al., 2000; 
Rougier et al., 1998; Santos et al., 2002). In contrast, the paternal genome 
exhibits the highest DNA methylation level of all murine cells and undergoes 
rapid and complete demethylation shortly after zygote formation (Dean et al., 
2001; Mayer et al., 2000; Oswald et al., 2000; Popp et al., 2010; Santos et al., 
2002). It has therefore been suggested that the paternal genome undergoes 
active demethylation. However, a mechanism to allow for such a process has 
proven elusive until very recently. Groundbreaking studies revealed that such 
active demethylation can take place by oxidation of 5-methylcytosine (5mC) 
through TET (ten-eleven translocation protein) enzymes into 5-
hydroxymethylcytosine (5hmC) and into further oxidized derivatives 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011; 
Kriaucionis and Heintz, 2009; Pfaffeneder et al., 2011; Tahiliani et al., 2009). 
These derivatives seem to compromise binding of the methylation 
maintenance machinery and thereby augment passive demethylation 
(reviewed in (Li et al., 2015)) (Figure 5). DNA demethylation through TET 
proteins may play a role in the first cell fate decision, where knockdown of 
Tet1 favored cell specification towards the TE (Ito et al., 2010). 
Another mechanism proposed to accomplish active demethylation is 
through deamination of 5-methylcytosine to thymidine (Morgan et al., 2004). 
This conversion triggers the base excision repair mechanism and results in 
restoration of unmethylated cytosine. Two members of the APOBEC family of 
cytosine deaminases that could fulfill such a function are the AID and 
APOBEC1 (Morgan et al., 2004; Rai et al., 2008). AID has been found to be 
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coexpressed with the pluripotency related factors Nanog and Stella in ES 
cells, oocytes and germ cells and has been implicated in the demethylation of 
Nanog and Oct4 promoters in somatic cell reprogramming (Bhutani et al., 
2010; Morgan et al., 2004). However, it is yet widely unknown if or how the 
enzyme plays a role in early demethylation events. 
 
 
Figure 5. DNA methylation cycle. DNA methylation is carried out at the 5’ carbon position of 
cytosine by DNMT enzymes and produces 5-methylcytosine (5mC). TET enzymes catalyze 
the oxidation of 5mC into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and finally 
5-carboxylcytosine (5caC). Compromised binding of the methylation machinery leads to 
enhanced passive demethylation. Alternatively, 5caC as well as 5hmC can be deaminated by 
deaminases such as AID or APOBEC1. The resulting thymidine is repaired through base 
excision repair (BER) and produces unmethylated cytosine. Refer to text for further 
information. TDG: Thymine DNA glycosylase. 
 
1.4.  STEM CELL CULTURE MODELS FOR BLASTOCYST LINEAGES 
The study of preimplantation development is often hampered by the 
limitations the system presents. A single embryo consists of not more than 8 
to 200 cells. If the lineages are to be analyzed separately they have to be 
painstakingly isolated, which further decreases sample size for high-
throughput biochemical analyses. Single cell approaches have proven 
successful but are difficult and time-consuming. To be able to further study 
the molecular mechanisms underlying the specification and maintenance of 
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the different preimplantation lineages, tissue culture models can be derived 
from blastocyst stage embryos (Figure 6). 
 
 
FIGURE 6. Stem cell types derived from the blastocyst. Stem cells can be derived from all 
three lineages of the late blastocyst stage embryo. Throphoblast stem (TS) cells are derived 
from the TE, extraembryonic endoderm stem (XEN) cells from the PrE and embryonic stem 
(ES) cells from the pluripotent EPI. Adapted from (Niakan et al., 2013). 
 
EMBRYONIC STEM CELLS AND INDUCED PLURIPOTENT STEM 
CELLS 
The most commonly known and widely studied cells derived from the 
blastocyst stage embryo are embryonic stem (ES) cells, foremost for their 
potential for regenerative medicine (reviewed in (Hochedlinger and Jaenisch, 
2003; Lerou and Daley, 2005)). ES cells are derived from the ICM of 
blastocyst stage embryos and represent the in vitro counterpart of the EPI 
lineage (Boroviak et al., 2014; Brook and Gardner, 1997). As such, they are 
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pluripotent – i.e. they have the potential to differentiate into all somatic tissues 
and germ cells – and capable of self-renewal – i.e. they can divide indefinitely. 
They express markers of the pluripotent epiblast, such as Nanog, Sox2, Oct4, 
Klf4 and Esrrb. Importantly, when injected into blastocysts they contribute 
solely to the EPI and all derivative germ layers in resulting chimeric embryos, 
the gold standard to test for developmental potential of any cell type (Bradley 
and Robertson, 1986).  
The first murine ES cells were successfully derived in 1981 by Evans 
and Kaufman on mitotically inactivated mouse embryonic fibroblast (MEF) 
feeder cells and in serum containing medium (Evans and Kaufman, 1981), as 
well as by Martin using teratocarcinomas cell-conditioned medium (Martin, 
1981). Advancements in understanding ES cell biology and pluripotency have 
since made it possible to derive and maintain ES cells in more defined 
conditions: 
Feeder cells are thought to aid ES cells by providing cell-cell 
interactions and secreting beneficial growth factors (Eiselleova et al., 2008; 
Lim and Bodnar, 2002; Ma et al., 2012; Meng et al., 2008; Villa-Diaz et al., 
2009), including leukemia inhibitory factor (LIF) (Hasegawa et al., 2011; 
Stewart et al., 1992). The benefit of adding LIF to ES culture media was found 
in 1988 and allows ES cell propagation in the absence of feeder cells 
(Williams et al., 1988). Similarly, it has been shown that teratocarcinoma stem 
cell-conditioned medium is equivalent to a 5-fold concentration of the LIF 
added to ES cell culture, explaining its effect in the original derivation process 
(Davies and Fairchild, 2012). In ES cells LIF activates the JAK/STAT 
pathway, which inhibits differentiation and promotes self-renewal activating 
core pluripotency genes, including Nanog, Oct4 and Klf4 (Hirai et al., 2011; 
Matsuda et al., 1999; Niwa et al., 1998; 2009; Smith et al., 1988). The effects 
of LIF in ES cell culture simulate activation of STAT3 in the preimplantation 
embryo in vivo through WNT/GSK3 signaling. 
Fetal bovine serum (FBS) is a non-chemically defined supplement 
used almost universally for cell culture because it promotes cell growth and 
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proliferation. It contains nutrients and growth factors for ES cells, but also 
potential differentiation factors (Mannello and Tonti, 2007; Ogawa et al., 2004; 
Vanroose et al., 2001). More chemically defined serum replacement formulae 
were therefore developed, both commercially (Knockout Serum Replacement, 
KSR) and non-commercially (N2B27) to maintain and derive murine ES cells 
(Price et al., 1998; Ying et al., 2003; 2008). The withdrawal of serum alone 
however cannot maintain pluripotency, as ES cells produce autocrine factors 
that lead to differentiation. An essential growth factor for ES cell self-renewal, 
which is contained in serum, is bone morphogenetic protein 4 (BMP4), which 
induces the expression of Id genes and inhibits MEK signaling (Kodaira et al., 
2006; Qi et al., 2004; Ying et al., 2003). LIF in synergy with BMP4 is therefore 
sufficient to maintain ES cell pluripotency and self-renewal in culture and can 
be used to substitute both feeder cells and serum or either one respectively. 
As in the ICM of the blastocyst, the autocrine differentiation-promoting 
factor secreted by ES cells is FGF4, which activates ERK signaling. On this 
basis Ying and colleagues proposed that LIF and BMP signals act 
downstream of ERK to shield the pluripotent state. They found that inhibiting 
differentiation through ERK, while promoting growth capacity through 
inhibition of glycogen synthase kinase-3 (GSK3) could maintain pluripotency 
without requirement of any growth factors or cytokines (Ying et al., 2008). 
Initially this was achieved through small-molecule inhibitors blocking FGF 
receptor tyrosine kinases, the ERK cascade and GSK3 (3i). A potent inhibitor 
of ERK however was able to substitute for inhibitors of FGFR and the 
downstream ERK cascade. This two-inhibitor culture condition (or 2i) was able 
to more effectively maintain the pluripotent state and has since revolutionized 
the culture and derivation of ES cells.  
Despite advancements in ES cell culture, their derivation remains often 
inefficient (10% - 30%) and can be highly strain dependent (Brook and 
Gardner, 1997; Kawase et al., 1994; McWhir et al., 1996; Robertson, 1997; 
Suzuki et al., 1999). For this reason researchers often employ additional 
strategies to increase yield, such as microsurgical isolation of the inner cell 
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mass, selective removal of differentiating cells or aggregation with outbred 
host embryos (Brook and Gardner, 1997; Gertsenstein et al., 2010; McWhir et 
al., 1996). Inhibition of GSK3 could further increase efficiency up to 76% for 
the permissible C57BL/6 strain and 31% for the less permissible BALB/c 
strain (Umehara et al., 2007). 
While the derivation and maintenance of murine ES cells is improving 
continuously, the study of human ES cells, essential for future applications in 
regenerative medicine, has been hampered by ethical and moral concerns 
surrounding the usage of live embryos for their derivation. A groundbreaking 
study in 2006 showed that overexpression of the transcription factors Oct4, 
Sox2, Klf4 and cMyc is sufficient to induce reprogramming of differentiated 
cells to a pluripotent state. These induced pluripotent stem (iPS) cells display 
morphological and functional characteristics of ES cells, including the 
expression of pluripotency markers and their developmental potential 
(Takahashi and Yamanaka, 2006). These iPS cells are derived from adult 
cells and could therefore be used to create patient specific pluripotent cells. 
Thus, great efforts are being made to study the mechanisms underlying 
cellular reprogramming, the actual similarity and potential disparities to ES 
cells as well as their safety and potential for medical use (for review, see 
(Buganim et al., 2013; Deng et al., 2015; Hanna et al., 2010; Inoue et al., 
2014; Lowry, 2012; Simonson et al., 2015)).  
TROPHOBLAST STEM CELLS 
Trophoblast stem (TS) cells represent a cell culture model for the 
trophectoderm lineage and its derivatives and are useful for modeling 
placental development. Specifically, TS cells are thought to stem from the 
polar TE, the part of the trophectoderm in direct contact with the ICM. The 
polar TE is a stem cell pool, which is maintained until postimplantation stages 
and fuels the continued production of tissue. It is suggested to give rise to 
cells of the extraembryonic ectoderm (ExE), the ectoplacental cone (EPC) 
and secondary trophoblast giant cell (Simmons and Cross, 2005; Tanaka et 
al., 1998; Uy et al., 2002). Accordingly, when injected into blastocysts, TS 
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cells only give rise to derivatives of the trophoblast lineage, such as the ExE, 
EPC and eventually the placenta (Tanaka et al., 1998). 
Trophoblast cells in vivo require FGF signaling through FGF4/FGFR2 
for their proliferation. In turn, the derivation of TS cells can be accomplished 
from outgrowths of blastocysts or explanted ExE isolated from 
postimplantation embryos and by supplementing the derivation medium with 
FGF4, the FGF receptor binding enhancer heparin and mouse embryonic 
fibroblast-conditioned medium (Tanaka et al., 1998).  
TS cells express characteristic markers of the trophoblast lineages, like 
Cdx2, Gata3 and Eomes and are devoid of OCT4. Remarkably, 
overexpression of Cdx2 or deletion of Oct4 in ES cells leads to their 
conversion to TS like cells, underlining these factors’ leading role in regulation 
of trophectoderm specification (Nichols et al., 1998; Niwa et al., 2000; 2005). 
EXTRAEMBRYONIC ENDODERM STEM CELLS 
Extraembryonic endoderm stem (XEN) cells, like ES cells, are derived 
from the ICM of blastocyst stage embryos. They are a morphologically 
heterogeneous cell type, comprising epithelial-like as well as refractile cells, 
and represent an in vitro model of the primitive endoderm lineage and its 
derivatives, the visceral (VE) and parietal endoderm (PE) (Kunath, 2005). 
They were first derived comparatively recently and express markers of PrE, 
VE and PE, like Pdgfra, Foxa2, Afp, Gata6, Gata4, Sox17 and Sox7 (Kunath, 
2005). However, when injected into blastocysts, XEN cells mainly contribute 
to the parietal endoderm and only rarely to the visceral endoderm. Their 
developmental potential may therefore be biased towards the PE (Brown et 
al., 2010; Kunath, 2005). However, conversion of XEN cells to a visceral 
endoderm-like state is possible through treatment with the transforming 
growth  Nodal or the growth factor-Cripto/FRL-
1/Cryptic co-receptor Cripto as well as with Bmp4, which in vivo are involved 
in the formation and maturation of multiple visceral endoderm derivatives 
(Artus et al., 2011; Julio et al., 2011).  
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Derivation of XEN cells from the blastocyst can be achieved in different 
ways leaning strongly on protocols described previously for ES and TS 
derivation (Kunath, 2005). Accordingly, either blastocyst outgrowths are 
allowed to form in culture similarly to ES and TS cell derivation procedures or 
ICMs are isolated through microsurgery as has been employed for ES cell 
derivations. Both culture conditions, the addition of LIF as for ES cells, or 
FGF4 as for TS cells can successfully be used to derive XEN cells. It will be 
important for future studies utilizing these cells, to establish more 
standardized and optimized protocols that point out modifications to select for 
XEN cell propagation over TS or ES cells in these cultures. 
Additionally it has been shown that treatment of ES cells with retinoic 
acid or formation of embryoid bodies can induce ES cells to trans-differentiate 
into XEN-like cells (Artus et al., 2010; Capo-Chichi et al., 2005; Coucouvanis 
and Martin, 1999; Soprano et al., 2007). Importantly, overexpression of the 
transcription factor Gata6 directs ES cells to a XEN like state, hinting at the 
role of this marker in the formation of the extraembryonic endoderm lineages) 
(Fujikura et al., 2002; Shimosato et al., 2007). 
1.5.  AIMS OF THIS WORK 
Preimplantation development is a tightly timed and regulated process. 
By the time of implantation of the embryo into the uterine wall, the 
extraembryonic lineages, trophectoderm and primitive endoderm, need to be 
properly formed for the embryo to be able to implant and develop. 
Concomitantly, the epiblast has to be specified and prepared to allow ready 
commitment to the somatic tissues upon differentiation cues. The 
establishment of the pluripotent epiblast and the primitive endoderm during 
the second cell fate decision in the mammalian embryo is therefore 
extensively studied. However, an intricate and interdependent network of 
transcription factors and signaling components are involved in the regulation 
of this process and the exact mechanisms of their roles and interactions are 
yet to be elucidated. 
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One potential master regulator for the second cell fate decision, 
GATA6, was reported in discordant roles and the main aim of this work was to 
elucidate its role in the second cell fate decision and its integration with known 
regulatory mechanisms. To this end, we analyzed in detail the Gata6 null 
mutant at preimplantation stages and developed a computational analysis 
pipeline, which enabled us to achieve unbiased, high throughput single cell 
quantitative protein expression measurments. 
The initiation of the second cell fate decision involves progressive 
transition from a homogenous to a heterogeneous cell population. A further 
aim of this work was to gain insights into possible mechanisms that could 
break this symmetry. We therefore analyzed the influence of relative 
transcription factor levels on PrE/EPI cell fate choice as well as their spatial 
expression patterns inside the ICM.  
This cell fate choice between EPI and PrE establishes the pluripotent 
state in vivo. Among the multitude of possible factors influencing the 
emergence as well as the stabilization of the pluripotent epiblast lineage, is 
epigenetic regulation. We specifically set out to determine the possible role of 
DNA demethylation through AID on the pluripotent state, by analyzing its 
influence on iPS reprogramming, as well as ES derivation efficiency. 
To ease future studies on preimplantation development as well as 
studies on ES cells and the multitude of potential applications they hold, we 
further aimed to develop improved and standardized protocols for the 
derivation of XEN and ES cells from mouse blastocysts. 
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SUMMARY
Cells of the inner cell mass (ICM) of the mouse
blastocyst differentiate into the pluripotent epiblast
or the primitive endoderm (PrE), marked by the
transcription factors NANOG and GATA6, respec-
tively. To investigate the mechanistic regulation of
this process, we applied an unbiased, quantitative,
single-cell-resolution image analysis pipeline to
analyze embryos lacking or exhibiting reduced levels
of GATA6. We find that Gata6 mutants exhibit a
complete absence of PrE and demonstrate that
GATA6 levels regulate the timing and speed of line-
age commitment within the ICM. Furthermore, we
show that GATA6 is necessary for PrE specification
by FGF signaling and propose a model where inter-
actions between NANOG, GATA6, and the FGF/ERK
pathway determine ICM cell fate. This study provides
a framework for quantitative analyses of mammalian
embryos and establishes GATA6 as a nodal point in
the gene regulatory network driving ICM lineage
specification.
INTRODUCTION
The first cell differentiation events during mammalian develop-
ment result in the segregation of two extraembryonic lineages,
the trophectoderm (TE) and the primitive endoderm (PrE), from
the pluripotent epiblast (EPI), the founder tissue of most of the
embryo proper (Saiz and Plusa, 2013; Schrode et al., 2013).
These three cell types, found in the late blastocyst, are thought
to arise through two sequential rounds of binary cell fate deci-
sions. In the mouse, the first cell fate decision begins at the 8-
to 16-cell stage, when the morula undergoes compaction and
cells on the surface acquire apicobasal polarity, eventually
becoming TE (Johnson and Ziomek, 1981). The second decision
involves scattered cell differentiation within the inner group of
cells, referred to as the inner cell mass (ICM), followed by cell
sorting, and results in the differentiation of PrE and EPI lineages.
GATA6 andNANOGare the earliest markers of the PrE and EPI
lineages, respectively; however, they are coexpressed in all ICM
cells at the early blastocyst stage (32–64 cells) (Plusa et al.,
2008). As embryos develop, individual ICM cells acquire exclu-
sive GATA6 or NANOG expression in an apparently stochastic
manner, which is thought to reflect the specification of PrE and
EPI fates (Chazaud et al., 2006; Plusa et al., 2008). This process,
proposed to be mediated both by stimulation of the fibroblast
growth factor (FGF)/extracellular signal-regulated protein kinase
(ERK) pathway (Chazaud et al., 2006; Kang et al., 2013a; Kraw-
chuk et al., 2013; Nichols et al., 2009; Yamanaka et al., 2010)
and by reciprocal repression between GATA6 and NANOG
(Singh et al., 2007), results in a salt-and-pepper distribution of
PrE and EPI precursors in the ICM of mid blastocysts (64–100
cells) (Chazaud et al., 2006). This scattered lineage specification
is followed by the sorting of PrE precursors to the surface of the
ICM in the late blastocyst (>100 cells), where they come to form
an epithelium separating the blastocyst cavity and the EPI (Meil-
hac et al., 2009; Plusa et al., 2008; Saiz et al., 2013). However,
the molecular mechanisms and gene regulatory networks gov-
erning the specification of PrE and pluripotent EPI within the
ICM of the early blastocyst are still poorly understood.
In the mouse, FGF signaling is critical for PrE specification
(Chazaud et al., 2006; Goldin and Papaioannou, 2003; Kang
et al., 2013a; Krawchuk et al., 2013; Nichols et al., 2009; Yama-
naka et al., 2010). FGF4 and FGFR2 are reciprocally expressed in
EPI- and PrE-biased cells, respectively. FGF4, produced by EPI-
biased cells (Guo et al., 2010; Ohnishi et al., 2014), has been
proposed to activate the FGF/ERK pathway in neighboring cells,
leading to the downregulation of NANOG and induction of the
PrE program. However, the mechanism has not yet been exper-
imentally addressed. Importantly, single-cell gene expression
profiling studies coupled with the analysis of mutants (Kang
et al., 2013a; Ohnishi et al., 2014) have suggested that FGF
signaling is not required for the initial establishment of the gene
regulatory network (GRN) in ICM cells but is essential for cells
to exit this immature multilineage priming state and differentiate
into EPI or PrE.
GATA6, a member of the GATA family of zinc-finger transcrip-
tion factors, is the earliest PrE marker expressed in the early
mouse embryo (Morrisey et al., 1996). It is first detected at
around the 8-cell stage in all blastomeres, and by the mid
blastocyst (64-cell stage) it is restricted to PrE progenitors
(Chazaud et al., 2006; Plusa et al., 2008). Ectopic expression of
GATA6 in mouse embryonic stem (ES) cells is sufficient to direct
them to a PrE-like state (Artus et al., 2010; Fujikura et al., 2002;
Shimosato et al., 2007). GATA6 therefore likely acts near the
top of the hierarchy regulating PrE development. However, the
position of GATA6 relative to NANOG and the FGF/ERK pathway
in the GRN driving ICM cell fate specification in vivo remains to
be established.
In this study, we have undertaken a quantitative, single-cell-
resolution analysis to understand the process of PrE segregation
from the pluripotent EPI and begin to mechanistically decipher
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the networks in which GATA6 engages to regulate this event. To
investigate the role of GATA6 in ICM development, we have
analyzed a wild-type, heterozygote, and null mutantGata6 allelic
series (Sodhi et al., 2006) using automated nuclear segmentation
(Lou et al., 2014) followed by single-cell-resolution quantitative
three-dimensional (3D) image analyses.
Our results demonstrate that the early spatial pattern of differ-
entiation of PrE versus EPI precursors is stochastic, and that
spatial order emerges gradually at later stages. GATA6 is
required for PrE cell fate specification and for the execution of
the PrE program. Gata6 null mutant embryos lack a PrE entirely,
and exhibit pan-ICM expression of the pluripotency-associated
factors NANOG, OCT4, and SOX2. In Gata6 heterozygotes the
proportion of ICM cells adopting a PrE fate is reduced and their
commitment is decelerated, such that the period of time over
which ICM cells make a PrE fate choice is extended. Exposure
to exogenous FGF4 failed to restore PrE precursors within
Gata6 null mutant embryos, indicating that GATA6 is required
for activation of the PrE program and the concomitant down-
regulation of Nanog induced by FGF4. Collectively, our findings
place GATA6 at the top of the hierarchy regulating PrE
specification.
RESULTS
Cell fate choice is, in large part, determined by the action of key
lineage-specific transcription factors. PrE and EPI lineage spec-
ification within the ICM of the mouse blastocyst appears to be
undertaken in a stochastic manner. A sequence of events
involving lineage specification and subsequent positional segre-
gation has been defined. It involves the initial coexpression of
factors within all ICM cells and progressive restriction of gene
expression to lineage precursors, followed by a combination of
cell sorting and cell death to refine their position (Artus et al.,
2013; Chazaud et al., 2006; Gerbe et al., 2008; Meilhac et al.,
2009; Plusa et al., 2008). Within this emergent mechanistic
framework, GATA6 is the earliest expressed PrE-specific tran-
scription factor, whereas NANOG is the earliest expressed
EPI-specific transcription factor. However, these factors are
initially coexpressed within the ICM and so are only markers
once they become mutually exclusive, and thus this initiation
and transition in marker localization are likely to be key to under-
standing the establishment of respective PrE and EPI fates.
A Pipeline for Single-Cell-Resolution Quantitative
Analysis of Expression and Position: Progressive
Distribution of GATA6 and NANOG
A rigorous mechanistic understanding of how single cells can
operate coordinately to produce global effects relies onmethods
to resolve single-cell-resolution information in the context of a
population. Thus far, attempts at single-cell analysis of cell fate
decisions in preimplantation mammalian embryos have been
hindered by time-consuming manual data processing at a small
scale. To decipher the details of the GRN operating within the
ICM, we assembled an unbiased single-cell-resolution analysis
pipeline. This pipeline comprised software specifically devel-
oped for automated nuclear segmentation of 3D image data of
mouse preimplantation-stage embryos (Lou et al., 2014),
followed by quantitative fluorescence and spatial data analyses.
The highly accurate segmentation afforded by our pipeline facil-
itates single-cell-resolution, large-scale comparisons of protein
concentrations represented by fluorescence intensities after
immunostaining and confocal imaging (Figure 1A). In this way,
an analysis could be undertaken at the level of the entire ICM,
taking into account all cells within each embryo analyzed.
A Method for Unbiased Assignment of Cell Fate
We performed immunohistochemistry using antibodies directed
against GATA6 and NANOG proteins on wild-type embryos
at several successive stages. As expected, wild-type morulae
and early blastocysts exhibited coexpression of GATA6 and
NANOG, which resolved in a mutually exclusive expression
pattern at the mid blastocyst and in sorted lineages by the late
blastocyst (Figures 1B and 2A). Applying our segmentation
pipeline, we extracted fluorescence intensities of GATA6 and
NANOG in each nucleus, estimated nuclear concentration
by subtracting background fluorescence, and corrected for
attenuation of fluorescence signals by tissue depth. Analysis of
nuclear concentrations as a function of stage (32–64 cells, 64–
128 cells, and >128 cells) revealed that at the early stage most
cells expressed high levels of both GATA6 and NANOG. At the
64- to 128-cell stage, however, most cells expressed either
high GATA6 and low NANOG or vice versa. At the last stage
analyzed, all cells were either GATA6 positive and NANOG
negative or NANOG positive and GATA6 negative (Figures 1B
and 1C). We used the nuclear concentrations at this stage to
empirically deduce a range over which cells could be defined
as either EPI or PrE. This procedure provided an unbiased,
reproducible, and quantitative method to assign fates to each
cell of any given embryo. It allowed us to assign cell fate
(Figure 1D), based on the automatic threshold procedure we
developed (Figure 1B), in the absence of arbitrary factors, such
as human user error.
The Early Spatial Pattern of Differentiation of PrE versus
EPI Precursors Is Stochastic, whereas Spatial Order
Emerges Gradually at Later Stages
We analyzed the pattern of emergence of cell differentiation to
determine the importance of stochastic effects versus cell-cell
communication or positional effects. We sought to determine
whether there are spatial correlations between the fates of cells
and/or the expression of NANOG and GATA6. Such correlations
would suggest that cell-cell interaction/communication or
position within the embryo plays a prominent role in early differ-
entiation. Alternatively, a lack of correlation would suggest that
stochastic, cell-autonomous processes are themain initial deter-
minants of fate choice. To distinguish between these two
scenarios, we computed the Pearson’s correlation coefficient
as a function of cell-cell distance. The coefficient measures the
strength of the relationship between two variables (for example,
cell fates). The coefficient can assume values between 1
(a perfect negative relationship) and 1 (a perfect positive relation-
ship). A correlation coefficient of 0 implies that the two variables
are independent, so that the status of one variable does not
inform the status of the other. To compute the correlation coef-
ficient, we binned data based on cell-cell distance choosing
bin sizes of about 10 mm, an estimate of cell diameter, ensuring
several data points present in each bin.
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Figure 1. Quantitative Analysis of GATA6 and NANOG Expression
(A) Image data-processing pipeline incorporating MINS software.
(B) Nuclear concentration of GATA6 andNANOGat different stages. Blue and red lines show the threshold function used to define cells as PrE and EPI precursors,
respectively. Cells that do not fall into either group are coexpressing NANOGandGATA6, and are classified as DP (double-positive, uncommitted ICM) cells. a.u.,
arbitrary units.
(C) Probability density of normalized NANOG concentration minus normalized GATA6 concentration (<Ng> and <G6> indicate the average concentrations of
NANOG and GATA6, respectively). Earliest stage (defined by total cell number) cells express both GATA6 and NANOG (unimodal distribution), but at the ‘‘salt-
and-pepper’’ stage, cells are either GATA6 positive or NANOG positive, resulting in a bimodal distribution.
(D) Correlation coefficient of cell fates and levels of GATA6 and NANOG as a function of cell-cell distance for three different stages. Correlation = 0, cells are
making their fate choice independent of other cells, and no fate prediction can be made; correlation = 1, certain prediction that cells with close distance are alike;
correlation = 1, certain prediction that cells with close distance are unalike. Error bars represent standard errors, estimated using Fisher transformation.
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Cell fates (EPI, PrE, or undifferentiated ICM) were assigned in
an automatic unbiased fashion (Figure 1B). We computed the
correlation coefficient as a function of distance for differentiated
cells (i.e., EPI and PrE), with undifferentiated cells excluded from
the calculation. We found that at the earliest stage (32–64 cells)
there was no correlation in the spatial pattern of cell differentia-
tion (Figure 1D), as expected for a random cell-autonomous de-
cision (Figure S1A available online). Consistently, the position of
cells that differentiated early was independent of the embryo’s
coordinates, such as distance from the blastocyst cavity (Fig-
ure S1B). This random pattern of early differentiation likely
reflected a lack of spatial correlation in the levels of NANOG
and GATA6 at this stage (measured across all cells), and sug-
gested that the earliest stages of cell specification are dominated
by cell-autonomous stochastic factors. At the salt-and-pepper
stage (64–128 cells), a pattern of correlation began to emerge
in both cell fate and NANOG and GATA6 levels, so that adjacent
cells had a slightly positive chance of exhibiting the same fate
(Figure 1D). This could, in principle, originate from the previous
uncorrelated pattern, if cells retained similar expression levels
and/or fate upon division. At the last stage analyzed (>128 cells),
after cells had sorted, a clear spatial correlation was present
between cell fates and the levels of both GATA6 and NANOG
(Figure 1D). Importantly, the dependency of the correlation coef-
ficient on cell-cell distance at this stage was similar to that
expected, given the geometry of the embryo and sorted cell fates
(see the comparison between a ‘‘virtual’’ embryo and our data;
Figure S1). Collectively, these results are consistent with amodel
in which the earliest steps of cell differentiation are dominated by
stochastic fluctuations of NANOG and GATA6, which later
resolve into a clear spatial pattern as a result of cell sorting.
Finally, we observed that the correlation in NANOG was slightly
lower than for GATA6 (many EPI cells at the >128-cell stage were
already downregulating NANOG expression), probably as a
result of its highly transient expression and its extinguishment
coincident with embryo implantation.
Gata6 Mutants Exhibit Pan-ICM NANOG Expression
GATA6, like NANOG, is initially expressed by all ICM cells, but
thereafter becomes exclusive to the PrE (Plusa et al., 2008). An
antagonistic interaction of GATA6 with NANOG has been
proposed to be at the core of the GRN regulating PrE versus
EPI specification (Frankenberg et al., 2011). Thus, we hypothe-
sized that if GATA6 acts near the top of the hierarchy regulating
PrE cell fate specification, its elimination must cause a profound
defect in lineage specificationwithin the ICM.We therefore deter-
mined the phenotype arising from the complete loss, as well as
reduction, of GATA6 inGata6/mutants andGata6+/ heterozy-
gotes, respectively. By contrast to wild-type stage-matched
embryos, Gata6/ embryos expressed NANOG starting at the
8-cell stage in all cells, and thereafter throughout the ICM (Fig-
ure 2A). Notably, GATA6was not detected at any stage analyzed,
indicating that the allele is a protein null and that the zygotic abla-
tion of Gata6 produces no protein, and suggesting no maternal
mRNA is transcribed and/or translated into detectable protein
(Figure 2A). To compound this observation, we analyzed Gata6
maternal zygotic mutant embryos. These exhibited an equivalent
phenotype to Gata6 zygotic mutant embryos, referred to as
Gata6/ throughout the text (Figure S2A).
BecauseGata6mutant embryos have been reported as exhib-
iting a defect at postimplantation stages, affecting the cardiac
mesoderm or visceral endoderm (Koutsourakis et al., 1999;
Morrisey et al., 1996), we collected embryos fromGata6+/ inter-
crosses at embryonic day (E)5.5. We failed to recover any
Gata6/ embryos among a total of 42 embryos obtained from
seven litters at E5.5 (Table S1). Immunofluorescence revealed
that both wild-type and heterozygous embryos exhibited a
normal morphology, with a GATA4-positive visceral endoderm
layer (Figure S2B). The apparent discrepancy between our
observation of a preimplantation defect, which never gave rise
to egg cylinder-stage embryos, and previous studies reporting
early postimplantation defects could be attributed to allele- or
strain-specific differences (Koutsourakis et al., 1999; Morrisey
et al., 1996).
Cells in Gata6 Mutant ICMs Do Not Upregulate NANOG
Expression
Previous studies have proposed that GATA6 and NANOG
function, at least in part, throughmutual repression (Frankenberg
et al., 2011; Singh et al., 2007). Such a mutual antagonism could
explain the mutually exclusive expression of markers and the
salt-and-pepper distribution of cells committed to PrE versus
EPI lineages. In accordance with such a model of mutual repres-
sion, the absence of GATA6 could relieve Nanog from GATA6-
mediated repression and result in elevated levels of NANOG.
To determine whether this is the case in vivo, we quantified
protein levels in all cells of wild-type, Gata6+/, and Gata6/
embryos by measuring fluorescence intensities after immuno-
staining and confocal imaging using the analysis pipeline we
constructed (Figure 1A).
Levels of NANOG protein were not elevated in the ICM cells of
Gata6/ embryos (n = 364 cells/12 embryos), compared to
NANOG-positive ICM cells in Gata6+/ or wild-type embryos
(n = 476 cells/25 embryos and n = 323 cells/17 embryos, respec-
tively) (Figure 2B), suggesting that some distinct or additional
mechanism must control NANOG levels within the ICM in vivo.
Interestingly, we noted that in wild-type embryos, the levels of
NANOG exhibited a broad dynamic range in the early blastocyst
but became more homogeneous as development proceeded,
accompanying the maturation of the EPI lineage (Figure 2B).
By contrast, Gata6/ embryos exhibited a decreased dynamic
range of NANOG levels earlier, which was comparable to that
observed in mature EPI cells in wild-type late blastocysts. These
data therefore suggest that in the absence of GATA6, all ICM
cells prematurely commit to an EPI fate.
GATA6 Is Involved in NANOG Repression in TE Cells
In addition to pan-ICM expression of NANOG, we also noted a
significantly increased number of NANOG-positive cells in the
TE ofGata6/ embryos compared to wild-type embryos at early
and mid blastocyst stages, which appeared to recover by the
late blastocyst stage (Figure 2C). These findings suggest that
GATA6 functions, at least in part, to actively repress NANOG in
TE cells. TE cells ectopically expressing NANOG also coex-
pressed TE markers such as CDX2, GATA3, and EOMES (Fig-
ure 2C). These TE cells appeared morphologically normal, and
blastocyst outgrowths of Gata6/ embryos showed expansion
of the TE and differentiation of trophoblast giant cells
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Figure 2. NANOG Is Expressed Ectopically in Gata6 Mutants
(A) Localization and distribution of NANOG (white) and GATA6 (red) in wild-type (Gata6+/+) and Gata6mutant mouse embryos from the morula to late/implanting
blastocyst stage. Blue in merge: Hoechst. The scale bars represent 20 mm. c, cells.
(legend continued on next page)
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(Figure S2C). Additionally, although postimplantation Gata6/
embryos could not be recovered, we noted Mendelian ratios of
empty implantation sites in uteri dissected after E5.5. Collec-
tively, these data suggest that, despite the ectopic expression
of NANOG, the TE is functional in Gata6/ embryos.
The PrE Lineage Is Not Specified in the Absence of
GATA6
PrE formation is accompanied by the sequential activation of a
number of factors regulating cell fate specification, proliferation,
and polarity, such as PDGFRA, SOX17, and GATA4, among
others (Artus et al., 2011; Gerbe et al., 2008; Kurimoto et al.,
2006; Morris et al., 2010; Niakan et al., 2010; Plusa et al.,
2008; Saiz et al., 2013). Having determined that Gata6 mutants
exhibit pan-ICM NANOG expression, we wanted to investigate
whether the PrE program is activated in the absence of
GATA6. To this end, we determined the expression of these
secondary PrE markers in Gata6+/+, Gata6+/, and Gata6/
embryos. Embryos lacking GATA6 failed to activate Pdgfra
expression, as assessed in Gata6/; PdgfraH2B-GFP/+ embryos
(Movie S1), and exhibited no SOX17 (n = 13 embryos) or
GATA4 (n = 4 embryos) expression at either mid (64–100 cells)
or late blastocyst (>128 cells) stages (Figure 3A).
At the late blastocyst stage, PrE cells polarize and form an
epithelium (Smyth et al., 1999). Markers of apicobasal polarity,
including aPKC and DAB2, become localized to the apical
surface of PrE cells, revealing their progressive epithelial matura-
tion (Gerbe et al., 2008; Saiz et al., 2013). By contrast to wild-type
embryos, we found thatGata6mutants failed to apically express
both aPKC and DAB2 (Figure 3A), indicating that their ICM cells
not only failed to upregulate PrE markers but also were unable to
form an epithelium, one of the defining features of the PrE (Saiz
et al., 2013).
Because all ICM cells in Gata6/ embryos expressed
NANOG, we assessed whether ICM cells in these embryos
adopted an EPI identity in the absence of GATA6. We found
that the pluripotency-associated factors SOX2 and OCT4 were
expressed in all ICM cells in Gata6/ embryos at all blastocyst
stages, whereas they were restricted to the EPI in control
Gata6+/+ or Gata6+/ late blastocysts (Figure 3B), thus suggest-
ing that all ICM cells had acquired EPI identity in the absence of
GATA6.
Of note, in 9 out of 20 Gata6/ blastocysts analyzed, we
identified between 1 and 3 cells on the surface of the ICM, out
of a total of between 15 and 40 cells, that did not express
NANOG, and thus were GATA6/NANOG double negative. Sur-
prisingly, these cells expressed the TEmarker CDX2 (Figure 3C),
which could suggest that in the absence of both NANOG and
GATA6, ICM cells might acquire an alternative cell fate resulting
in their upregulation of TE markers such as CDX2 if positioned
adjacent to the blastocyst cavity. However, when embryos
were allowed to develop in vitro this cell population did not
expand over time, suggesting that CDX2-positive GATA6/
NANOG-negative cells were either transient or the result of
delayed CDX2 downregulation in some ICM cells, although the
latter might also be expected to be CDX2/GATA6 and/or
NANOG positive.
One mechanism to ensure balanced lineage representation
and proper allocation of progenitors within the ICM of the blasto-
cyst is apoptosis (Plusa et al., 2008; Artus et al., 2013). To deter-
mine whether the lack of PrE cells was due to selective apoptosis
at an early stage or to a cell fate switch, we calculated the
average total cell number per embryo and the relative distribu-
tion of cells to the TE and ICM compartments. We noted that
neither embryo size nor relative ICM size differed significantly
between wild-type (n = 17) and Gata6/ embryos (n = 12) at
any stage (Figures 3D and 3E), suggesting there was no increase
in cell death in the absence of GATA6.
Collectively, our data demonstrate that, in the absence of
GATA6, ICM cells failed to adopt a PrE fate, and a PrE epithelial
layer was altogether absent. Absence of GATA6 results in
absence of the PrE lineage coupled to acquisition of EPI fate.
GATA6 Levels Influence Both the Timing and Frequency
of PrE Cell Specification
BecauseGATA6 is necessary for PrE specification, wewanted to
explore whether the amount of GATA6 protein present in individ-
ual ICM cells has any influence on their fate choice. To address
this question, we quantified PrE and EPI cell numbers as well as
GATA6 expression levels in wild-type and Gata6+/ embryos.
Quantification of fluorescence intensity levels revealed a signifi-
cant reduction in GATA6 protein in Gata6+/ PrE cells (n = 444
cells/25 embryos) compared to wild-type cells (n = 470 cells/
17 embryos) (Figure 4A).
Interestingly, Gata6+/ embryos displayed coexpression of
GATA6 and NANOG within a subpopulation of ICM cells until
later stages than wild-type embryos (Figure 4B), suggesting
that cell fate specification is delayed or less abrupt when
GATA6 levels are reduced. To distinguish between these two
scenarios, and to further characterize the effects of reduced
levels of GATA6 on the dynamics of cell fate specification, we
quantified the frequency of PrE and EPI cells as a function of
cell number. This analysis revealed that in wild-type embryos
the specification of both EPI and PrE cells occurs over a short
period of time (until 100-cell stage). In Gata6+/ embryos,
specification of PrE cells was significantly retarded, indicating
that wild-type GATA6 levels are required for rapid commitment
to PrE cell fate (Figure 4C). Interestingly, specification of the
EPI exhibited a similar abruptness, but it occurred at a slightly
earlier time (Figure 4C). As a consequence of the slow commit-
ment of PrE cells, undifferentiated ICM cells were observed
at later stages than in wild-type embryos (Figures 4B and 4C).
Furthermore, the number and proportion of PrE cells in Gata6+/
embryos were significantly reduced (n = 17) compared to
(B) Distribution of NANOG protein levels as measures of logarithm-transformed fluorescence intensity of each EPI cell (upper panel) and averaged for each
embryo (lower panel) in NANOG-positive ICM cells of Gata6+/+, Gata6+/, and Gata6/ embryos of the stages indicated. Data are represented as Tukey box
plots. ns, not significant.
(C) Localization and distribution of NANOG (white) and TEmarkers GATA3, CDX2, and EOMES (green) inGata6mutant embryos at early, mid, and late blastocyst
stages (upper panel). Percentage of NANOG-positive cells in the TE of Gata6+/+ and Gata6/ embryos at early, mid, and late blastocyst stages (lower panel).
Error bars represent standard errors. Asterisks indicate statistical significance: *p < 0.05.
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wild-type embryos (n = 25), whereas the number of EPI cells was
increased (Figure 4B). Collectively, these data indicate that
GATA6 protein concentration is important for PrE fate specifica-
tion, and that a reduction leads to a deceleration in the rate of PrE
fate specification as well as a reduction in the number of cells
adopting a PrE fate within the ICM. Because Gata6+/ animals
were viable, this reduction in the number of PrE cells did not
appear to affect the function of the PrE lineage. It is possible
that PrE cell numbers either recovered at postimplantation
stages or that the PrE might tolerate cell number variability.
FGF Signaling Is Not Sufficient to Direct PrE
Specification in the Absence of GATA6
There is increasing evidence that differential activation of the
FGF/mitogen-activated protein kinase pathway in individual
ICM cells determines EPI or PrE cell fate choice in mice
(Chazaud et al., 2006; Nichols et al., 2009; Yamanaka et al.,
2010). Our experiments have revealed a failure in PrE cell
specification in Gata6/ embryos, a phenotype that resembles
that observed in mutants in which FGF signaling components
have been perturbed (Chazaud et al., 2006; Kang et al.,
2013a; Krawchuk et al., 2013) or in wild-type embryos
treated with inhibitors of FGF signaling (Nichols et al., 2009;
Yamanaka et al., 2010). In our previous analysis of Fgf4
mutant embryos, we noted that GATA6 expression was initi-
ated at the early blastocyst stage but failed to be maintained
in the absence of FGF4, resulting in a lack of PrE cells (Kang
et al., 2013a).
To determine the relative positions of FGF signaling and
GATA6 in the hierarchy governing PrE specification, we treated
Figure 3. PrE Cannot Be Specified in the Absence of GATA6
(A) Localization and distribution of PrE markers SOX17 and GATA4 and epithelial markers DAB2 and aPKC (red) in wild-type (Gata6+/+) andGata6/ embryos at
the 64- to 128-cell and >128-cell stage, respectively. Blue in merge: Hoechst.
(B) Localization and distribution of EPI markers OCT4 and SOX2 (white) in wild-type (Gata6+/+) andGata6/ embryos at the >128-cell stage. OCT4 staining in TE
cells is cytoplasmic. Dashed yellow lines indicate the PrE layer. Blue in merge: Hoechst.
(C) Localization and distribution of NANOG (white) and CDX2 (green) in Gata6 mutant mouse embryos at the 64- to 128-cell stage. Arrowheads indicate CDX2-
expressing cells in the ICM.
(D) Average number of total cells in Gata6+/+ and Gata6/ embryos at early, mid, and late blastocyst stages. Error bars represent standard errors.
(E) Cell composition inGata6+/+,Gata6+/, andGata6/ embryos at the stages indicated. Cell numbers are shown as percentages of the total number of cells per
embryo.
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Gata6/ embryos with saturating doses of FGF, which have
been previously shown to induce a PrE identity throughout
the ICM in wild-type embryos (Yamanaka et al., 2010) and
Fgf4 mutants (Kang et al., 2013a). Because timed treatments
have revealed variations in the sensitivity to FGF signaling
through preimplantation development (Frankenberg et al.,
2011; Grabarek et al., 2012; Yamanaka et al., 2010), we used
two regimes in a parallel set of experiments (Figures 5A and
6A). First, we applied exogenous FGF for 48 hr starting at
E2.5 (8- to 16-cell stage), prior to the initiation of any differ-
entiation, when NANOG and GATA6 are coexpressed (Fig-
ure 5A). Gata6/ embryos failed to respond to doses of
between 500 and 1,000 ng/ml of either FGF4 (Figures 5A and
5B) or FGF2 (Figure S3). They maintained NANOG expression
throughout the ICM, with levels comparable to those of
untreated embryos (Figures 5B and 5D). By contrast, wild-
type embryos displayed pan-ICM GATA6 or SOX17 expression
and complete absence of NANOG expression (Figures 5B–5D),
as previously described (Saiz et al., 2013; Yamanaka et al.,
2010). Gata6+/ embryos exhibited a comparable response to
wild-type embryos, although some cells expressing NANOG
could be identified (Figure 5C), suggesting that the kinetics of
the effect produced upon FGF treatment was altered by a
reduction in the dose of GATA6. FGF treatment also failed to
induce expression of later PrE markers, such as SOX17, in
Gata6/ embryos (Figure 5B).
Collectively, these data led us to hypothesize that whereas
FGF4 acts as an instructive signal to activate the PrE program,
GATA6 is necessary to execute it. Thus, in the absence of
GATA6, FGF treatment of embryos fails to activate the PrE
program. Alternatively, Gata6/ embryos may exhibit aberrant
expression of FGF receptors on their ICM cells and fail to mount
a response to an FGF signal.
ERK Inhibition Promotes NANOG Upregulation in the
Absence of GATA6
Upon FGF/ERK stimulation of wild-type E2.5 embryos, NANOG
is repressed and GATA6 is activated in all ICM cells (Yamanaka
et al., 2010). If GATA6 were the factor directly mediating NANOG
repression upon FGF/ERK stimulation, we would hypothesize
that inhibition of the pathway in Gata6/ embryos would have
no effect on NANOG expression compared to untreated,
Gata6/ embryos. Culture in the presence of 1 mM ERK1/2
inhibitor PD0325901 (Nichols et al., 2009) resulted in a marked
upregulation of NANOG throughout the ICM in all embryos,
regardless of their genotype (Figure 5D). These data indicate
that, whereas GATA6 is necessary for NANOG downregulation,
an additional ERK1/2-mediated mechanism operates to main-
tain NANOG levels within EPI cells.
Collectively, these results demonstrate that GATA6 is neces-
sary to cell-autonomously mediate FGF/ERK signaling up-
stream of ERK1/2, which in turn mediates NANOG repression.
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Figure 4. Protein-Level Analysis Reveals Dosage Effect in Gata6+/– Embryos
(A) GATA6 protein levels as measures of logarithmically transformed fluorescence intensity in GATA6-positive ICM cells ofGata6+/+ andGata6+/ embryos at the
indicated stages. Data are represented as Tukey box plots.
(B) ICM composition in Gata6+/+, Gata6+/, and Gata6/ embryos. Cell numbers are shown as percentages of total ICM number. PrE: GATA6+; DP: NANOG+,
GATA6+; EPI: NANOG+. Asterisks indicate statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001.
(C) Frequency of cell fate specification as a function of cell number for undifferentiated ICM (DP) cells, EPI precursors, and PrE precursors. Probability functions
were estimated by logistic regression. Shaded areas show 95% confidence intervals (upper panel). Data points were fitted using logistic regression. Error bars
represent standard deviation estimated using binomial distribution. p values were computed using the c2 test. PrE induction is slower (p < 105) and loss of ICM is
also slower (p < 104), whereas induction of EPI is faster (p = 0.01).
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Furthermore, the effects of ERK inhibition reveal a distinct
role for FGF signaling in EPI cells, potentially acting to inhibit
levels of NANOG so as to maintain them within a physiological
range.
Modulation of FGF Signaling Cannot Induce an ICM Fate
Switch after PrE and EPI Specification
Next, we cultured embryos in the presence of FGF4 for 24 hr
from E3.5 (early-to-mid blastocyst stage), when PrE and EPI
specification has already begun (Figure 6A). By contrast to
FGF4 treatment experiments from E2.5, exposure to 500 ng/ml
of FGF4 from E3.5 did not result in pan-ICM expression of
GATA6 in either wild-type or Gata6+/ embryos (Figures 6B
and 6C). Although we did observe a moderate expansion of
the PrE compartment, most wild-type embryos retained a
NANOG-positive population (Figure 6C). Similarly, Gata6/
embryos exhibited no reduction in the size of the NANOG-
positive compartment upon FGF4 treatment (Figures 6B and
6C). We observed a proportion of ICM cells that expressed
neither NANOG nor PrE markers (GATA6 or SOX17), regardless
of their genotype (triple negative). This population, albeit larger in
Gata6+/ and Gata6/ embryos, did not change significantly
upon FGF treatment, suggesting it resulted from developmental
downregulation of NANOG as the EPI matures, rather than a
consequence of FGF treatment.
In agreement with these results, we observed that inhibition of
ERK1/2 at E3.5 with 1 mM PD0325901 did not result in down-
regulation of GATA6 in wild-type or Gata6+/ embryos, as pre-
viously described (Nichols et al., 2009). On the other hand,
consistent with our previous observations from incubations initi-
ated at E2.5, ERK1/2 inhibition resulted in upregulation of
NANOG throughout the EPI regardless of embryo genotype
(Figure 6B).
These results suggest that desensitizing cells to FGFmay be a
mechanism operating to prevent changes in ICM lineage
composition upon sustained FGF production. Such a model is
supported by the fact that XEN stem cells, which represent the
primitive endoderm lineage, can be derived from Fgf4 mutants,
demonstrating a temporally restricted requirement for FGF/
ERK signaling within the PrE lineage (Kang et al., 2013b).
The Induction of Gata6 Expression Is Independent of
NANOG Repression
It has been proposed that NANOG directly repressesGata6 (Mit-
sui et al., 2003; Singh et al., 2007) and that downregulation of
NANOG through FGF signaling alleviates Gata6 suppression,
leading to its upregulation and differentiation of cells toward a
PrE fate. It has been shown in embryonic stem cells (ESCs)
that activation of FGF/ERK signaling directly represses Nanog
transcription (Santostefano et al., 2012). To test whether this
Figure 5. FGF4 Is Not Sufficient to Direct PrE Specification in the Absence of GATA6, whereas ERK Inhibition Results in NANOGUpregulation
(A) Experimental timeline.
(B) Representative immunofluorescence images of Gata6+/+ and Gata6/ embryos cultured from the morula (E2.5) stage for 48 hr in culture medium alone
(untreated), medium + 1 mg/ml FGF4 + 1 mg/ml heparin (+FGF4), or medium + 1 mM PD0325901 (+ERKi). Blue: Hoechst; white: NANOG; red: SOX17. Scale bars
represent 20 mm.
(C) ICM composition in Gata6+/+, Gata6+/, and Gata6/ embryos after culture as in (A). Cell numbers are shown as percentages of the total ICM number. TN,
triple negative for NANOG, PrE marker, and CDX2.
(D) Fluorescence levels of NANOG as the measure of the average per embryo in Gata6+/+, Gata6+/, and Gata6/ ICMs after culture as in (A). Data are rep-
resented as Tukey box plots. Asterisks indicate statistical significance: **p < 0.01, ***p < 0.001. ns, not significant.
(E) RT-PCR on Gata6+/+ and Gata6/ ESCs after 48 hr culture in standard LIF-containing medium (+LIF), after LIF withdrawal (LIF), and in the presence of
250 ng/ml FGF (+FGF).
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downregulation of NANOG leads to an upregulation of Gata6 or
whether FGF signaling can directly influence Gata6 expression,
we derived Gata6+/+ and Gata6/ ESCs (Czechanski et al.,
2014) and analyzed gene expression after culture in the presence
of FGF. Whereas undifferentiated Gata6+/+ and Gata6/ ESCs
cultured in leukemia inhibitory factor (LIF) exhibited little or no
expression of Gata6, Gata6 transcripts were detected in
Gata6+/+ and Gata6/ ESCs maintained in the presence of
FGF (Figure 5E). As a control, Gata6+/+ and Gata6/ ESCs
were also allowed to differentiate in the absence of LIF and
without addition of FGF. These cells exhibited an upregulation
of Gata6 comparable to cells treated with FGF. These data
suggest that Gata6 is activated upon differentiation of ESCs in
a GATA6-independent manner. Additionally, the absence of a
downregulation of Nanog in the absence of GATA6 (Figures 5D
and 5E) suggests that, if FGF signaling is involved in the upregu-
lation of Gata6, it does so directly and independent of NANOG
repression. However, because Gata6 was detected both in the
presence and absence of FGF, we were unable to exclude the
possibility that this repression occurred independently of FGF
signaling.
DISCUSSION
With the aim of obtaining unbiased quantitative information on
individual cells to understand how they direct the behavior of a
population within early mammalian embryos, we developed a
pipeline involving single-cell-resolution, quantitative immuno-
fluorescence image analysis, coupled with Cartesian coordinate
information of cellular position. This allowed us to account for
how the salt-and-pepper distribution of emergent PrE and EPI
lineage progenitors arises within the ICM of the mouse blasto-
cyst. The method we developed extends previous findings using
single-cell microarray-based expression analyses (Ohnishi et al.,
2014), as it also incorporates positional information for individual
cells. Our results suggest that the early pattern of cell differenti-
ation is purely stochastic, andmight be dominated by cell-auton-
omous noisy expression of NANOG and GATA6. Following this
initial phase, order starts to emerge, most likely as the result
of cell division, cell motility, and the acquisition of apicobasal
polarity (Gerbe et al., 2008; Meilhac et al., 2009; Saiz et al.,
2013) as well as apoptosis of misplaced cells (Artus et al.,
2013; Plusa et al., 2008). In future studies, it will be important
to determine whether the early stochastic differentiation is
propagated to later stages, or whether corrective feedback
mechanisms operate to ensure that the embryo ends up with
the correct number of EPI and PrE progenitors, despite an early
phase of stochastic differentiation.
The distribution of lineage progenitors is reflected by the
expression of the key lineage-specific transcription factors
GATA6 and NANOG. Because it is the earliest expressed PrE
factor, we reasoned that GATA6 might be responsible for direct-
ing ICM cell fate choice. To gain insight into the mechanisms
driving cell fate decision away from pluripotency, we analyzed
embryos exhibiting a reduction (heterozygotes) or absence
(null mutants) of Gata6. Our studies reveal a strict GATA6 dose
dependence in both the rate and probability of PrE specification
within the ICM, which is manifest as a reduction in PrE cells in
Gata6 heterozygotes and an absence of a PrE lineage in Gata6
mutants. The phenotype observed in Gata6 mutants appears
more specific, and more severe, with respect to the ICM than
mutants in FGF signaling components, such as Fgf4, which
also exhibit a lack of PrE (Kang et al., 2013a). By contrast to
Gata6 mutants, which fail to activate any PrE markers, Fgf4
mutants initially express but fail to maintain GATA6, as well as
later PrE-specific factors, such as PDGFRA (Artus et al., 2010;
Kang et al., 2013a; Plusa et al., 2008). Furthermore, and unlike
Gata6 mutants, Fgf4 mutant embryos exhibit a reduction in em-
bryo cell number, as well as defects in the TE, due to a mitogenic
role of FGF/ERK signaling in this lineage (Kang et al., 2013a).
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Figure 6. Changes in FGF Signaling Cannot Induce Cell Fate Switch after PrE and EPI Specification
(A) Experimental timeline.
(B) Representative immunofluorescence images of Gata6+/+ and Gata6/ embryos cultured from the salt-and-pepper (E3.5) stage for 24 hr in medium without
(untreated) or with 500 ng/ml FGF4 + 1 mg/ml heparin (+FGF4) or medium + 1 mM PD0325901 (+ERKi). Blue: Hoechst; white: NANOG; red: GATA6. Scale bars
represent 20 mm.
(C) Percentages of embryos falling into one of five FGF-response categories: 0% EPI, 1%–20% EPI, 21%–40% EPI, 41%–60% EPI, and >60% EPI in ICMs of
embryos treated as in (A).
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Although Gata6 mutants display ectopic expression of NANOG
in TE cells, this did not appear to impair TE function. Rather, it
suggests that GATA6 may be involved in the repression of
NANOG in these cells. Interestingly, the mechanism by which
this happens appears to be distinct from that in ICM cells,
because Fgf4 mutant embryos exhibit expression of NANOG in
the TE (Kang et al., 2013a), suggesting this process is indepen-
dent of FGF signaling.
All cells within Gata6 mutant ICMs express the pluripotency-
associated factors NANOG, SOX2, and OCT4 at all blastocyst
stages. Indeed, NANOG has been proposed to interact with
GATA6 in a mutually repressive manner (Frankenberg et al.,
2013). In the absence of GATA6-mediated repression, one might
predict an increase in NANOG levels. However, NANOG levels
were not observed to increase in Gata6 mutant embryos, sug-
gesting that GATA6 itself may be regulating the on/off switch
of NANOG, rather than fine-tuning its expression. On the other
hand, NANOG expression was decreased and its range was
narrowed earlier in Gata6/ than in Gata6+/+ ICM cells (64- to
128-cell stage, compared to >128-cell stage). NANOG levels
therefore appeared more comparable to mature EPI cells
observed in late blastocyst-stage wild-type embryos. We spec-
ulate that the absence of GATA6 does not necessarily result in a
novel ICM cell type; rather, cells maintain NANOG levels compa-
rable to those of mature EPI cells of wild-type embryos, where
GATA6 is repressed without a concomitant increase in NANOG
levels. One could argue that cells in Gata6/ early ICMs are
less plastic than cells in stage-matched wild-type ICMs, and
so may already be committed to an EPI fate. Relative, rather
than absolute, protein concentrations in any given cell might
ensure this, and one might envisage a scenario in which
GATA6 and NANOG, acting through mutual repression, maintain
an equilibrium that restrains cells from committing to either EPI
or PrE fate until an appropriate time. At some point the balance
is stochastically disturbed, disequilibrium ensues, and one of
these two factors predominates. This event drives the onset of
cell lineage choice and commitment to PrE or EPI fates. In
Gata6/ embryos, this initial balance of transcription factors is
never established, and consequently all ICM cells prematurely
differentiate to a mature EPI state.
In heterozygous embryos, GATA6 protein levels were reduced
compared to stage-matched wild-type embryos. Indeed,
Gata6+/ embryos exhibited a significantly lower number of
PrE cells and a slower commitment, so that at later stages
more GATA6/NANOG double-positive (DP) ICM cells were
observed in an uncommitted (NANOG+;GATA6+) state. The
commitment to an EPI fate appeared slightly faster, although
more data are required to confirm this hypothesis.
Given these data, the GRN driving ICM lineage choice can be
subject to geometric reasoning (Corson and Siggia, 2012). Our
observations are compatible with a simple geometric model of
cell differentiation (Waddington landscape). We propose that
GATA6 and NANOG mutual repression generates a system
with two stable states (valleys): NANOG-positive;GATA6-nega-
tive and NANOG-negative;GATA6-positive. Stochastic fluctua-
tions in the levels of GATA6 and NANOG push the cells toward
one or the other fate. The time required to reach a stable state
is controlled by how much the relative levels of the two factors
deviate from the unstable region in which cells remain DP (Fig-
ure 1B) ICM (the peak in the landscape). In the absence of
GATA6 the landscape changes, so that the only stable state is
the NANOG-positive;GATA6-negative state, which should,
therefore, display similar levels of NANOG to wild-type EPI cells.
In Gata6+/ embryos, levels of GATA6 are reduced and, there-
fore, a higher number of cells end up in the EPI state, as a result
of the relatively higher levels of NANOG compared to GATA6. In
cells in which levels of GATA6 are still sufficient to drive the PrE
fate, the GATA6:NANOG ratio should be reduced and, therefore,
result in a slower transition toward the PrE fate. The model
predicts that the opposite would be observed in Nanog+/
embryos. Additional experiments are required to test this model
and determine the importance of relative versus absolute levels
of GATA6 and NANOG for ICM cell differentiation.
How the transcriptional network involving this interaction of
GATA6 and NANOG is integrated with signaling cues to regulate
ICMcell fate specification remains an open question. Modulation
of FGF signaling, in mutants or using inhibitors or growth factors,
affects NANOG and GATA6 expression in wild-type blastocysts
(Frankenberg et al., 2011; Kang et al., 2013a; Nichols et al., 2009;
Yamanaka et al., 2010). However, treatment of Gata6 mutants
with exogenous FGF4 failed to direct cells toward a PrE fate.
These results show that GATA6 is required for FGF-mediated
downregulation of NANOG. However, inhibition of ERK in
Gata6 mutants resulted in robust upregulation of NANOG, sug-
gesting that FGF/ERK signaling can directly regulate NANOG
levels. These results reveal that FGF signaling is necessary but
not, as previously assumed, sufficient to repress NANOG and
induce PrE differentiation. Instead, this process is GATA6
dependent, with GATA6 acting upstream of ERK. We suggest
a tunable system with three nodes, consisting of GATA6, FGF
receptor (FGFR), and NANOG, in which GATA6 is upregulating
and possibly mediating stabilization of FGFR (or another
upstream element in the cascade), thereby cell-autonomously
allowing for elevated stimulation or attenuation of the FGF/ERK
pathway by FGF4. Increased ERK signaling would then be able
to repress NANOG, which in turn would lead to decreased
GATA6 repression by NANOG (Figure 7). Through this extended
feedback loop a PrE fate would be reinforced. In EPI cells, very
low levels of GATA6 would be insufficient to upregulate FGFR,
and baseline levels of the receptor would only allow for marginal
induction of FGF/ERK signaling, which would not be able to
repress but instead merely moderate NANOG levels, as
observed in wild-type EPI cells (Figure 7). Single-cell gene
expression profiling demonstrated expression of Fgfr1 in all
ICM cells, and notably a correlation of Gata6 and Fgfr2 mRNA
levels in blastocysts (Ohnishi et al., 2014). Further studies will
be needed to determine whether there is a direct link between
GATA6 and FGFR expression, but such a mechanism could
produce a general effect on receptor tyrosine kinases (RTKs),
as our results also demonstrate the absence of the related
RTK PDGFRA in the absence of GATA6.
Unexpectedly, we also noted that, independent of genotype,
stimulation of the FGF/ERK pathway at blastocyst stages failed
to induce a PrE fate in cells that had presumably already
acquired an EPI state. These results suggest that a subpopula-
tion of EPI cells may be lineage committed soon after the estab-
lishment of a salt-and-pepper distribution of cells within the ICM
and less responsive to FGF signaling cues, in agreement with
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previous reports (Grabarek et al., 2012). Because FGF signaling
fails to repress NANOG in the absence of GATA6 (Figure 5), this
phenomenon can be explained if, in mature EPI cells, GATA6 is
repressed and they concomitantly cease to respond to FGF
signaling. Such a mechanism could operate to prevent
committed EPI cells from switching their fate in the FGF-rich
environment of the sorted EPI compartment of the late blasto-
cyst. However, additional experiments will be required to eluci-
date the mechanistic details behind these observations.
Importantly, recent studies in other mammals (Kuijk et al.,
2012; Niakan and Eggan, 2013; Roode et al., 2012; Van der
Jeught et al., 2013) have revealed that GATA6 and NANOG
are expressed early within the ICM and exhibit a sequence of
expression that is comparable to that of the mouse (Chazaud
et al., 2006; Dietrich and Hiiragi, 2007; Plusa et al., 2008), sug-
gesting that some aspects of the GRN driving ICM lineage
choice are evolutionarily conserved. Surprisingly, it was recently
noted that by contrast to rodents (Kang et al., 2013a; Nichols
et al., 2009; Roode et al., 2012; Yamanaka et al., 2010),
modulation of FGF signaling does not elicit an effect on ICM
lineage commitment in human and bovine blastocysts (Kuijk
et al., 2012; Roode et al., 2012; Van der Jeught et al., 2013). If
the role of FGF signaling in ICM lineage specification is a rodent
species-specific adaptation, our studies lead us to speculate
that GATA6 might be a key evolutionarily conserved transcrip-
tion factor driving PrE lineage specification across eutherian
mammals.
EXPERIMENTAL PROCEDURES
Mouse Husbandry
Mouse strains used were Gata6cKO/cKO (Sodhi et al., 2006), CAG:Cre (Sakai
and Miyazaki, 1997), Zp3:Cre (de Vries et al., 2000), PdgfraH2B-GFP/+
(Hamilton et al., 2003), and wild-type CD1 (Taconic). Gata6KO/+ animals were
of a mixed (CD1/B6/129) strain background and were generated by crossing
Gata6cKO/cKO to aCAG:Cre strain. Embryos with maternal and zygotic ablation
of Gata6 were obtained by breeding Gata6cKO/cKO; Zp3:CreTg/+ females with
Gata6cKO/cKO males. Work on mice was subject to approval by, and carried
out in accordance with guidelines from, the Memorial Sloan Kettering Cancer
Center Institutional Animal Care and Use Committee.
Embryo Collection and Handling
Mice were maintained under a 12 hr light cycle. Preimplantation embryos were
flushed from uteri or oviducts in flushing holding medium (FHM, HEPES-
buffered potassium simplex optimized medium [KSOM] based; Millipore) as
described (Nagy et al., 2003). The zona pellucida was removed from blasto-
cysts by brief incubation in acid Tyrode’s solution (Sigma). Embryos were fixed
in 4% paraformaldehyde in PBS for 10 min at room temperature and stored in
PBS at 4C.
Embryo In Vitro Culture
Embryos were cultured in drops of KSOM-AA (KSOM supplemented with
amino acids; Millipore) under mineral oil (Sigma) at 37C in a 5% CO2
Figure 7. Working Model
GATA6 potentiates the upregulation of FGFR2, thereby cell-autonomously stimulating the FGF/ERK pathway activated by FGF4. Increased ERK signaling leads
to repression of NANOG, which in turn releases GATA6 repression. This feedback loop reinforces a PrE fate. In EPI cells, very low levels of GATA6maintain but do
not upregulate FGFR2. Baseline levels of the receptor allow for marginal induction of FGF/ERK signaling, which in turn moderates NANOG levels. Within the
insets: lines with arrowheads, positive regulation; lines with blocks, negative regulation; dashed lines, hypothesized regulation; grey lines, weak effects due to low
protein concentrations.
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atmosphere. For live imaging, embryos were cultured on glass-bottom dishes
(MatTek) in an environmental chamber (Solent Scientific) as described previ-
ously (Piliszek et al., 2011). Embryos at postcavitation stages were cultured
without zona pellucidae. For FGF treatment experiments, FGF4 or FGF2
(R&D Systems) was added to culture medium at 500–2,000 ng/ml in the pres-
ence of 1 mg/ml heparin (Sigma). For ERK inhibition experiments, 1 mMERK1/2
inhibitor PD0325901 (Stemgen) was added to the culture. Embryos were
cultured from E2.5 or E3.5 for various periods of time.
Immunostaining
Immunofluorescence staining was performed as previously described
(Frankenberg et al., 2013). The following primary antibodies were used:
goat anti-SOX2 (R&D Systems) at a dilution of 1:50; mouse anti-OCT4
(Santa Cruz), goat anti-GATA4 (Santa Cruz), goat anti-GATA6 (R&D Systems),
and goat anti-SOX17 (R&D Systems) at 1:100; rabbit anti-PKCz (Santa Cruz),
mouse anti-DAB2 (BD Transduction Laboratories), and mouse anti-CDX2
(BioGenex) at 1:200; rabbit anti-NANOG (Cosmo Bio), mouse anti-GATA3
(BioLegend), and rabbit anti-EOMES (Abcam) at 1:500. Secondary Alexa
Fluor-conjugated antibodies (Invitrogen) were used at a dilution of 1:500.
DNA was visualized using 5 mg/ml Hoechst 33342 (Invitrogen) in PBS.
Image Data Acquisition and Processing
Laser-scanning confocal images were acquired on a Zeiss LSM 510 META.
Embryos were mounted in PBS on glass-bottom dishes. Fluorescence was
excited with a 405 nm laser diode (Hoechst), 488 nm argon laser (GFP, Alexa
Fluor 488), 543 nm HeNe laser (Alexa Fluor 543, 555), and 633 nm HeNe laser
(Alexa Fluor 633 and 647). Images were acquired using a Plan-Neofluar 403/
1.3 Oil DIC objective, with an optical section thickness of 1–1.2 mm. Raw data
were processed using ZEN (Carl Zeiss Microsystems), ImageJ (NIH), and
MINS (Lou et al., 2014) software. Three-dimensional time-lapse imaging was
performed on a Zeiss LSM 510 META. Embryos were placed in drops of
KSOM under mineral oil on glass-bottom dishes (MatTek). Time intervals
between z stacks were 15 min, for a 15–20 hr total. Raw data were processed
using Zeiss ZEN software.
Image Segmentation and Quantitative Fluorescence Intensity
Analysis Pipeline
For cell counting and quantification, MINS software (http://katlab-tools.org)
was used (Lou et al., 2014). Details of the analyses are provided in Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, one table, and one movie and can be found with this article online
at http://dx.doi.org/10.1016/j.devcel.2014.04.011.
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SUPPLEMENTAL FIGURES AND LEGENDS 
 
 
 
Figure S1, related to Figure 1: Observed correlations in cell fates are consistent with an 
early random commitment and geometrical constraints at later stages. 
A simplified 2D geometry mimicking the mouse blastocyst was generated on a uniformly 
spaced lattice. Cell fates were assigned either randomly (32-64 cell stage) or in a pattern 
resembling the embryo after sorting of PrE and EPI cells. The Pearson’s correlation coefficient 
of cell fates as a function of cell distance was computed for virtual embryos and compared to 
the measured data of real embryos. The simulated dependency of the correlation function is in 
good agreement with the measured correlations, suggesting that early cell fate specification is 
controlled by random commitment, and that the correlations observed in late embryos are 
controlled by their geometry. B Average difference in the (x,y,z) coordinates of EPI and PrE 
cells as a function of developmental stage (see cartoon for information on coordinates; at the 
32-64 cells stage, this computation was performed on the few cells that have already 
committed to EPI or PrE fate- see data in Figure 1B). At all stages, embryos do not show 
asymmetries in x and z, as expected. At the 32-64 cells stage, there is no asymmetry in y, 
suggesting that early commitment is controlled by cell autonomous stochastic factors. 
Asymmetries in y become evident at the 64-128 cells stage and further increase at the >128 
cells stage. These observations suggest that the movement of EPI cells away from the cavity 
and PrE cells towards the cavity is subsequent to the random cell fate commitment observed at 
the earlier stages. 
 
Figure S2, related to Figure 2: Marker expression in maternal zygotic Gata6 mutant, wild-
type and heterozygote embryos at different stages and in blastocyst outgrowths. 
A Localization and distribution of CDX2 (green), NANOG (white) and GATA6 (red) in maternal 
zygotic E3.5 Gata6 mutant blastocysts. Blue in merge: Hoechst. B Localization and distribution 
of GATA4 (green) and GATA6 (red) in E5.5 Gata6+/+ and Gata6+/- embryos. Blue in merge: 
Hoechst. White in merge: Phalloidin. C Localization and distribution of EOMES (green) and 
NANOG (white) in outgrowths of Gata6+/+ and Gata6-/- embryos 4 days after plating. Blue in 
merge: Hoechst. BF: Brightfield. 
 
Figure S3, related to Figure 3: CDX2 expression in ICM cells after prolonged culture in 
FGF.  
Localization and distribution of CDX2 (green), NANOG (white) and GATA6 (red) in Gata6 wild-
type and mutant mouse embryos. Embryos were cultured from the 8-cell stage (E2.5) for 72h 
to assess whether the population of CDX2+ cells in the ICM expanded over time as a 
consequence of exposure to FGF. Arrowheads indicate CDX2 expressing cells in the ICM. 
 
Figure S4, related to Figure 5: NANOG/GATA6 negative cells in the ICM of FGF-treated 
embryos are OCT4 positive. 
Localization and distribution of OCT4 (green), NANOG (white) and SOX17 (red) in Gata6 wild-
type and mutant blastocysts after culture in 2 µg/mL FGF from E3.5 for 24 h (A), from E2.5 for 
48 h (B) and untreated (C). Blue in merge: Hoechst.  
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 Genotype  
Stage of embryo Gata6+/+ Gata6+/- Gata6-/- 
Total no. of embryos 
recovered 
<64 cells 
early blastocyst 
28 68 34 130 
64-128 cells 
mid-blastocyst 
19 40 20 79 
>128 cells 
late blastocyst 
10 10 12 32 
E5.5 
post-implantation 
8 34 0 42 
 
Table S1, related to Figure 2: Genotypes of embryos recovered from Gata6 
heterozygous intercrosses at various stages. 
 
 
 
 
 
 
 
 
 
  
 SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Image data acquisition and processing 
Laser scanning confocal images of immunostained embryos were acquired on a Zeiss LSM 
510 META. Embryos were mounted in PBS on glass-bottom dishes. Fluorescence was excited 
with a 405-nm laser diode (Hoechst), a 488-nm Argon laser (GFP, Alexa Fluor 488), a 543-nm 
HeNe laser (Alexa Fluor 543, 555) and a 633-nm HeNe laser (Alexa Fluor 633 and 647). 
Images were acquired using a Plan-Neofluar 40×/1.3 Oil DIC objective, with an optical section 
thickness of 1–1.2 µm. Raw data were processed using ZEN (Carl Zeiss Microsystems), 
ImageJ (NIH) and MINS (Lou et al., 2014) software. 3D time-lapse imaging was performed on 
a Zeiss LSM 510 META. Embryos were placed in drops of KSOM under mineral oil on glass-
bottom dishes (MatTek Corp). Time intervals between z-stacks were 15 minutes, for 15-20 
hours total. Raw data were processed using Zeiss ZEN software (Carl Zeiss Microsystems). 
 
Image segmentation and quantitative fluorescence intensity analysis pipeline 
For cell counting and quantification MINS software (http://katlab-tools.org/) was used (Lou et 
al., 2014). Confocal images in *.lsm format were loaded into the MINS pipeline, which detects 
nuclei, accurately segments them and exports results of nuclear count, size, position and 
fluorescence intensity of all channels in table format, and as images of numbered nuclei 
(Figure 1). The MINS output was checked for over- or under-segmentation and tables were 
corrected manually. Mitotic cells were also found and excluded from the analysis. TE cells were 
defined molecularly and positionally, as nuclei positive for CDX2 in cells located on the surface 
of the embryo. For representation of fluorescence intensity distribution throughout ICMs, data 
was subject to logarithm transformation to reduce the technical variability due to the loss of 
fluorescence along the z-axis. For statistical comparison of intensity distributions, these values 
were plotted as the average log intensity per embryo rather than per cell. A Wilcoxon Mann-
Whitney Test was performed to compare two populations, a Kruskal-Wallis Test for more than 
two populations. All analysis of fluorescence intensity levels and statistics were performed 
using R (http://www.r-project.org/). For correlation and probability functions nuclear 
concentrations were extracted from nuclear intensity measurements by first subtracting 
background fluorescence, and then correcting for the decrease in fluorescence intensities due 
to tissue depth in z-stacks of image data. Background intensities for both NANOG and GATA6 
were estimated from the average fluorescence intensity values (at the >128 cell stage) of half 
of the TE cells having the lowest intensities. The value obtained for GATA6 was comparable to 
the one obtained by imaging Gata6-/- embryos and the value for NANOG was very low and 
similar to the one observed in PrE cells at late stages, thereby validating our procedure. A 
correction factor as a function of axial position (z coordinate) in the embryo was estimated by 
determining how the signal intensity of the DAPI channel scaled with z. The DAPI intensities of 
all nuclei in an embryo were fitted as a function of z using the Smoothing Splines function in 
MATLAB (http://www.mathworks.com/products/matlab/), and the fit was then used to correct 
the fluorescence intensities. The number of PrE and EPI cells was established using the 
threshold functions shown in Figure 1B. Correlation functions were computed by evaluating the 
Pearson’s correlation coefficient for each pair of cells as a function of the distance between 
them. The probabilities of cell specification (as well as their 95% confidence intervals) as a 
function of cell number were estimated through logistic regression using the Curve Fitting 
Toolbox in MATLAB.  
 
Genotyping 
Following image acquisition embryos were genotyped as described previously (Kang et al., 
2013a) using the following primers: Gata6cKO-fw: 5′-GTGGTTGTAAGGCGGTTTGT-3′, 
Gata6cKO-rev: 5′-ACGCGAGCTCCAGAAAAAGT-3′, Gata6KO-fw: 5′-
AGTCTCCCTGTCATTCTTCCTGCTC-3′, Gata6KO-rev: 5′-
TGATCAAACCTGGGTCTACACTCCTA-3′, GFP-fw: 5′-AAGTTCATCTGCACCACCG-3′, GFP-
rev: 5′-TGCTCAGGTAGTGGTTGTCG-3′. 
 
Embryo-derived stem cell derivation and culture 
ES cell lines were derived from embryos collected from Gata6+/– intercrosses according to 
standard procedures (Czechanski et al., 2014). Embryonic day (E) 3.5 embryos were on 
mitotically inactivated murine embryonic fibroblast (MEF) feeder cells for 9 days. Outgrowths 
were disaggregated and passaged into 24-well dishes. Medium was replaced every 2 days. 
Emerging ES cell colonies were passaged into new 24-well plates until confluence. Cells were 
then cultured in the absence of MEFs and genotyped. All cells were grown at 37°C in 5% CO2. 
ES cells were routinely cultured as described previously (Kang et al., 2013a).  
 
 
RT-PCR 
RNA from Gata6+/+ and Gata6-/- ES cells was isolated using Trizol Reagent (Life Technologies) 
according to the manufacturer’s instructions. Reverse transcription (RT) and genomic DNA 
digestion was performed using QuantiTect Reverse Transcrption Kit (Qiagen) according to the 
manufacturer’s instructions. PCR was performed on the prepared cDNA using the following 
primer sequences: Gapdh-fw: 5’-GTGTTCCTACCCCCAATGTGT-3’, Gapdh-rev: 5’-
ATTGTCATACCAGGAAATGAGCTT-3’, Gata6-fw: 5’-AGACGGCACCGGTCATTACC-3’, 
Gata6-rev: 5’- TCACCCTCAGCATTTCTACGCC-3’, Nanog-fw: 5’-
TGCGGACTGTGTTCTCTCAGG-3’, Nanog-rev: 5’-CCACTGGTTTTTCTGCCACCG-3’, Fgf4-
fw: 5’-ACTACCTGCTGGGCCTCAAA-3’, Fgf4-rev: 5’-AAGGCACACCGAAGAGCTTG-3’, 
Fgfr1-fw: 5’-CACCTGCATCGTGGAGAATG-3’, Fgfr1-rev: 5’-CAAGTTGTCTGGCCCGATCT-3’, 
Fgfr2-fw: 5’-CCTTCGGGGTGTTAATGTGG-3’, Fgfr2-rev: 5’-GGGTACAGCATGCCAGCAAT-
3’. Primers were designed for amplicons to span exon borders to avoid possible amplification of 
genomic DNA. Gata6 primers were designed to bind outside of Exon2, which is deleted in 
Gata6 mutant cells. 
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Movie S1. PdgfraH2B-GFP PrE Reporter Is Not Activated 
during Gata6 Mutant Blastocyst Development, Related to Figure 3.   
Time series of early to late blastocyst stage embryos from a Gata6+/−; 
PdgfraH2BGFP × Gata6+/− cross. Time total: 20 hr; time interval: 15 min; z-
total: 62 μm; z-interval: 2 μm. Labels indicate genotypes. 
 
Location: 
http://www.sciencedirect.com/science/article/pii/S1534580714002317  
with Supplemental Information 
 
Download: 
http://www.sciencedirect.com/science/MiamiMultiMediaURL/1-s2.0-
S1534580714002317/1-s2.0-S1534580714002317-
mmc2.mp4/272236/html/S1534580714002317/ac5f3215afa970b1112cd1554
87d008a/mmc2.mp4 
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ADDITIONAL RESULTS 
 
 
Figure 7. Gata6
H2B-Venus
 reporter expression in blastocyst stage embryos and 
immunohistochemistry for GATA6 and NANOG protein. Gata6
H2B-Venus
 knock-in reporter 
expression creates embryos, which phenocopy Gata6 heterozygous and null mutant 
embryos. Gata6
H2B-Venus
 displays expression in the absence of GATA6 protein. (Freyer et al., 
submitted). 
 
 
 
Figure 8. ICM composition in wildtype late blastocyst stage embryos. Each stacked bar 
represents one wildtype embryo ICM, showing that proportions of epiblast (EPI) and primitive 
endoderm (PrE) are relatively stable at the mid to late blastocyst stage, with around 40 % and 
60 %, respectively. 
2.  RESULTS 
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IntroductIon
The mouse embryo ~3.5 d after fertilization forms a blastocyst 
comprising three lineages1: the extraembryonic trophectoderm 
(TE), the PrE and the pluripotent Epi (Fig. 1) from which cognate 
ex vivo stem cells can be derived. TS cells are derived from the TE2, 
XEN cells from the PrE3 and ES cells from the Epi (refs. 4,5; Fig. 2) 
(reviewed in ref. 6). Notably, each of these stem cell lines is a useful 
model of the blastocyst cell lineage that they represent. Mouse ES 
and TS cells have been used successfully for many years to model 
Epi or TE biology, including the mechanisms of pluripotency main-
tenance and placental development, respectively. Recently derived 
XEN cell lines have the distinctive characteristic of cells with at least 
two morphologies: they are highly refractile as well as epithelial-
like3 (Fig. 2), and they are only beginning to be used to understand 
the mechanisms of PrE development with significance for stem cell 
and developmental biology.
Mouse ES cells can be directed to differentiate into extraembry-
onic lineages by the overexpression of single transcription factors, 
such as the caudal-related homeodomain transcription factor Cdx2 
(to derive TS cells)7 or the GATA transcription factor Gata6 (to 
derive XEN cells)8. Retinoic acid treatment of mouse ES cells9–11 
or embryoid body aggregation12 has been shown to promote a het-
erogeneous mixture of XEN-differentiated cells. Notably, these cells 
have not been demonstrated to self-renew indefinitely, unlike bona 
fide XEN cell lines. We have recently demonstrated that mouse ES 
cells can be converted to stable XEN cell lines using retinoic acid 
together with activin13. In this protocol, we focus on the derivation 
of XEN cells from embryos and ES cells.
The molecular mechanisms underlying XEN cell establishment 
and maintenance are beginning to be understood. Robust methods 
for XEN cell derivation from embryos and ES cells, as well as the 
concomitant availability of XEN cell lines, will further facilitate 
and improve our understanding of the key fate decisions that occur 
within the early embryo, including unraveling mechanisms under-
lying cellular differentiation and pluripotency14,15. As a stem cell 
type that can be derived from both embryos and ES cells, XEN cells 
are emerging as a valuable tool for modeling the XEN lineage.
Applications of XEN cells
XEN cell derivation can be used as a phenotypic tool to assess the 
requirement of genes for XEN cell specification, maintenance or 
expansion, as we have previously demonstrated for SRY-box con-
taining gene 17 Sox17)4, platelet-derived growth factor receptor 
alpha (Pdgfra)11 and fibroblast growth factor 4 (Fgf4)16. Notably, 
established XEN cell lines serve as a paradigm for XEN biology 
and for the differentiation of the PrE into derivatives such as 
visceral17–19 and parietal endoderm.
Given the fact that reciprocal inductive interactions between the 
pluripotent Epi and its adjacent extraembryonic tissues, including the 
visceral endoderm (reviewed in refs. 20 and 21), are crucial to pattern-
ing the early embryo, XEN cells can be used as an ex vivo tool for teasing 
apart the underlying mechanisms and for identifying the key molecules 
involved12. XEN cells can be used as an important in vitro tool for eluci-
dating details of additional patterning activities of the extraembryonic 
endoderm, such as identifying factors involved in cardiac induction22–24. 
Moreover, as they can be propagated in large quantities and do not 
require growth factor supplements to culture media, these cells are a cost-
effective, attractive and tractable system for high-throughput analyses. 
They can be used in screens for PrE-differentiating factors or in proteom-
ics analyses to identify secreted factors that mediate tissue patterning 
(for example, during cardiac induction)22–24. XEN cells show paternally 
imprinted X-chromosome inactivation3, and thus they serve as a use-
ful model for understanding the molecular basis of post-translational 
and epigentic modifications25. Furthermore, as the extraembryonic 
endoderm has recently been shown to contribute to the gut endoderm 
in vivo26, XEN cells may also serve as an alternative self-renewing source 
of definitive endoderm-derived cells and tissues for regenerative medi-
cine. Intriguingly, XEN cells rapidly silence retroviral transcription 
compared with mouse ES and TS cells and may therefore also repre-
sent a useful model to study how viral gene expression is regulated27.
XEN cell establishment from embryos
Several protocols describe the derivation of XEN cells from mouse 
embryos, including the direct plating of blastocyst stage embryos3 
Derivation of extraembryonic endoderm stem (XEN) 
cells from mouse embryos and embryonic stem cells
Kathy K Niakan1,2,5, Nadine Schrode3, Lily T Y Cho1,4 & Anna-Katerina Hadjantonakis3
1The Anne McLaren Laboratory for Regenerative Medicine, University of Cambridge, Cambridge, UK. 2Centre for Trophoblast Research, Department of Physiology, 
Development and Neuroscience, University of Cambridge, Cambridge, UK. 3Developmental Biology Program, Sloan-Kettering Institute, New York, New York, USA. 
4Department of Surgery, University of Cambridge, Cambridge, UK. 5Present address: Division of Stem Cell Biology and Developmental Genetics, Medical Research Council 
National Institute for Medical Research, London, UK. Correspondence should be addressed to K.K.N. (kniakan@nimr.mrc.ac.uk) or A.-K.H. (hadj@mskcc.org).
Published online 2 May 2013; doi:10.1038/nprot.2013.049
at the time of implantation in the maternal uterus, the mouse blastocyst possesses an inner cell mass comprising two lineages: 
epiblast (epi) and primitive endoderm (pre). representative stem cells derived from these two cell lineages can be expanded and 
maintained indefinitely in vitro as either embryonic stem (es) or Xen cells, respectively. Here we describe protocols that can be 
used to establish Xen cell lines. these include the establishment of Xen cells from blastocyst-stage embryos in either standard 
embryonic or trophoblast stem (ts) cell culture conditions. We also describe protocols for establishing Xen cells directly from es 
cells by either retinoic acid and activin-based conversion or by overexpression of the Gata transcription factor Gata6. Xen cells are 
a useful model of pre cells, with which they share gene expression, differentiation potential and lineage restriction. the robust 
protocols for deriving Xen cells described here can be completed within 2–3 weeks.
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or immunosurgery, to isolate and to plate 
the inner cell mass28,29. In 2005, Kunath 
et al.3 reported the first isolation and 
 characterization of XEN cells using methods 
based on existing protocols of deriving ES28 
and TS cells2,30,31. In this case, embryonic 
day 3.5 blastocysts were cultured on mouse 
embryonic fibroblast (MEF) cells until 
they formed an outgrowth that, as in rou-
tinely used ES and TS cell derivation protocols, was subsequently 
disaggregated to promote the proliferation of the different cell 
types present in the blastocyst. In both procedures, XEN cell out-
growths could be observed alongside ES or TS cells, respectively, 
suggesting that these conditions are also permissive for XEN 
cell derivation.
Our experience has been that slight modifications to these pro-
tocols (especially media conditions and time of disaggregation) 
can favor the propagation of XEN cells over that of ES or TS cells. 
We have also found that, in our hands, TS cell conditions are gen-
erally less efficient for the derivation of XEN cell lines compared 
with ES cell conditions (21% and 56% efficiency, respectively). ES 
cells start appearing from the outgrowths first and are less resil-
ient, which might facilitate the ability of XEN cells to outcompete 
them in a culture dish. TS cells, in contrast, reach their proliferative 
peak around the same time as XEN cells and tend to outcompete 
XEN cells present in the same cultures, especially in the presence of 
recombinant FGF4 (ref. 2) or FGF2 (bFGF), the latter of which can 
elicit the same effect31 and is slightly more cost effective.
XEN cell establishment by transcription factor overexpression
In classical experiments, Davis et al.32 demonstrated that the expres-
sion of a single transcription factor, MyoD, was sufficient to con-
vert fibroblasts into myogenic cells. More recently, transcription 
 factor–mediated cell-fate switches have been demonstrated for sev-
eral other cell types, including the reprogramming of fibroblasts 
into induced pluripotent stem cells via ectopic expression of the 
POU domain, class 5, transcription factor 1 (Pou5f1, also known as 
Oct4), Klf4, Sox2 and Myc (also known as c-Myc)33.
Ectopic transcription factor expression has also been shown to 
induce the conversion of XEN cells from ES cells (reviewed in ref. 
6). Niwa and colleagues8,34 demonstrated that the expression of 
Gata4 or Gata6 alone is sufficient to induce the conversion of ES 
cells into XEN cells. Notably, these GATA-derived XEN cells share 
the molecular and functional characteristics of embryo-derived 
XEN cells, including contribution to PrE lineages in chimeric 
embryos34. XEN-like cells have also been generated by ectopic 
expression of Sox17 (refs. 14,35–37). It is unclear whether Sox17 
alone is sufficient to drive XEN cell commitment, as these cells 
retain the expression of ES cell–associated genes, such as Nanog 
and Oct4 (refs. 14,35,38), and their contribution to chimeras has 
not yet been reported. Moreover, it is unclear whether alternative 
PrE-associated transcription factors can be used to convert ES to 
XEN cells.
The simplest method used to derive XEN cells from ES cells is 
the expression of Gata6 either by transfection of a circular plasmid 
or a linearized DNA using chemical or nonchemical (e.g., electro-
poration) methods. There are several chemical-based transfection 
approaches. The most widely used methods for ES cells are lipid-
based lipopolyamines39 and cationic polymer–based transfection 
(reviewed in ref. 40). Lipopolyamines (e.g., lipofection) work by 
coating a Gata6-cDNA plasmid with a cationic lipid, allowing the 
DNA to cross the negatively charged phospholipid ES cell mem-
brane by endocytosis41,42. Cationic polymers (e.g., Xfect) act by 
binding DNA and condensing it, thereby facilitating DNA entry 
into the cell cytoplasm40,43. An advantage of lipopolyamines and 
cationic polymers is that they do not require specialized equipment, 
although the reagents may be cytotoxic and the ratio of DNA to 
transfection reagent needs to be optimized to the specific cell type42 
(reviewed in ref. 44).
Electroporation is the principal alternative to chemical-based trans-
fection approaches and is routinely used for ES cell transfection45–47. 
Electroporation allows for permeabilization of the ES cell membrane 
and transfection of a Gata6 cDNA via the application of a transient 
electrical field. Depending on the purity of the DNA preparation, this 
can be a highly efficient method and is most commonly used for gene 
targeting of ES cells. The choice of whether the Gata6 cDNA plasmid 
is introduced as a circular plasmid or as a linearized DNA can affect 
transfection efficiency, as supercoiled or open-circular DNA is optimal 
for transient expression, whereas linearized DNA is more recombino-
genic and best suited for stable transfection48–50.
Continued passage of transiently transfected cells will result in the 
dilution of the exogenous DNA and may restrict the time window 
for subsequent analysis. Therefore, although it is initially more time 
consuming, the generation of stable transfected ES cells that have 
integrated a linearized Gata6 cDNA into the genome can be experi-
mentally more consistent compared with transient transfection. 
By including a drug-resistance gene in the Gata6 cDNA–targeting 
plasmid, drug selection can be used to expand only targeted 
ES cells that retain the ability to overexpress the Gata6 cDNA. 
Figure 1 | Overview of early embryonic 
development. Proper lineage segregation 
before implantation is ensured by two cell-
fate decisions, with the first giving rise to 
trophectoderm and inner cell mass, and the 
second leading to the allocation of primitive 
endoderm and epiblast. Lineage-associated gene 
expression is noted below each cell type. After 
implantation, the PrE differentiates into visceral 
and parietal endoderm. E: embryonic day.  
Scale bars, 50 µm.
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Another important consideration is the use 
of an efficient and robust promoter to drive 
exogenous Gata6 expression. In mouse ES 
cells, the cytomegalovirus (CMV) promoter 
may be silenced51. In contrast, the ubiqui-
tin C (UBC) promoter, elongation factor 
1α (EF1A) promoter, and the chicken β-actin (ACTB) promoter 
coupled with the CMV early enhancer (CAGG) have been reported 
to be more robustly expressed51.
Although these are not described here, alternative approaches for 
Gata6 overexpression include viral transduction. Owing to potential 
toxicity, viral production and transduction require at least a category 
II tissue culture facility, and the silencing of retroviral transcription 
in XEN cells may obviate this approach27. Moreover, reversible over-
expression of Gata6 can be engineered using an inducible expression 
system containing a tetracycline-responsive element (controlled by 
tetracycline or doxycycline), a mutant estrogen-responsive element 
(controlled by 4-hydroxytamoxifen) or a glucocorticoid-responsive 
element (controlled by dexamethasone). When combined with drug 
selection, an inducible system is an effective means of overexpressing 
Gata6 simultaneously in all cells. Although overexpression of Gata6 
may initially be a simpler method to drive XEN differentiation, a 
major note of caution is that its ubiquitous expression may hinder the 
ability of converted XEN cells to differentiate into subtypes of XEN 
cells. One major limitation may be that constitutive Gata6 expression 
blocks differentiation of induced XEN cells into visceral endoderm 
subtypes, as in vivo these cells lack Gata6 expression while retaining 
the expression of Gata4 (refs. 52,53). Here we describe a method to 
constitutively express Gata6 in mouse ES cells, which can be modified 
to overexpress other genes such as Gata4 or to introduce an inducible 
expression system as has been described previously34,54,55. Moreover, 
transposon systems such as piggyBac56 may also be used, although 
these methods have not yet been shown to convert ES to XEN cells.
XEN cell establishment by growth factor conversion of ES cells
Although ES cells largely contribute to the Epi in chimera embryos, 
it has been observed that committed XEN and TS cells also arise 
within pluripotent culture conditions14,57,58. The presence of TS- 
and XEN-like cells within ES cell cultures suggests that ES cells may 
have a broader cell fate potential and are therefore able to differenti-
ate into stable extraembryonic stem cell lines directly. Indeed, ES 
cell aggregation results in the formation of embryoid bodies with an 
outer layer of XEN cells12, and growth factors such as retinoic acid 
have been shown to differentiate embryonic carcinoma and ES cells 
into XEN-like cells9–11,59. Moreover, the culture of ES cells in serum-
free medium on fibronectin-coated dishes at high density has been 
suggested to promote visceral endoderm differentiation60. However, 
it was unclear whether self-renewing XEN cells could be differenti-
ated directly from mouse ES cells without gene manipulation. We 
have recently expanded on these studies by developing a technique 
to convert ES cells directly into stable XEN (cXEN) cell lines that 
are equivalent to embryo-derived XEN cells13. We previously dem-
onstrated that cXEN cells are molecularly indistinguishable from 
embryo-derived XEN and iXEN (i.e., transcription factor induced) 
cells and are equivalently responsive to differentiation-promoting 
factors (i.e., bone morphogenetic protein (BMP)-induced visceral 
endoderm differentiation). Our efforts to generate chimera embryos 
from cXEN cells resulted in contribution to the parietal endoderm 
at early postimplantation stages (K.K.N., M. Kang and A.-K.H., 
unpublished observations), as has been reported for XEN cells 
derived from embryos3. Here we describe our method for convert-
ing mouse ES cells into stable cXEN cell lines using growth factors. 
Specifically, we use retinoic acid together with activin, which has 
been demonstrated to promote primitive endoderm development 
in vivo and in vitro17,61. Notably, although retinoic acid and activin 
have been shown to differentiate ES cells into neurons and definitive 
endoderm, respectively, we find that the combination of both factors 
promotes XEN cell differentiation. We previously tested a range of 
retinoic acid concentrations from 0 to 100 µM and a range of activin 
concentrations from 0 to 20 ng ml − 1. Although XEN-like cells can 
emerge in the absence of exogenous retinoic acid and activin14, 
the proportion of XEN-like cells is enhanced (40.3%) in 0.01 µM 
retinoic acid and 10 ng ml − 1 activin13. We therefore use the lowest 
dose of retinoic acid and activin that gives us the highest efficacy of 
XEN cell emergence, although it is presently unclear whether differ-
ent concentrations of these growth factors influence the identity of 
the XEN cells obtained. Thus far, we have been able to derive XEN 
cell lines from any mouse ES cell line and mouse strain unless the 
cells are mutant for a gene required for XEN establishment and/or 
maintenance13, although the speed of conversion can vary with any 
given cell line. An important consideration is the initial heterogene-
ity that emerges after growth factor treatment. As with the protocol 
for XEN cell derivation from embryos, selecting cells with XEN cell 
morphology facilitates the expansion of stable cXEN cells that are 
able to self-renew indefinitely. This ES cell conversion protocol is 
particularly useful for determining the genetic requirement for XEN 
cell function using mutant mouse ES cells without the necessity for 
mutant mice.
Figure 2 | Stem cell types that can be derived 
and propagated in culture representing the three 
blastocyst lineages. Embryonic stem (ES) cells 
represent the epiblast, trophoblast stem (TS) cells 
represent the trophectoderm and extraembryonic 
endoderm (XEN) cells represent the primitive 
endoderm cell lineage. Heterogeneities in XEN cell 
morphology are indicated: highly refractile phase-
bright and epithelial-like. Cognate embryo–
derived stem cells retain the expression of key 
lineage-associated genes. GF, growth factor; iPS, 
induced pluripotent stem; OKSM, Oct4, Sox2, Klf4 
and c-Myc. Scale bars, 100 µm.
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MaterIals
REAGENTS
Derivation from embryos using modified ES cell conditions
Pregnant mouse, 3.5 days post coitum (d.p.c.) ! cautIon Experiments 
involving rodents must conform to all relevant institutional and govern-
mental regulations.
Mitotically inactivated MEF cells (Reagent Setup)
MEF medium (DMEM supplemented with FBS (Gibco, cat. no. 
10082147), L-glutamine, β-mercaptoethanol, MEM non-essential amino 
acids and sodium pyruvate. Optionally, add penicillin-streptomycin;  
see Reagent Setup)
M2 medium (Millipore, cat. no. MR-015-D)
ES cell medium (DMEM supplemented with FBS (ES cell qualified; Gibco,  
cat. no. 16141079), L-glutamine (Gibco, cat. no. 25030-081), β-mercaptoetha-
nol (Sigma-Aldrich, cat. no. M6250), MEM non-essential amino acids (Gibco, 
cat. no. 11140035), sodium pyruvate (Gibco, cat. no. 11360-070), leukemia 
inhibitory factor (LIF; Millipore, cat. no. ESG1106); optional: penicillin-
 streptomycin (Invitrogen, cat. no. 15140122); see Reagent Setup)
Ethanol, 70% (vol/vol; Sigma-Aldrich, cat. no. E7023) ! cautIon Ethanol is 
flammable and may be harmful if inhaled or ingested.
PBS, 1×, sterile (Ca2 +  and Mg2 +  free; Gibco, cat. no. 14190-094)
Trypsin-EDTA, 0.25% (wt/vol; Gibco, cat. no. 25200-056)
Derivation from embryos using modified TS cell conditions
Pregnant mouse, 3.5 d.p.c.
Mitotically inactivated MEF cells (Reagent Setup)
TS cell medium (includes advanced RPMI 1640 (Gibco, 12633-012), FBS 
(Gibco, cat. no. 10082147), L-glutamine, β-mercaptoethanol, sodium 
pyruvate; optional: 1% (vol/vol) penicillin-streptomycin. Aliquots are sup-
plemented with recombinant FGF2 or FGF4 (Sigma-Aldrich, cat. no. F8424) 
and heparin (Sigma-Aldrich, cat. no. H3393); see Reagent Setup)
MEF-conditioned medium (Reagent Setup)
M2 medium (Millipore, cat. no. MR-015-D)
Ethanol, 70% (vol/vol; Sigma-Aldrich, cat. no. E7023) ! cautIon Ethanol is 
flammable and may be harmful if inhaled or ingested.
PBS, 1×, sterile (Ca2 +  and Mg2 +  free; Gibco, cat. no. 14190-094)
Trypsin-EDTA, 0.25% (wt/vol; Gibco, cat. no. 25200-056)
Derivation from mouse ES cells by Gata6 overexpression
Mitotically inactivated MEF cells (Reagent Setup)
MEF medium (Reagent Setup)
ES cells (Reagent Setup)
ES cell medium (Reagent Setup)
Ethanol, 70% (vol/vol; Sigma-Aldrich, cat. no. E7023) ! cautIon Ethanol is 
flammable and may be harmful if inhaled or ingested.
Gelatin, 0.1% (wt/vol; Sigma-Aldrich, cat. no. G1890) made up in sterile 
dH2O (Sigma-Aldrich, cat. no. W1503) and autoclaved to dissolve
PBS, 1×, sterile (Ca2 +  and Mg2 +  free; Gibco, cat. no. 14190-094)
Trypsin-EDTA, 0.05% (wt/vol; Gibco, cat. no. 25300054)
Xfect (Clontech, cat. no. 631320) or Lipofectamine 2000 (Invitrogen,  
cat. no. 11668030)
Opti-MEM I (Invitrogen, cat. no. 51985)
Bio-Rad Gene Pulser II Xcell eukaryotic system (Bio-Rad, cat. no. 377267)
Cuvette, 4 mm (Cell Projects, cat. no. EP-104)
Agarose (Sigma-Aldrich, cat. no. A9414)
Maxi-prep kit (Qiagen, cat. no. 12262)
Gata6 cDNA vector (Origene, cat. no. MC219384)
Isopropanol (Sigma-Aldrich, cat. no. I9516)
Sodium acetate (Fluka, cat. no. 71196)
Wizard SV genomic DNA purification system (Promega, cat. no. A2360)
Derivation from mouse ES cells using growth factors
cXEN derivation medium (standard XEN medium supplemented with  
all-trans retinoic acid (Sigma-Aldrich, cat. no. R2625) dissolved in DMSO 
plus activin A (R & D Systems, cat. no. 338-AC-010); Reagent Setup)
Mitotically inactivated MEF cells (Reagent Setup)
MEF medium (Reagent Setup)
ES cells (Reagent Setup)
ES cell medium (Reagent Setup)
Ethanol, 70% (vol/vol; Sigma-Aldrich, cat. no. E7023) ! cautIon Ethanol is 
flammable and may be harmful if inhaled or ingested.
Gelatin, 0.1% (wt/vol; Sigma-Aldrich, cat. no. G1890) made up in sterile 
dH2O (Sigma-Aldrich, cat. no. W1503) and autoclaved to dissolve
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PBS, 1×, sterile (Ca2 +  and Mg2 +  free; Gibco, cat. no. 14190-094)
Trypsin-EDTA, 0.05% (wt/vol; Gibco, cat. no. 25300054)
EQUIPMENT
Conical tubes (15 ml; BD Falcon, cat. no. 352095)
Conical tubes (50 ml; BD Falcon, cat. no. 352070)
Tissue culture–treated plate (six well; Corning, cat. no. 3516)
Tissue culture–treated plate (12 well; Corning, cat. no. 3512)
Tissue culture–treated plate (24 well; Corning, cat. no. 3524)
Tissue culture–treated dish (100 mm; Corning, cat. no. 430167)
Tissue culture–treated dish (150 mm; Corning, cat. no. 430599)
Tissue culture–treated plate (96-well flat bottom; Corning, cat. no. 3595)
Tissue culture–treated plate (96-well round bottom; Corning, cat. no. 3799)
Plate (four well; Nunc, cat. no. 12566300)
Cryotube vials (Nunc, cat. no. 144444)
Filter, 0.22 µm (Corning, cat. no. 431097)
Flame-pulled glass Pasteur pipettes (unpulled; e.g., Fisher Scientific, 13-678-20D)
Dissecting microscope (e.g., Leica M80)
Inverted microscope (e.g., Olympus CKX41)
Water bath (e.g., Grant JB Aqua 12)
Centrifuge (e.g., Eppendorf Centrifuge 5804)
Hemocytometer (e.g., Hausser scientific, cat. no. 3110)
CO2 incubator (e.g., Sanyo)
Dissection tools
Scissors (e.g., Roboz, cat. no. RS-5910)
Forceps (e.g., Dumont no. 5, Roboz; cat. no. RS-4976)
Syringes with 27-gauge needles (10 ml; BD Biosciences, cat. no. 309623)
Mouth-controlled pipette (Reagent Setup)
Plastic mouthpiece (MedTech, cat. no. 1501P-B4036-2)
Rubber tubing (Fisher Scientific, cat. no. 22-362-772)
Filtered pipette tip, P1000 (USA Scientific, cat. no. 1126-7810)
REAGENT SETUP
Mitotically inactivated MEF cells Mitotically inactivated MEFs should 
be plated on pregelatinized cell culture–treated plates 1 d before initiating 
XEN derivation MEFs can be derived from CF1 mice that are dissected 12.5–13.5 
d.p.c.; cells are passaged 3–5 times before inactivation, either by γ irradiation or by 
mitomycin C treatment.
ES cells ES cells should be thawed ~1–2 weeks before initiating XEN  
differentiation and passaged at least twice. ES cells are typically maintained 
on MEFs.
ES cell medium Prepare a solution of the following: DMEM supplemented 
with 15% (vol/vol) FBS (ES cell qualified), 2 mM L-glutamine,  
0.1 mM β-mercaptoethanol, 0.1 mM MEM non-essential amino acids,  
1 mM sodium pyruvate and 103 IU leukemia inhibitory factor. Optionally, 
add 1% (vol/vol) penicillin-streptomycin. Medium should be prepared in a 
sterile tissue culture hood and filter sterilized. The medium can be stored for 
up to 1 month at 4 °C.
MEF medium Prepare a solution of the following: DMEM supplemented 
with 15% (vol/vol) FBS, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol,  
0.1 mM MEM non-essential amino acids and 1 mM sodium pyruvate. 
Optionally, add 1% (vol/vol) penicillin-streptomycin. Medium should be 
prepared in a sterile tissue culture hood and filter sterilized. The medium can 
be stored for up to 1 month at 4 °C.
TS cell medium Prepare a solution of the following: advanced RPMI 
1640 supplemented with 20% (vol/vol) FBS, 2 mM L-glutamine , 0.1 mM 
β-mercaptoethanol, 1 mM sodium pyruvate; optional: 1% (vol/vol) penicillin-
streptomycin. Medium should be prepared in a sterile tissue culture hood and 
filter sterilized. The medium can be stored for up to 1 month at 4 °C. Prepare 
a freshly made aliquot supplemented with 24 ng ml − 1 recombinant FGF2 or 
FGF4 and 1 µg ml − 1 heparin.
MEF-conditioned medium Preparation of MEF-conditioned medium 
should begin at least 10 d before initiating the XEN derivation protocol B.  
Thaw and culture three 150-mm tissue culture plates of mitotically inacti-
vated MEFs in 25 ml of standard TS cell medium (not supplemented with 
FGF2/FGF4 and heparin) for 3 d. Collect the medium in 50-ml conical tubes 
and store the medium at  − 20 °C. Add another 25 ml of TS cell medium to 
each plate and repeat the procedure twice until 225 ml of MEF-conditioned 
medium have been collected. Thaw the frozen batches and centrifuge the 
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medium at 2,300g for 20 min at room temperature (20–25 °C) to remove 
debris. Filter-sterilize the medium and store it at 4 °C.
Standard XEN medium Prepare a solution of advanced RPMI 1640  
supplemented with 15% (vol/vol) FBS and 0.1 mM β-mercaptoethanol. 
Optionally, add 1% (vol/vol) penicillin-streptomycin. Medium should be 
prepared in a sterile tissue culture hood and filter sterilized. The medium can 
be stored for up to 1 month at 4 °C. Advanced RPMI 1640 contains glutamine; 
alternatively, RPMI medium can be used and requires the addition of 2 mM 
L-glutamine.
cXEN derivation medium Freshly prepare a solution of standard XEN  
medium supplemented with 0.01 µM all-trans retinoic acid dissolved in 
DMSO plus 10 ng ml − 1 activin A. A wide range of retinoic acid concentra-
tions can be used, ranging from 0.01 to 10 µM. The derivation medium  
can also be supplemented with 24 ng ml − 1 recombinant FGF2 or FGF4 and  
1 µg ml − 1 heparin, although this is not required if endogenous Fgf4 is intact. 
 Box 1 | Preparation of Gata6 cDNA for transfection or electroporation  
● tIMInG ~2 d 
1. In order to ensure sufficient quantity of plasmid DNA, a large-scale preparation of Gata6 cDNA plasmid by maxiprep is required for 
transfection. A circular Gata6 cDNA plasmid is generally used for chemical-based transfection, whereas for electroporation, the plasmid 
should be linearized using a unique restriction enzyme at a non-essential region, which will not affect the function of the gene and 
drug selection.
2. If linearized DNA is required then cut one time with a unique restriction enzyme that is in a region of the plasmid that will not 
affect the function. Linearize 100 µg of Gata6 cDNA plasmid by restriction enzyme digestion overnight at the optimal incubation  
temperature. Run a small aliquot on a 0.8% (wt/vol) agarose gel to ensure linearization.
3. For high-purity plasmid preparation, precipitate the linearized Gata6 cDNA with a 1/10-volume of salt (3 M sodium acetate) and 
2.5 volumes of 100% ethanol; store at  − 20 °C overnight.
4. The next day, spin the DNA at 16.1 × 103g for 5 min at 4 °C and wash the pellet once with 500 µl of 70% (vol/vol) ethanol.
5. Remove the supernatant and allow any remaining ethanol to evaporate in the hood for several min.
 crItIcal step To ensure sterility, work in a sterile tissue culture hood for this and subsequent steps.
6. Resuspend the DNA pellet in 100 µl of sterile PBS without Mg2 +  or Ca2 +  (a final DNA concentration of 1 µg µl − 1).
 crItIcal step The presence of salts could be detrimental to transfection efficiency and interfere with electroporation.
 pause poInt Plasmid DNA preparation can be done any time before transfection. The resuspended DNA can be kept at  − 20 °C for 
several months.
! cautIon Retinoic acid is light sensitive and may be harmful if ingested  
or absorbed.
Freezing medium Freshly prepare a solution of 10% (vol/vol) DMSO 
(Sigma-Aldrich, cat. no. D2650) and 90% (vol/vol) FBS. Keep the solution on 
ice or at 4 °C until immediately before use.
Gata6 cDNA for transfection Prepared as described in Box 1.
EQUIPMENT SETUP
Mouth-controlled pipette Assemble a mouth-controlled pipette. This is 
used for handling embryos and for dissociating blastocyst in vitro–matured 
outgrowths. Mouth-controlled pipettes can be assembled in a variety of 
designs (for variations see Nagy et al.28). A simple mouth pipettor can be 
made by inserting the pointed end of a P1000 filter tip into one end of a cut 
rubber tube and attaching a plastic mouthpiece to the other. A pulled glass 
Pasteur pipette can now be attached to the filter tip. Pasteur pipettes can be 
pulled either over a flame or by using a micropipette puller (Fig. 3).
Preparation of M2 drops
Petri dish
Tweezers
M2
M2
M2
Syringe
Flushing
Glass Pasteur pipette
Mouth-controlled
pipette
Stem cell
derivation
Mouthpiece Plastic tubing
Wash #1
Wash #2
Uterus
M2
Figure 3 | Recovery of blastocyst-stage embryos from uteri of adult female 
mice. Several drops of M2 medium are prepared on the lid of a 100-mm dish. The 
dissected and cleaned uterine horn of a pregnant female (3.5 d.p.c.) is placed 
in one drop. While securing the uterine horn with forceps, the needle of a 1-ml 
syringe is inserted and the uterine horn is flushed with ~0.2 ml of M2 medium. 
The flushed blastocysts are located under high magnification and transferred 
to a fresh drop of M2 medium using a mouth-controlled pipette. This transfer is 
repeated at least twice to wash away debris, lipid drops and blood cells.
procedure
preparation of MeF feeders ● tIMInG 15–30 min
1| Pregelatinize tissue culture plates for  >10 min with 1–2 ml of 0.1% (wt/vol) gelatin. Aspirate the gelatin before  
seeding the cells.
? trouBlesHootInG
2| One day before starting the derivation, place a frozen vial of mitotically inactivated MEFs in a 37 °C water bath until 
nearly thawed and transfer the contents into a 15-ml Falcon tube containing 5 ml of MEF medium. Centrifuge the medium at 
200g for 4 min at room temperature and aspirate the supernatant.
? trouBlesHootInG
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3| Resuspend the cell pellet in MEF medium and plate it at a density of 6 × 104 MEFs per well for a four-well plate,  
1.3 × 105 MEFs per well for a six-well plate or 7.8 × 105 cells per 100-mm tissue culture plate, and then incubate the plates 
overnight at 37 °C. The number of plates to prepare depends on the number of XEN cell derivations to be performed.  
Generally, four plates (4-well plates) per pregnant mouse for Steps 6A and 6B are sufficient, or a six-well plate for  
Steps 6C–F.
? trouBlesHootInG
4| The morning before starting the derivation, aspirate the medium on the MEF feeders and replace it with ES cell  
medium for derivation using ES cell conditions (Step 6A), with TS cell medium for derivation using TS cell conditions  
(Step 6B) or with XEN cell medium for derivation from ES cells (Steps 6C–F). When required, plate MEFs that  
carry drug-resistance genes, such as DR4 MEFs (resistant to neomycin, hygromycin, puromycin and Zeocin) (table 1).
? trouBlesHootInG
cell preparation
5| If you are deriving cells using ES or TS cell conditions, follow option A to collect E3.5 blastocysts. If you are deriving 
XEN cells from ES cells, follow option B.
(a) collecting e3.5 blastocysts (flushing)
 (i)  Dissect out the uterine horns of a pregnant mouse at 3.5 d.p.c. and place them on the lid of a 100-mm culture dish in 
a drop of M2 medium.
 (ii)  Under a dissection microscope (approximately ×10 total magnification), remove large fat pads and cut away the  
ovaries and oviducts. Place each of the cleaned uterine horns in a fresh drop of M2 medium.
 (iii)  With a 1-ml syringe, take up 0.5 ml of M2 medium and attach a needle (27 gauge). While securing the uterine horn 
with forceps, insert the needle and flush the uterine horn with ~0.2 ml of M2 medium (Fig. 3) and remove the uterine 
horn from the drop. Repeat this process with the second uterine horn.
 (iv)  Under higher magnification (~×30–×40), find the flushed blastocysts in both drops. 
? trouBlesHootInG
 (v)  By using a mouth-controlled pipette, transfer the blastocysts to a new drop of M2 medium. Repeat the step twice to 
wash away debris, lipid drops and blood cells.
 (vi)  Proceed with the derivation of XEN cells using either option A (ES cell conditions) or option B (TS cell conditions) in 
Step 6.
(B) es cell maintenance in medium with serum
 (i)  Thaw the ES cells rapidly in a 37 °C water bath and transfer them into a 15-ml Falcon tube containing 5 ml of MEF 
medium.
 (ii)  Centrifuge the tube at 200g for 4 min at room temperature, aspirate the supernatant and resuspend the ES cell pellet 
using 1 ml of ES cell medium.
 (iii)  Aspirate the medium on the irradiated MEFs and replace it with ES cell medium. Plate ~3 × 105 ES cells onto MEFs in 
one well of a six-well plate or 2 × 106 ES cells on a 100-mm tissue culture dish. Incubate the cells at 37 °C. 
 crItIcal step All 37 °C incubations should be carried out in a 5% CO2 humidified incubator.
 (iv)  Change the ES cell medium daily to maintain the cell line and monitor the cells. Proceed to the next step (passage) 
when they reach ~80% confluency; this typically occurs every 2–3 d.
 (v)  To passage the ES cells, wash the well that contains the cells with 1 ml of 1× PBS to remove residual proteins. Aspirate 
the PBS and add 0.25 ml of 0.05% (wt/vol) trypsin for a six-well plate. Rock the plate back and forth to dissociate the 
cells. Incubate the plate at room temperature for no more than 5 min until all the cells are nearly detached. Do not 
leave the cells in trypsin for longer than necessary.
 (vi)  Neutralize the trypsin with 1 ml of ES cell medium. Pipette the solution up and down with a P1000 pipette 
 approximately ten times to dissociate the cells into small clumps and single cells.
 (vii)  With a P1000 pipette, add 50 µl of the dissociated ES cells onto a freshly prepared MEF well in 2 ml of fresh ES cell 
medium to continue growing the cell line at a ~1/25 dilution (roughly, a 1/10 dilution should be ready for passag-
ing in 2 d, a 1/25 dilution in 3 d and a 1/40 dilution in 4 d). The trace amount of trypsin on the first day will not 
adversely affect the cells. 
 crItIcal step The use of a pipette smaller than P1000 can damage the cells and should be avoided, except to pick 
colonies or count cells on a hemocytometer. In order to ensure healthy recovery after thawing, ES cells should be  
passaged at least once before proceeding with the steps below.
 (viii)  If you are electroporating the cells for XEN derivation, passage the cells the day before. If the cells are grown on MEF, 
MEF-deplete the cells at the same time (see Step 5B(ix)).
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 (ix)  MEF-deplete the ES cells. This step is unnecessary if the ES cells are grown in MEF-free conditions. Plate the cells onto 
a pregelatinized plate in ES cell medium the day before proceeding to XEN derivation. Alternatively, ES cells may be 
MEF-depleted on the day of derivation by plating them on a pregelatinized 100-mm plate containing 7–10 ml of ES 
medium (no LIF) for 30 min. After 30 min, the majority of MEFs should have adhered to the pregelatinized plate.  
Tilt the 100-mm plate to collect the supernatant medium plus ES cells and transfer it into a 15-ml Falcon tube. Do not 
wash the plate with fresh medium as this may dislodge the attached MEFs.
Xen derivation ● tIMInG 15–20 d
6| If you are deriving XEN cells under ES cell conditions, follow option A. If you are deriving XEN cells under TS cell condi-
tions, follow option B. If you are chemically transfecting ES cells with a Gata6 cDNA plasmid using cationic polymer, follow 
option C. If you are chemically transfecting ES cells with a Gata6 cDNA plasmid using lipopolyamine, follow option D. If you 
are electroporating ES cells with a Gata6 cDNA plasmid, follow option E. If you are deriving XEN cells from ES cells using 
growth factors, follow option F.
? trouBlesHootInG
(a) Xen cell derivation under es cell conditions
 (i)  Day 1. Thoroughly clean a dissection microscope with 70% (vol/vol) ethanol. By using a mouth-controlled pipette, 
place one blastocyst per feeder-covered well in the prepared four-well plates (Fig. 4). 
 crItIcal step The plates should be incubated in a 5% CO2 humidified incubator at 37 °C, except while performing 
Step 6A(i–iv), which can be performed under ambient conditions. 
? trouBlesHootInG
 (ii)  Day 2. Observe the plates under a microscope. The blastocysts should have hatched from the zona pellucida and attached 
to the feeder layer (Fig. 4).
 (iii)  Day 3. Observe the plates under 
a microscope. The blastocysts 
should have started to form an 
outgrowth (Fig. 4). Carefully 
aspirate the medium and replace 
it with fresh ES cell medium. 
? trouBlesHootInG
 (iv)  Day 4. Thoroughly clean a dis-
section microscope with 70% 
(vol/vol) ethanol. Dilute 0.25% 
(wt/vol) trypsin to a sufficient 
volume of 0.01% (wt/vol) 
trypsin/1× PBS. Wash the cells 
with 500 µl of 1× PBS. Aspirate 
the PBS and add 100 µl of 0.1% 
Figure 4 | Timeline for XEN cell derivation from 
mouse blastocysts. Protocol for the derivation  
of XEN cells from blastocysts. Day 0: feeder  
cell–coated four-well plates are prepared. Day 1:  
medium is replaced and a freshly flushed E3.5 
blastocyst is placed in the center of the well. 
Day 2: the blastocyst hatches and attaches 
to the feeder cells. Day 3: the blastocyst has 
formed an outgrowth. Medium is replaced. Day 
4: the prominent outgrowth is trypsinized and 
disaggregated with a P20 pipette. Days 5–10: the 
medium is replaced every other day and the plate 
is observed daily. Days 10–15: XEN-like cells with 
stellate and refractile morphology will emerge. The 
medium is replaced every other day and the plate 
is observed daily. Day 15 and onward: After 70% 
confluency is attained, the XEN cells are passaged 
onto a well in a six-well plate and subsequently 
into a 100-mm dish. After three more passages 
they can be MEF-depleted and the XEN cell line 
can be frozen. Scale bars, 100 µm.
Day 1
Plate out embryos
on MEFs
Prepare MEF feeder cells
Disaggregate outgrowth
by pipetting up and down
Change medium every
other day
Observe: XEN cell
colonies are forming
Change medium every
other day
Wait until 70% confluency
is achieved and passage
to a bigger well. After three
passages it is possible to
remove the feeder cells.
Replace medium and
place E3.5 blastocyst
Observe: blastocyst
hatches and attaches
to feeders
Observe: outgrowth is
formed
Replace medium
Disaggregate
outgrowths
XEN cell lines
> Day 15Day 4
Day 0
Day 4 Days 5–10 Days 10–15 ∞
Day 1 Day 2 Day 3
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(wt/vol) trypsin to each well. Incubate the plates at 37 °C for 5 min. While observing the cells under a cleaned  
dissection microscope, use a P20 pipette to disaggregate the outgrowth by pipetting up and down several times.  
Add 400 µl of fresh ES cell medium.
 (v) Day 5. Carefully replace the medium with fresh ES cell medium.
 (vi) Days 6–14. Replace the medium every other day until XEN cell colonies can be observed (Fig. 4).
 (vii)  Day 15–indefinite. When 70% confluency is achieved, passage the cells onto a feeder-covered well of a six-well plate. 
From this point onward, the cells can be cultured in standard XEN medium. Repeat the step, but passage the cells onto 
a feeder-covered 100-mm dish. Passage the cells two more times. If desired, remove feeders and freeze the XEN cell 
line as described in Step 7.
(B) Xen cell derivation under ts cell conditions
 (i)  Day 1. Thoroughly clean a dissection microscope with 70% (vol/vol) ethanol. By using a mouth-controlled pipette, 
place one blastocyst per feeder-covered well in the prepared four-well plates (Fig. 4). 
 crItIcal step The plates should be incubated in a 5% CO2 humidified incubator at 37 °C, except while performing 
(Step 6B(i–iv)), which can be performed under ambient conditions. 
? trouBlesHootInG
 (ii)  Day 2. Observe the plates under a microscope. The blastocysts should have hatched from the zona pellucida and  
attached to the MEF feeder layer (Fig. 4).
 (iii)  Day 3. Observe the plates under a microscope. The blastocysts should have started to form an outgrowth (Fig. 4). 
Carefully aspirate the medium and replace it with fresh TS cell medium. 
? trouBlesHootInG
 (iv)  Day 4. Thoroughly clean a dissection microscope by wiping it with 70% (vol/vol) ethanol. Dilute 0.05% (wt/vol) 
trypsin to a sufficient volume of 0.01% (wt/vol) trypsin/1× PBS. Wash the cells with 500 µl of 1× PBS. Aspirate the 
PBS and add 100 µl of 0.01% (wt/vol) trypsin to each well. Incubate the plates at 37 °C for 5 min. While observing 
the cells under a dissection microscope, use a P20 pipette to disaggregate the outgrowth by pipetting up and down 
several times. Add 400 µl of 30% TS cell medium/70% MEF-conditioned medium.
 (v) Day 5. Carefully replace the medium with fresh 30% TS cell medium/70% MEF-conditioned medium.
 (vi) Days 6–14. Replace the medium every other day until XEN cell colonies are observed (Fig. 4).
 (vii)  Day 15–indefinite. When cells reach 70% confluency, passage the cells onto a feeder-covered well of a six-well plate. 
From this point onward, the cells can be cultured in standard XEN medium. Repeat the step, but passage the cells onto 
a feeder-covered 100-mm dish. Passage the cells two more times. If desired, remove the feeders and freeze the XEN 
cell line as described in Step 7.
(c) chemical transfection of es cells with a Gata6 cdna plasmid using a cationic polymer (e.g., Xfect) for transient or 
stable transfection
 (i)  Day 1. Re-plate MEF-depleted cells onto pregelatinized plates. Cells plated at a density of 7 × 104 per well of a 24-well 
plate will be ready for transfection ~12 h after plating.
 (ii)  Day 2. On the day of transfection, ensure that the ES cells are ~80% confluent. All subsequent volumes are for one well 
of a 24-well plate and may be scaled up or down according to the manufacturer’s recommendations (Clontech).
 (iii)  Prepare two tubes: the first tube contains a 25-µl solution of 1 µg of Gata6 cDNA plasmid diluted with Xfect reaction 
buffer in a sterile 1.5-µl Eppendorf tube; the second tube contains 0.5 µl of Xfect polymer (prevortexed) plus 24.5 µl 
of Xfect reaction buffer in a separate 1.5-µl Eppendorf tube. Use an empty plasmid (i.e., typically the same plasmid 
containing a constitutively active fluorescent reporter instead of Gata6) or sterile dH2O as negative controls.
 (iv)  Vortex each tube, and then add the polymer solution to the DNA solution (total volume  =  50 µl) and vortex again. 
Incubate the DNA-polymer solution for 10 min at room temperature.
 (v)  To one well of the 24-well plate, add the 50 µl of DNA-polymer solution dropwise. Mix the solution gently by tilting 
the plate back and forth, and then incubate the plate in a 5% CO2 humidified incubator at 37 °C for 3 h.
 (vi)  Aspirate the medium containing the DNA-polymer complex from the ES cells, replace it with 0.5 ml of fresh ES cell 
medium and incubate the plate in a 5% CO2 humidified incubator at 37 °C overnight. 
? trouBlesHootInG
 (vii)  Day 3. Replace the ES medium in each well with 0.5 ml of XEN medium and incubate the plate overnight in a 5% CO2 
humidified incubator at 37 °C.
 (viii)  Days 4–10. If the Gata6 cDNA plasmid has been engineered to also express a drug-resistance gene, then drug selection 
can be used to expand successfully transfected cells. Replace with XEN cell medium supplemented with the appropri-
ate drug selection (table 1). Replace with fresh XEN medium containing drug selection daily for ~10 d. XEN-like cells 
should appear within 5 d.
 (ix)  Day 11–indefinite. Enzymatically passage the Gata6 cDNA–transfected cells with 0.05% (wt/vol) trypsin onto a prege-
latinized 100-mm dish. Continue selection with drugs in order to establish a XEN cell line. Collect a fraction of the 
cells for genotyping and freeze the remaining XEN cells as described in Step 7.
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(d) chemical transfection of es cells with a Gata6-cdna 
plasmid using lipopolyamine (e.g., lipofectamine 2000) 
for transient or stable transfection
 (i)  Day 1. Re-plate MEF-depleted cells onto pregelatinized 
plates. Cells plated at a density of 7 × 104 per well of 
a 24-well plate will be ready for transfection ~12 h 
after plating.
 (ii)  Day 2. On the day of transfection, ensure that the ES 
cells are ~80% confluent. All subsequent volumes are 
for one well of a 24-well plate and may be scaled up 
or down according to the manufacturer’s recommenda-
tions (Invitrogen).
 (iii)  Prepare two tubes: the first tube contains a 50-µl solu-
tion containing 1 µg of Gata6 cDNA plasmid diluted with 
Opti-MEM I in a sterile 1.5-µl centrifuge tube; the second 
tube contains 4.5 µl of Lipofectamine 2000 plus 45.5 µl 
of Opti-MEM I in a separate 1.5-µl centrifuge tube. Use an 
empty plasmid (i.e., typically the same plasmid contain-
ing a constitutively active fluorescent reporter instead of 
Gata6) or sterile dH2O as negative controls. Incubate the 
tubes for 5 min at room temperature.
 (iv)  Gently mix the diluted plasmids (Gata6 or  
control) with the diluted Lipofectamine reagent (total 
volume  =  100 µl) and incubate the tubes for 20 min at room temperature to allow for the formation of DNA-liposome 
complexes. During the 20-min incubation period, replace the medium of the plated cells with 0.5 ml of fresh ES cell 
medium without antibiotics.
 (v)  To one well of the 24-well cell culture dish, add 100 µl of DNA-liposome complex dropwise. Mix gently by tilting the 
plate back and forth, and then incubate the plate overnight in a 5% CO2 humidified incubator at 37 °C. 
? trouBlesHootInG
 (vi)  Day 3. Replace the ES medium in each well with 0.5 ml of XEN medium and incubate the plate overnight in a 5% CO2 
humidified incubator at 37 °C.
 (vii)  Days 4–10. If the Gata6-cDNA plasmid has been engineered to also express a drug-resistance gene, then drug selection 
can be used to expand successfully transfected cells. Replace the medium with XEN cell medium supplemented with 
the appropriate drug selection (table 1). Replace with fresh XEN medium containing drug selection daily for ~10 d. 
XEN-like cells should appear within 5 d.
 (viii)  Day 11–indefinite. Enzymatically passage the Gata6 cDNA–transfected cells with 0.05% (wt/vol) trypsin onto a 
 pregelatinized 100-mm dish. Continue selection with drugs to establish a XEN cell line. Collect a fraction of the cells 
for genotyping and freeze the remaining XEN cells as described in Step 7.
(e) electroporation of es cells with a Gata6 cdna plasmid for transient or stable transfection
 (i)  Day 1. On the day of electroporation, ensure that the ES cells are ~80% confluent in one 100-mm tissue culture plate. 
Aspirate the medium from the 100-mm culture plate and wash the cells with 5 ml of PBS.
 (ii)  Aspirate the PBS and trypsinize the cells with 1 ml of 0.05% (wt/vol) trypsin. Quench the trypsinized cells with 3 ml 
of MEF medium.
 (iii)  Transfer the ES cells to a 15-ml Falcon tube and pellet the cells at 200g for 4 min at room temperature. Aspirate the 
MEF medium and resuspend the ES cell pellet with 5 ml of PBS.
 (iv) Pellet the cells at 200g for 4 min at room temperature. Aspirate the PBS and resuspend the ES cells in 0.7 ml of PBS.
 (v)  Gently mix the linearized Gata6 cDNA sample with the resuspended cells and incubate the mixture for 5 min at  
room temperature.
 (vi)  Transfer the DNA-cell mixture to a 4-mm electroporation cuvette. Electroporate the mixture at 500 µF/230 V. The time 
constant should be between 6 and 8 ms.
 (vii)  Allow the ES cells to recover in the cuvette for 5 min at room temperature and then transfer the cells into 10 ml of ES 
cell medium; plate the entire volume onto a MEF-coated 100-mm plate. Mix gently by tilting the plate back and forth, 
and then incubate the plate overnight at 37 °C.
 (viii)  Day 2. Exchange the medium with 10 ml of standard ES cell medium and incubate the plate overnight in a 5% CO2 
humidified incubator at 37 °C.
 (ix)  Days 3–9. If the Gata6-cDNA plasmid has been engineered to also express a drug-resistance gene, then drug selection 
can be used to expand successfully transfected cells. Exchange the medium with 10 ml of standard XEN cell medium 
taBle 1 | Drug selection.
Marker Gene product selection method
Neo Aminoglycoside 
 phosphotransferase; neo 
gene from the bacterial 
transposon Tn5
Select cells in G418  
(0.1–1.0 mg ml − 1), an 
aminoglycoside that blocks 
protein synthesis and is  
similar to kanamycin
Hyg Hygromycin-B-transferase; 
hyg gene from Escherichia 
coli
Select cells in hygromycin-B 
(10–300 mg ml − 1), an amino-
cyclitol that inhibits protein 
 synthesis
Pac/Puro Puromycin-N-acetyl 
 transferase; pac gene from 
Streptomyces alboniger
Select cells in puromycin 
(0.5–5 mg ml − 1), an 
 antibiotic that inhibits  
protein synthesis
Zeo Bleomycin-binding 
 protein; a zeo gene (a.k.a. 
blaR) is located on the 
bacterial transposon Tn5
Select cells in bleomycin 
or commercially available 
Zeo (50–500 mg ml − 1), an 
 antibiotic that binds DNA and 
blocks RNA synthesis
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supplemented with the appropri-
ate drug selection (table 1). 
Replace the medium with fresh 
XEN medium containing drug se-
lection daily for ~10 d. XEN-like 
cells should appear within 5 d. 
? trouBlesHootInG
 (x)  Day 10–indefinite. Enzymatically passage the Gata6 cDNA–transfected cells with 0.05% (wt/vol) trypsin onto a prege-
latinized 100-mm dish. Continue selection with drugs to establish a XEN cell line. Collect a fraction of the cells for 
genotyping and freeze the remaining XEN cells as described in Step 7.
(F) cXen cell derivation from es cells
 (i) Day 1. Enzymatically passage MEF-depleted ES cells with 0.05% (wt/vol) trypsin. Inhibit the trypsin with XEN medium.
 (ii)  Centrifuge the ES cells at 200g for 4 min at room temperature and aspirate the supernatant. Be stringent in aspirating (without 
touching the pellet). This step removes ES medium, which is important as lingering LIF potentially inhibits cXEN derivation.
 (iii)  Resuspend the pellet in ~5 ml of standard XEN medium. Mix the tube well and immediately remove two 20-µl aliquots to count 
MEF-depleted ES cells on a hemocytometer. Take the average (n  =  3) number of cells in one big square (16 little squares), 
multiply by 104 and multiply by the number of milliliters of medium, which will be equal to the total number of cells.
 (iv)  Remove the gelatin from the six-well cXEN derivation plate and add fresh standard XEN medium. Add the appropriate 
volume of trypsinized ES cells to start the cXEN derivation procedure for a final density of 1 × 104 cells per cm2  
(i.e., 9.6 × 104 cells per well of a six-well plate; Fig. 5). Incubate the plate overnight at 37 °C in standard XEN  
medium. The cell density is an important determinant of differentiation efficiency, and as different ES cell lines 
 proliferate at different rates, we recommend determining the optimal density for each line.
 (v)  Day 2. Twenty-four hours after the initial plating, aspirate the standard XEN medium and replace it with 2 ml of cXEN 
derivation medium per well (Fig. 5). Incubate the plate overnight in a 5% CO2 humidified incubator at 37 °C.
 (vi)  Day 3. Aspirate the cXEN derivation medium and replace it with fresh cXEN derivation medium. Incubate the plate 
overnight in a 5% CO2 humidified incubator at 37 °C.
 (vii)  Day 4. Enzymatically passage the cells with 0.05% (wt/vol) trypsin. Quench the trypsin with 0.5 ml of standard XEN 
medium. Aspirate the MEF medium in a MEF-coated six-well plate and replace it with 2 ml of standard XEN medium per 
well. Transfer the entire contents of the differentiated cells and distribute the cells evenly into the well of the MEF-
coated plate (1:1 dilution; Fig. 5).
 (viii)  Days 5–11. Aspirate the medium from the cXEN cells and replace it with fresh standard XEN medium every day or every 
other day depending on confluency. XEN-like cells with stellate and refractile morphology will emerge ~5 d after the 
first passage on MEFs; however, the well will also contain cells of different morphologies. Use standard XEN medium 
hereafter. During the first (and sometimes second) passage, the cXEN cells recover better when MEFs are present, 
although they are not a requirement. FGF2/FGF4 and heparin can also be added during the derivation, but they too are 
not a requirement as long as endogenous Fgf4 is intact.
Figure 5 | Timeline for cXEN cell derivation  
from mouse ES cells. Protocol for the conversion 
of ES cells to cXEN cells using growth factors.  
Day  − 1: ES cells are maintained in ES medium  
on MEFs. Day 0: ES cells are passaged onto a  
pregelatinized plate for MEF depletion.  
Day 1: ES cells are enzymatically passaged with  
0.05% (wt/vol) trypsin and plated at a density of  
1 × 104 cells per cm2 in standard XEN medium. 
Days 2 and 3: the medium is replaced with cXEN 
derivation medium daily (0.01–10 µM retinoic 
acid plus 10 ng ml − 1 activin A). Days 4–11: 
cells are enzymatically passaged onto MEFs in 
XEN medium. The medium is replaced every day 
or every other day depending on confluency. 
XEN-like cells with stellate and refractile 
morphology will emerge within ~5 d. Days 12–19: 
XEN-like cells are picked manually and placed 
in a MEF-coated or pregelatinized plate in XEN 
medium. They are passaged two more times onto 
pregelatinized plates and the cXEN cell line is 
frozen. Scale bars, 100 µm.
Day 1
Day –1
Days 4–11 Days 12–19 ∞ ∞
Day 0 Day 1 Days 2 and 3
Plate MEF-
depleted mESCs
Maintain mESCs on
MEFs
Passage on MEFs in XEN
medium; Observe: cXEN cell
colonies are forming
Pick cXEN colonies into
new well in XEN medium
Wait until 70% confluency
is achieved and passage to
a bigger well without MEFs
cXEN cell line
Perform MEF depletion
in mESC medium
Plate cells at a density of
1 × 104 cells per cm2 in
XEN medium
Replace with cXEN
derivation medium
Passage
cXEN cells
cXEN cells lines
Day 4 > Day 20
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 (ix)  Days 12–19. Manually pick XEN-like cells using a 20-µl pipette under a microscope to facilitate the ES to cXEN cell 
derivation (Fig. 5). Depending on the density, place the isolated cells in a MEF-coated (low density of XEN-like cells) or 
pregelatinized plate (high density of XEN-like cells) in XEN medium and continue feeding with standard XEN medium. 
? trouBlesHootInG
 (x)  Day 20–indefinite. Once the cells reach 70–90% confluency, passage the cells enzymatically with 0.05% (wt/vol) 
trypsin and plate them onto a pregelatinized or MEF-coated 100-mm plate or several wells of a six-well plate. The 
majority of cells should morphologically resemble XEN cells. If there are any contaminating cells that are not XEN-like 
cells, aspirate, pick away or reciprocally pick the XEN-like cells to enrich for this population in a new plate or well. 
Passage two more times onto pregelatinized plate or well and freeze the cXEN cell line (Step 7).
dna extraction and freezing cells ● tIMInG 1–2 d
7| cXEN or XEN cells can be frozen and thawed using conventional stem cell freeze-thaw protocols in freezing medium. 
Passage as above and resuspend the trypsinized cell pellet in prechilled (4 °C) freezing medium as described in option A. If 
you wish to extract DNA from Gata6 cDNA–targeted ES cells, there are a number of different extraction protocols that may be 
used. Option B describes the Promega SV Wizard purification system.
(a) Freezing cells
 (i) Transfer the resuspended cells into prelabeled cryotube vials.
 (ii)  Quickly transfer the cryotube vials to  − 80 °C freezer overnight covered with Styrofoam. 
 pause poInt For long-term storage, keep cells frozen in a liquid nitrogen dewar.
(B) lysing cells for genomic dna extraction
 (i)  Enzymatically passage cells as above and resuspend the cell pellet in the Promega Wizard SV lysis buffer according to 
the manufacturer’s instructions, and then mix the cell lysate by pipetting. 
 pause poInt The cell lysates can be frozen at  − 80 °C until needed.
 (ii) Transfer each sample lysate from the cell culture plate to a separate Wizard SV minicolumn assembly.
 (iii) Spin the assembly at 16.1 × 103g for 3 min at room temperature.
 (iv)  Remove the minicolumn from the assembly and discard the liquid in the collection tube. Replace the minicolumn into 
the collection tube.
 (v)  Add 650 µl of Wizard SV wash solution (with 95% (vol/vol) ethanol added) to each assembly. Centrifuge the tube at 
16.1 × 103g for 1 min at room temperature. Discard the liquid from the collection tube.
 (vi) Repeat Step 7B(v) for a total of four washes.
 (vii)  Discard the liquid from the collection tube and reassemble the minicolumn assembly. Centrifuge for 2 min at 16.1 × 
103g at room temperature to dry the binding matrix.
 (viii)  Transfer the Wizard SV minicolumn to a new 1.5-ml tube. Add 50 µl of room-temperature, nuclease-free water. Incu-
bate the minicolumn for 2 min at room temperature.
 (ix) Centrifuge the minicolumn at 16.1 × 103g for 1 min at room temperature.
 (x) Remove the minicolumn and store the purified DNA at  − 20 or  − 70 °C for several months or years, respectively.
? trouBlesHootInG
Troubleshooting advice can be found in table 2.
taBle 2 | Troubleshooting table.
step problem possible reason solution
1–6 Contamination Poor sterile technique Ensure that all surfaces are thoroughly cleaned 
with 70% (vol/vol) ethanol before use and 
observe proper tissue culture technique
5A(iv) Finding blastocysts Lipid drops, blood cells and debris are 
impeding the view
Adjust magnification and mirror angle to 
 identify blastocysts by their distinctive 
 surrounding zona pellucida
6A(i), 6B(i) Differentiation Blastocyst misattachment Blastocysts should be placed in the center of 
the well to avoid attachment to the sides of 
the well
(continued)
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● tIMInG
Steps 1–5, preparation of MEF feeders: 15–30 min
Step 6, XEN derivation: 15–20 d
Step 7, DNA extraction and freezing cells: 1–2 d
Box 1, preparation of Gata6 cDNA for transfection or electroporation: ~2 d
antIcIpated results
We have used the protocols described here to establish XEN cell lines from either mouse blastocysts or ES cells. XEN cell lines 
exhibit characteristic heterogeneous morphology with both highly refractile phase-bright and epithelial-like cells (Figs. 2, 
4 and 5). XEN cells can be distinguished from mouse ES cells as the latter form dome-shaped clusters of cells with charac-
teristic high nuclear-to-cytoplasmic ratio4,5, whereas the former grow as individual cells and the nucleus of each cell is not 
clearly distinguishable (compare Fig. 2). XEN cells are also distinct from TS cells that grow as epithelial colonies comprising 
cells with distinct nuclei and can differentiate into multinucleated trophoblast giant cells in vitro2 (compare Fig. 2). It was 
previously demonstrated that XEN cells oscillate between these two morphologies3. All XEN cell lines retain the expression of 
key XEN-associated genes including the GATA transcription factor Gata4, the SOX factor Sox7 and Disabled homolog 2  
Dab2 (supplementary Fig. 1). Notably, these genes are not homogeneously expressed in all cells within a XEN cell line 
(supplementary Fig. 1), and it remains unclear whether heterogeneity in morphology and gene expression reflects a fixed or 
oscillating heterogeneity representing distinct XEN cell types or substrates present in culture. Notably, mouse XEN cells  
usually lack the expression of ES cell–associated genes including octamer-binding transcription factor Oct4 (supplementary 
Fig. 1) and Nanog. XEN cells self-renew indefinitely in culture in the absence of exogenous growth factors such as FGF2  
(refs. 13,16). Moreover, XEN cells can be directed to differentiate into α-fetoprotein (Afp)-expressing visceral endoderm-like 
cells with the addition of BMP4 (refs. 18,19) and are committed to primitive endoderm-derived lineages in chimeric  
embryos3,34. Although not reported in the literature, in our own experience the karyotype of XEN cells can change over 
time and cell lines can acquire karyotypic anomalies with extended passage in culture (N.S. and A.-K.H., unpublished 
 observations). It is therefore preferable to work with cells that are of as low a passage as possible. It should be noted 
that even clonal XEN cell lines exhibit some degree of variability, for example, in the ratio of cells exhibiting different 
 morphologies and/or in the expression of molecular markers. It is currently not clear whether this inherent variability reflects 
the cell of origin within an embryo or ES cell culture, cell culture history or an unidentified stochastic or deterministic 
 factor. Furthermore, although there is no ‘gold standard’ XEN cell line that is used across laboratories, as a point of reference, 
taBle 2 | Troubleshooting table (continued).
step problem possible reason solution
6A(iii), 6B(iii) Small outgrowth Insufficient time to develop If no prominent outgrowth can be observed, 
wait an additional day before proceeding with 
the next steps
6 Low cell density Low viability and/or contamination It is imperative to closely observe the cells 
daily. XEN cell colonies can be observed as 
early as 10 d but might take up to 15 d to 
appear. Check for possible contamination
6B TS cells outcompeting XEN 
cells
Addition of FGF and heparin; dissociation 
of the outgrowth
TS cells are more likely to outcompete the XEN 
cells later on. If this is observed, desist from 
adding FGF and heparin to the TS cell medium, 
and dissociate the outgrowth less rigorously. 
In some cases, it can be beneficial to entirely 
refrain from dissociating the outgrowth
6C, 6D, 6E Insufficient expression of 
exogenous Gata6
CMV promoter may be silenced in ES cells We recommend using a plasmid with an EF1A 
or CAGG promoter to ensure robust expression
6D Low transfection efficiency Serum in the medium may interfere with 
DNA-liposome complex formation
Opti-MEM I can be used during the overnight 
incubation instead of ES cell medium without 
penicillin or streptomycin to improve the 
transfection efficiency; however, this may 
compromise ES cell viability
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especially when first establishing methods for XEN cell culture within a laboratory, it is advisable to obtain an established 
and characterized XEN cell line from another laboratory. In contrast to ES cells, no clear strain biases have been reported 
for the derivation of XEN cells from embryos or conversion from ES cells. This is likely because the protocols for XEN cell 
derivation, as provided here, are very efficient as compared with most non-inhibitor protocols for ES cell derivation. Notably, 
even though XEN cells are a relatively new stem cell type, which can be used in a number of applications, in the future, it 
will be important to compare the differentiation efficiency and molecular identity of XEN cells derived under distinct culture 
conditions to determine whether there may be biases in potential and/or differences in gene expression. In all, XEN cells are 
emerging as a useful stem cell model for understanding the convergence of signaling and transcriptional control during XEN 
cell–fate specification and differentiation.
Note: Supplementary information is available in the online version of the paper.
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Molecular characteristics of XEN cell lines. Immunofluorescence analysis of mouse ES cells 
(mESC), embryo-derived XEN cells, cXEN cells and iXEN cells generated by Gata6-
overexpression (OE) in mESCs after 6 days. Cell lines were analyzed for the expression of 
Oct4 (sc-5279, Santa Cruz Biotech, 1:500), Dab2 (SC-13982, Santa Cruz Biotech, 1:500), 
Gata4 (SC-9053, Santa Cruz Biotech, 1:500) or Sox7 (MAB2766, R&D, 1:500) (red) with 
DAPI (blue) merge using the method described in reference 14. Scale bars: 100 µm.
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IntroDuctIon
Embryonic stem cells (ESCs) are the ex vivo equivalent of the 
epiblast lineage of the blastocyst, and therefore they share the 
same developmental potential to differentiate into any one of 
the three primary germ layers: mesoderm, definitive endoderm 
and ectoderm (Fig. 1). This developmental pluripotency com-
bined with a high capacity for self-renewal in vitro are the defin-
ing features of ESCs. Mouse embryonic stem cells (mESCs) are 
derived from preimplantation-stage embryos1,2. The progenitor 
cells that give rise to mESCs reside in the epiblast of the late blasto-
cyst (~4  d post coitum (d.p.c.)) and express several pluripotency- 
associated factors, including OCT3/4 (officially known as POU5F1) 
and NANOG3. In addition to their capacity for self-renewal and 
stable pluripotency in vitro, mESCs have the defining capacity to 
populate the germline after microinjection into, or aggregation 
with, host embryos, making mESCs essential tools for genetic 
engineering4. The Nobel prize–winning discovery that genes could 
be genetically modified in mice by using mESCs was published 
over 30 years ago, and since then nearly 50,000 genetically modi-
fied alleles have been created by individual investigators around 
the world and by the International Knockout Mouse Consortium 
(IKMC, http://www.mousephenotype.org/martsearch_ikmc_
project) which endeavors to create null and/or conditional null 
alleles for every gene in the mouse genome5,6. mESCs are also 
used for basic research on pluripotency and for the development 
of stem cell–based therapies as the starting material for directed 
differentiation of enriched, defined cell types in vitro.
Derivation of mESCs
Despite knowledge of the basic requirements for mESCs to main-
tain pluripotency, derivation of mESCs remained inefficient, and 
it was limited to just a few mouse strains for many years7. These 
so-called permissive strains included 129 substrains, as well as 
the most commonly used inbred mouse strain C57BL/6. Early 
protocols showed the requirement of leukemia inhibitory factor 
(LIF) to activate signal transducer and activator of transcription 3 
(STAT3), bone morphogenetic protein (BMP) (or serum) and 
mitotically inactivated feeder layers, preferably mouse embryonic 
fibroblasts (MEFs), to prevent the differentiation of mESCs in vitro. 
However, derivation efficiency in permissive strains was at best 
30%, as determined by the percentage of embryos giving rise 
to stable mESC lines8,9. Moreover, in nonpermissive mouse 
strains, such as CBA, NOD, DBA and others, derivation efficiency 
was either extraordinarily low or nonexistent7. Therefore, for 
mammalian geneticists who rely on specific inbred strain back-
grounds for human disease modeling, genetically engineered 
alleles created in 129, C57BL/6 or hybrid ES cells required 10–20 
backcross generations (up to 2 years) to create the desired genetic 
background. Moreover, for mammalian species other than the 
mouse, genetic engineering was simply not possible owing to 
an inability to derive legitimate ES cells despite considerable 
effort over many years. Recent advances in site-specific nuclease 
technologies (e.g., zinc-finger nucleases (ZFNs), transcription 
activator–like effector nucleases (TALENs) and clustered regularly 
interspersed short palindromic repeats (CRISPRs)/Cas)) are 
enabling direct, targeted deletion and targeted, sequential gene 
modifications via pronuclear injection of mouse embryos10 and 
other species, including rat11,12. For genetic engineering, these 
technologies circumvent the need for ES cells. However, the appli-
cability for multifaceted genomic modifications via homologous 
recombination with large inserts, across a variety of strains, has 
not yet been demonstrated.
Derivation of mESCs from nonpermissive strains
To overcome strain and species limitations to ES cell derivation, 
a variety of approaches have been used. For example, on the basis 
of the premise that the presence of primitive endoderm caused 
loss of pluripotency in mES cell progenitors within the inner cell 
mass (ICM), careful excision of the epiblast by biopsy or immu-
nosurgery was shown to improve the derivation efficiency3,13. 
In addition, for many years, delayed implantation or diapause 
induction by ovariectomy or tamoxifen injection was also used to 
promote derivation efficiency, possibly via developmental stasis, 
during which epiblasts have an opportunity to expand. Finally, 
as knowledge of the genes required for early lineage specification 
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and pluripotency has grown, protocols for the efficient derivation 
of mES cells by promoting or inhibiting the expression of specific 
genetic pathways were developed. Oct4 (Pou5f1) is a transcription 
factor that is essential for the maintenance of pluripotency in cells 
of the ICM, the epiblast and in mES cell lines. Importantly, loss 
of Oct4 was shown to be a feature of cultured embryos that failed 
to give rise to stable ES cell lines14. On the basis of this discovery, 
culture conditions that promote Oct4 expression, namely inhi-
bition of the MAP kinase pathway, were introduced. However, 
successful derivation of mES cells from the recalcitrant strain 
background, CBA, still required a combination of diapause 
induction, epiblast excision and inhibition of MEK kinase via 
PD98059 (ref. 14). In the context of these modifications to 
traditional ES cell derivation protocols, derivation efficiency in 
the CBA strain was ~25%, which is a significant advance for a 
nonpermissive strain14.
The pluripotent ground state and overcoming barriers to 
mESC derivation
The discovery that self-renewal and pluripotency are intrinsic 
properties of mESCs was demonstrated by Smith and colleagues14, 
who showed that the inhibition of MEK/ERK and glycogen syn-
thase kinase-3 (GSK3) signaling (three inhibitors (3i): PD184352, 
PD173074/SU5402 and CHIR99021, respectively) were together 
sufficient, combined with activation of STAT3 by LIF (3i/LIF), 
to promote the pluripotent ground state of emergent ESCs from 
mice and from rats15–17. These laboratories went on to show that 
the inhibition of FGF receptor signaling is dispensable in the con-
text of more potent inhibition of MEK signaling (2i: CHIR99021 
to inhibit GSK3β and PD0325901 to inhibit MEK1/2)16. Both 
3i/LIF and, subsequently, 2i/LIF culture conditions have since 
been successfully applied for efficient (50–70%) derivation of 
germline-competent mESCs from recalcitrant strains such as 
NOD, CBA and DBA18–21. Moreover, these culture conditions 
have been used to successfully derive germline-competent rat 
ESCs from rat embryos16,17, which is an accomplishment that 
quickly led to the creation of the first rat gene knockout by 
homologous recombination in rESCs22. The successful deriva-
tion of ESCs from recalcitrant strains and from rat by using 2i/LIF 
culture conditions suggests that emergent ESCs from these strains 
or species are unable to maintain a pluripotent ground state under 
traditional ESC culture conditions (serum + LIF). In fact, it was 
later shown that, unlike emergent ESCs from permissive strain 
background (e.g., 129), emergent ESCs from nonpermissive strain 
backgrounds (e.g., NOD) are unstable and differentiate to a more 
advanced epiSC (postimplantation epiblast stem cell) state, which 
has been termed a primed pluripotent state, in the absence of 
exogenously provided inhibitors of ERK signaling23.
Although the basis of strain and species recalcitrance to ESC 
derivation is not yet fully understood, these results suggest that 
inhibition of the pathways responsible for differentiation of ICM 
epiblast cells to postimplantation epiblast cells might be sufficient 
to overcome barriers to mESC derivation in all inbred strain back-
grounds. This new model of the pluripotent, ground state of ESCs 
is an important advance in our understanding of early lineage 
commitment, and it has informed our mESC derivation protocol, 
which is highly efficient, regardless of strain background.
Experimental design
We previously published efficient derivation of germline-competent 
mESC lines from the recalcitrant strain DBA/2J (ref. 20). Crucial 
to the success of this protocol was the exclusion of serum 
during the outgrowth phase, combined with the inhibition 
of MEK/ERK (1i: PD98059) signaling during the outgrowth 
phase and during subsequent culture of emergent ES cell lines 
(3i: CHIR99021, PD173074 and PD0325901). As published data 
later showed the FGF receptor inhibitor PD173074 to be dis-
pensable and the MEK inhibitor PD98059 to be redundant, in the 
context of the more potent MEK inhibitor PD0325901 (ref. 16), 
our current protocol uses the now standard 2i combination 
(CHIR99021 and PD0325901) to achieve the same exogenous 
inhibition with simpler media formulae.
Our protocol begins with the collection and culture of late 
blastocyst–stage embryos, which can be generated by natural 
mating or by in vitro fertilization. These embryos are then 
cultured in derivation medium to allow for ICM outgrowth. 
Unlike traditional ESC derivation medium, which contains 
serum, our derivation medium uses serum replacement in 
the form of an artificial serum replacement or, in the case of 
nonpermissive strain backgrounds, we use defined serum-free 
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Figure 1 | Overview of preimplantation development in mice. The pre-epiblast lineage in the early embryo is defined by lineage-restricted expression of the 
Oct3/4, Nanog and Gata6 genes. As early lineage specification proceeds, the pluripotent epiblast lineage is defined by Nanog expression. The epiblast lineage 
will give rise to all three definitive germ layers of the embryo-proper, namely all somatic cells and germ cells, and it is the population from which mESCs are 
derived. mESC cell lines retain the developmental potential of the epiblast lineage, and as such they can contribute to all three germ layers and the germ line 
of host blastocyst- or morula-stage embryos.
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medium24. The exclusion of serum from the derivation medium 
was previously shown to promote mESC derivation efficiency9,25, 
and we have found that it promotes NANOG expression in 
ICM outgrowths (Fig. 2). NANOG, which is essential for the 
acquisition and maintenance of pluripotency, is a biomarker 
of mESC progenitor cells and is a more reliable readout of 
cell potency than OCT3/4 (refs. 14,26). Upon ICM disaggre-
gation, incipient mESC lines are cultured either in traditional 
ESC medium + 2i/LIF (variant A; see Step 10A) or in defined 
serum-free medium + 2i/LIF (as described by Silva et al.18, Ying 
and Smith24 and this protocol, variant B (Step 10B)). We and 
others have found the latter culture conditions to be essential 
for robust derivation of ES cell lines from the recalcitrant NOD 
and its derivative strains (NSG and NRG) (Table 1)19. Although 
the original defined, serum-free + 2i/LIF conditions were 
created for feeder-free derivation and culture, feeder layers 
improve derivation efficiency, promote colony attachment 
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+ Serum – KOSR – serum+ KOSRFigure 2 | NANOG immunolabeling in ICM outgrowths grown in the  
presence of 2i/LIF with or without serum or KOSR. (a,b) ICM outgrowths 
grown in traditional derivation medium containing serum have minimal 
NANOG expression (a) and exhibit differentiation (orange arrowheads) (b). 
(b) Outgrowths grown in the presence of KOSR contain  
NANOG-expressing cells (white arrowhead) but also exhibit differentiation 
(b, orange arrowheads). (c) Outgrowths grown in serum-free  
medium exhibit NANOG-expressing cells (white arrowhead) with  
minimal differentiation. Scale bars, 50 µm. All procedures involving  
mice were approved by The Jackson Laboratory’s and Sloan-Kettering 
Institute’s Institutional Animal Care and Use Committees and were  
performed in accordance with NIH guidelines for the care and use of  
animals in research. 
taBle 1 | Derivation efficiencies in selected strain backgrounds using traditional derivation conditions versus this protocol.
strain background
reported efficiency in standard es cell 
derivation conditions (serum, lIF31) ref.
efficiency achieved using this protocol  
(2i, lIF)
DBA 1% (DBA/1lacJ) 32 60% (ref. 20) (DBA/2J)
BALB/c 2.4% 7 90%a (BALB/cJ)
C3H 3% 33 90%a (C3H/HeJ)
NOD 1.5% 34 75%a,b (NOD/ShiLtJ)
NSG Unreportedc 34 65% a,b (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)
A/J Unreported NA 90%a
PWD/J Unreported NA 60%a
C57BL6 17–80% 3,7,35 100%a (C57BL/6J)
CBA 0% 14 Not attempted
Substrains are provided if known/reported. Efficiency is the percentage of disaggregated embryos that gave rise to stable mESC lines, as defined by morphology and survival through passaging. In the litera-
ture, efficiency is defined by the number of stable mESCs generated from the number of embryos collected. With this protocol, the vast majority (90%) of embryos give rise to an outgrowth, but not every 
outgrowth is disaggregated due to budget constraints. Therefore an efficiency calculation based on the number of embryos collected would be a gross underestimate.
aOur unpublished data. bRequired serum-free culture conditions (as described by Ying and Smith24 and this protocol, variant B). cPresumed similar permissiveness to NOD, as NSG is a derivative strain.
(which is favorable for subcloning, a key manipulation in 
gene-targeting experiments) and may provide enhanced 
karyotypic stability. Therefore, we use feeder layers of mitotically 
inactivated embryonic fibroblasts. Importantly, this protocol 
provides all the steps necessary to derive and establish low- 
passage (passage (P)3) ES cell lines from any inbred strain 
background, as well as detailed instructions for quality assur-
ance and characterization. Regardless of the culture condi-
tions, pluripotency and euploidy degrade with increasing 
passage number in mESCs (P20 and higher). Therefore, newly 
established mESC lines should be maintained with an eye toward 
maximizing and preserving low-passage stocks.
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MaterIals
REAGENTS
Derivation of mES cells
Pregnant mouse, 3.5 d.p.c. ! cautIon Experiments involving rodents must 
conform to all relevant governmental and institutional (i.e., institutional 
animal care and use committee (IACUC)) standard operating procedures 
and regulations.
MEFs (see Reagent Setup)
Mitomycin C (Sigma, cat. no. M0503; prepare 1 mg/ml stock in PBS and 
store it at 4 °C for up to 6 months)
2-Mercaptoethanol, 55 mM (Invitrogen, cat. no. 21985-023)  
! cautIon This reagent is a biohazard; adequate safety instructions should 
be taken when handling it.
B27 supplement (Invitrogen, cat. no. 17504-044)
CHIR99021 (Stemgent, cat. no. 04-0004; see Reagent Setup)
Defined trypsin inhibitor (Invitrogen, cat. no. R-007-100)
DMEM, high glucose, no glutamine, no sodium pyruvate (Invitrogen,  
cat. no. 11960069)
DMEM/F-12 medium (Invitrogen, cat. no. 11320-033)
DMSO (Sigma-Aldrich, cat. no. D2650) ! cautIon This reagent is a  
biohazard; adequate safety instructions should be taken when handling it.
Ethanol, 70% (vol/vol) (Sigma-Aldrich, cat. no. E7023) ! cautIon This 
reagent is highly flammable, and it is a skin and eye irritant.
FBS, ES cell grade (Lonza, cat. no. 14-501F)  crItIcal FBS should be  
lot-tested for maximum ES cell viability and growth. Filter it through  
a 0.45-µm filter, and store it in 25-ml single-use aliquots at −20 °C for  
up to 1 year.
Gelatin, 0.1% (wt/vol) (STEMCELL Technologies, cat. no. 07903)
GlutaMAX (Invitrogen, cat. no. 35050061)
KnockOut serum replacement (KOSR; Invitrogen, cat. no. 10828-028);  
store 25-ml single-use aliquots of the reagent at −20 °C for up to 1 year
EmbryoMax potassium simplex optimized medium (KSOM) embryo  
culture (1×) medium, powder (Millipore, cat. no. MR-020-P)
LIF, 107 units (Millipore, cat. no. ESG1107)
EmbryoMax M2 medium (1×), powder (Millipore, cat. no. MR-015-D)
MEM nonessential amino acid solution (NEAA; Invitrogen,  
cat. no. 11140050)
N-2 supplement (Invitrogen, cat. no. 17502-048)
Neurobasal medium (Invitrogen, cat. no. 21103-049)
PBS without calcium and magnesium (Invitrogen, cat. no. 20012027)
PD0325901 (Stemgent, cat. no. 04-0006; see Reagent Setup)
Penicillin-streptomycin, 100× (Invitrogen, cat. no. 15140122)
Sodium pyruvate, 100 mM (Invitrogen, cat. no. 11360070)
Trypsin-EDTA, 0.05% (wt/vol) (Invitrogen, cat. no. 25300054)
Karyotyping
Colcemid, 10 µg/ml (Invitrogen, cat. no. 15212-012)
Glacial acetic acid (Sigma-Aldrich, cat. no. A6283) ! cautIon This  
reagent is a biohazard and a severe irritant; adequate safety instructions 
should be taken and all work with this chemical should be conducted  
in a fume hood.
KCl, 0.56% (vol/vol) (Sigma-Aldrich, cat. no. P9541)
Methanol (Sigma-Aldrich, cat. no. 494437) ! cautIon This reagent is a 
biohazard; adequate safety instructions should be taken when handling it.
Vectashield hard-set mounting medium with DAPI (Vector Laboratories, 
cat. no. H-1500)
Immunolabeling
DAPI (Invitrogen, cat. no. D1306; see Reagent Setup) or Hoechst  
(Invitrogen, cat. no. 33342)
FBS (Lonza, cat. no. 14-501F)
Goat anti-mouse IgG Alexa Fluor 488 (Invitrogen, cat. no. A11029)
Goat anti-rabbit IgG Alexa Fluor 488 (Invitrogen, cat. no. A11034)
Goat anti-mouse IgM Alexa Fluor 488 (Invitrogen, cat. no. A21042)  
 crItIcal Secondary antibodies conjugated to fluorescent dyes are  
light-sensitive. A broad array of Alexa fluorophores (Invitrogen)  
are available depending on the desired excitation/emission spectra.  
Moreover, alternatives to Alexa Fluor dyes are widely available, including 
FITC, Texas Red, rhodamine and others.
Mouse IgG anti-OCT3/4 antibody (Santa Cruz Biologicals, cat. no. sc-5279; 
see Reagent Setup)
•
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•
•
•
•
•
•
•
•
•
•
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Mouse IgM anti-SSEA-1 antibody (Santa Cruz Biologicals, cat. no. sc-21702; 
see Reagent Setup)
Rabbit IgG anti-Nanog antibody (Abcam, cat. no. ab21603)
PBS without calcium and magnesium (Invitrogen, cat. no. 20012027)
Paraformaldehyde, 4% (wt/vol) (PFA; Electron Microscopy Sciences,  
cat. no. 157-4) ! cautIon This reagent is a biohazard; adequate safety 
instructions should be taken when handling it.
Triton X-100 (Promega, cat. no. H5142)
SNP panel or genotyping
DNeasy blood and tissue kit (Qiagen, cat. no. 69506)
Tris, 1 M, pH 8.0 (Invitrogen, cat. no. AM9856)
Pathogen testing
Sabouraud dextrose agar deep-fill plates (BD, cat. no. 221180)
Tryptose phosphate broth (Sigma-Aldrich, cat. no. T8159) 
EQUIPMENT
Filter unit such as Stericup-GV, 0.22 µm (Millipore, cat. no. SCGVU05RE)
Biosafety cabinet (e.g., Nuaire, model NU-425-400 or equivalent)
Calibrated, glass micropipettes, 50 µl (Drummond Scientific, cat.  
no. 2-000-050). Note that the aspirator apparatus required for the  
mouth-controlled embryo transfer pipette is supplied with the  
micropipettes (see Equipment Setup). Alternatively, 9-inch glass  
Pasteur pipettes, pulled over a flame, can be assembled with a plastic  
mouthpiece and P1000 pipette tip, as shown in Figure 3.
Cell counter, automatic (e.g., Nexcelom Cellometer Auto T4) or  
manual hemocytometer (e.g., Reichert Bright-Line, Fisher Scientific,  
cat. no. 02-671-5)
Conical tubes, 15 ml (USA Scientific, cat. no. 1475-0511)
CoolCell LX (Biocision, cat. no. BCS-405)
Cover glass, 24 × 60 mm (Fisher Scientific, cat. no. 12-548-5P)
Cryovials, 2 ml (USA Scientific, cat. no. 5612-2263)
Micro-dissecting scissors (e.g., Roboz, cat. no. RS-5610)
Forceps, two pairs (e.g., Roboz, cat. no. RS-4984)
Microscope, inverted (e.g., Nikon, model TS100 or equivalent)
Microscope, stereo (e.g., Leica, model MZ12.5 or equivalent)
Microscope slides (Fisher Scientific, cat. no. 12-550-15)
Pasteur pipettes, borosilicate, 9 inches, unplugged (Fisher Scientific,  
cat. no. 13-678-20C)
Serological pipettes, 5 ml (USA Scientific, cat. no. 1075-0810)
Serological pipettes, 10 ml (USA Scientific, cat. no. 1071-0810)
Syringes, 5 ml (BD, cat. no. 309646) with 27-G needle (BD, cat. no. 305109)
Tissue culture–treated plate, four wells (Corning Life Sciences,  
cat. no. 353654)
Tissue culture–treated plate, six wells (USA Scientific, cat. no. 5665-7160)
Tissue culture–treated dish, 35 mm (USA Scientific, cat. no. CC7682-3340)
Tissue culture–treated dish, 60 mm (USA Scientific, cat. no. CC7682-3359)
Tissue culture–treated dish, 100 mm (USA Scientific, cat. no. 5666-4160)
Vacuum pump (Fisher Scientific, cat. no. 13-878-40 or equivalent)
Water bath (Thermo Scientific, model 2864 or equivalent)
Water-jacketed CO2 incubator, 37 °C, 5% CO2 with HEPA filtration and 
95% humidity (Thermo Scientific, model 3120 or equivalent) 
REAGENT SETUP
Cryopreservation medium Cryopreservation medium is 80% culture 
medium (FBS or serum-free ES cell medium, depending on the medium used 
for the mESC line), 10% (vol/vol) FBS and 10% (vol/vol) DMSO.  
The medium can be stored at 4 °C for up to 1 week.
EmbryoMax KSOM and M2 embryo culture media The EmbryoMax 
KSOM and M2 embryo culture media are freshly made according to the 
manufacturer’s instructions on the day of embryo collection.  
 crItIcal The reagents must be freshly prepared.
KOSR ES medium KOSR ES medium is DMEM-high glucose  
supplemented with 15% (vol/vol) KOSR, 1× penicillin-streptomycin,  
2 mM GlutaMAX, 1 mM sodium pyruvate, 0.1 mM MEM NEAA, 0.1 mM 
2-mercaptoethanol, 103 IU of LIF, 1 µM PD0325901 and 3 µM CHIR99021. 
Sterilize the medium through a 0.22-µm filter and store it at 4 °C for up to  
1 week, protected from light.
FBS ES medium FBS ES medium is DMEM-high glucose supplemented 
with 15% (vol/vol) FBS, 1× penicillin-streptomycin, 2 mM GlutaMAX, 1 mM 
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sodium pyruvate, 0.1 mM MEM NEAA, 0.1 mM 2-mercaptoethanol, 103 IU  
of LIF, 1 µM PD0325901 and 3 µM CHIR99021. Sterilize the medium through 
a 0.22-µm filter and store it at 4 °C for up to 1 week, protected from light.
Serum-free ES medium Serum-free ES medium is a 1:1 mixture of  
DMEM-F12/N2 (DMEM-F12 supplemented with N-2) and Neurobasal/B27 
(Neurobasal supplemented with B27) with 1× (vol/vol) penicillin- 
streptomycin, 1 mM GlutaMAX, 0.5 mM sodium pyruvate, 0.1 mM MEM 
NEAA, 0.1 mM 2-mercaptoethanol, 103 IU of LIF, 1 µM PD0325901 and  
3 µM CHIR99021. Sterilize the medium through a 0.22-µm filter and store it  
at 4 °C for up to 1 week, protected from light.
MEF medium MEF medium is DMEM-high glucose supplemented 
with 10% (vol/vol) FBS, 1% (vol/vol) penicillin-streptomycin and 2 mM 
GlutaMAX. Sterilize the medium through a 0.22-µm filter and store it at  
4 °C for up to 1 week, protected from light.
CHIR99021 Prepare a stock solution of 30 mM by resuspending 2 mg in  
140 µl of DMSO. Divide the solution into single-use aliquots and store them 
at −20 °C for up to 6 months.
PD0325901 Prepare a stock solution of 10 mM by resuspending 2 mg in  
414 µl of DMSO. Divide the solution into single-use aliquots and store them 
at −20 °C for up to 6 months.
Methanol:glacial acetic acid, 3:1 In a fume hood, mix methanol and  
glacial acetic acid at a ratio of 3:1. Use 10 ml of fresh fixative per cell line. 
Keep the reagent on ice until it is ready for use.  crItIcal The reagent 
must be freshly prepared.
Blocking buffer Combine PBS with 5% (vol/vol) FBS and 0.1% (vol/vol) 
Triton X-100. Store the buffer at 4 °C for up to 1 week.
DAPI stock solution Prepare a stock solution by dissolving 10 mg of DAPI 
in 2 ml of sterile molecular biology–grade water. Store this solution at 4 °C 
for up to 1 year, protected from light. Use it at a dilution of 1:2,500.
Primary antibody solution Dilute the primary antibodies to 1:250 in  
PBS with 1% (wt/vol) FBS. The working concentrations for antibodies  
can vary depending on the supplier and/or the lot, and therefore they may 
need to be determined empirically. We usually use dilutions of 1:250 for 
the anti-OCT3/4, 1:250 for the anti-SSEA-1 and 1:250 for the anti-NANOG 
antibodies listed in the Reagents section. Store the diluted antibodies at 4 °C 
for up to 1 month. For longer-term storage, divide the diluted antibody into 
single-use aliquots and store them at −20 °C.
Secondary antibody solution Dilute the secondary antibodies to 1:1,000 in 
PBS with 1% (vol/vol) FBS. The working concentrations for antibodies can 
vary depending on the supplier and/or the lot, and therefore they may need 
to be determined empirically. We usually use dilutions of 1:1,000 for the  
anti-mouse IgG, 1:1,000 for the anti-rabbit IgG and 1:1,000 for the anti-mouse 
IgM antibodies listed in reagents. Store the diluted antibodies at 4 °C for  
up to 1 month. For longer-term storage, divide the diluted antibody into 
single-use aliquots and store them at −20 °C.
Mitomycin C Prepare a 1 mg/ml stock in PBS and store it at 4 °C for  
up to 6 months.
MEFs Derive MEFs from embryonic day (E) 12.5–14.5 embryos that have 
been decapitated and eviscerated. Collect embryos from a pregnant mouse 
12.5–14.5 d.p.c. Wash the decapitated and eviscerated embryos in PBS and 
place them in a clean 100-mm culture dish containing 3–5 ml of 0.05% 
(wt/vol) trypsin-EDTA. Coarsely mince the embryos with sterile forceps 
and a razor blade. Draw the resulting fragments into a 10-ml syringe and 
pass them through a 16-G needle two or three times to reduce the tissue to a 
slurry. Add the slurry to a 50-ml conical tube containing an equal volume of 
MEF medium and allow any remaining large fragments to settle. Transfer  
the contents (avoiding settled material) to a new 50-ml conical tube, and 
centrifuge at 150g for 5 min. Resuspend the pellet in MEF medium, count  
the cells and plate them onto a 100-mm, gelatinized dish (expect a yield of  
~1 × 106 cells per embryo and plate at ~1 × 105 cells per cm2, which is  
approximately one 100-mm dish per embryo). When the cells are confluent 
(~2 d), passage 1:3 by using 0.05% (wt/vol) trypsin-EDTA. After three pas-
sages, mitotically inactivate the MEFs by using mitomycin C or γ-irradiation.  
! cautIon Experiments involving rodents must conform to all relevant  
governmental and institutional (IACUC) standard operating procedures  
and regulations.
Mitotic inactivation of MEFs using mitomycin C Grow MEFs until they  
are confluent, and then replace the medium with fresh medium containing 
10 µg/ml mitomycin C. Return the plates to the incubator for 2–3 h. Wash 
the MEFs extensively (two or three times) with PBS, collect them using 
0.05% (wt/vol) trypsin-EDTA and then count the cells. Resuspend the cells in 
cryopreservation medium at a concentration of ~1 × 107 cells per ml, quickly 
divide the suspension into 1-ml aliquots in cryovials and temporarily store 
the aliquots at −80 °C in a CoolCell LX or an equivalent container, which will 
allow for an optimum freeze rate of −1 °C per minute. Transfer the frozen 
cells to liquid nitrogen storage within 1 week. MEFs can be stored in liquid 
nitrogen indefinitely. To prepare feeder layers, thaw one vial and resuspend it 
in ~100 ml of MEF medium and plate it onto gelatinized dishes at a density 
of 1 × 105 cells per cm2.
Mitotic inactivation of MEFs using -irradiation Expose confluent  
MEFs to γ-rays and achieve an exposure of 5,000–10,000 rads. Collect  
and resuspend the MEFs in cryopreservation medium, as described for  
mitomycin-treated MEFs.
EQUIPMENT SETUP
Mouth pipette Heat the center of a glass, calibrated micropipette over a  
gas microburner, stretch the pipette by hand and then break the pipette  
in the center. Assess the broken end under a stereomicroscope. Keep only 
those pipettes that are thin, even and that have a diameter 1.5-2× that of  
a standard mouse blastocyst. Insert the pulled pipette into an aspirator  
apparatus (Fig. 3). If mouth pipetting is not possible or desirable,  
micropipette aids are commercially available (e.g., Drummond, Captrol III, 
cat. no. 3-000-752), and they can be used in place of the mouth-controlled 
aspirator apparatus shown in Figure 3.
Gelatinized plates  Gelatinize all tissue culture plates and dishes to promote 
cell attachment. Pipet a sufficient amount of 0.1% (wt/vol) gelatin to cover the 
surface of a tissue culture–treated plate. Incubate the plate for at least 15 min at 
room temperature (20–25 °C). Aspirate the gelatin and dry it briefly.
MEF feeder cell plates Thaw and resuspend MEFs in MEF medium at a 
seeding density of ~1 × 105 cells per ml, and use the appropriate volume for 
~1 × 105 cells per cm2 according to the growth area of the required plate or 
dishes. Prepare MEF feeder plates at least 1 d before use. MEF feeders may 
be used up to 1 week after plating. Before use, rinse the MEF feeder plates 
with PBS.  crItIcal MEF viability is highly variable in serum-free culture 
medium, and generally low-passage (P2–P3) MEFs are more tolerant. Test 
higher-passage (<P3) MEFs empirically for long-term survival (5–10 d) in 
serum-free medium.
Surface sterilization In accordance with aseptic technique, sterilize all  
surfaces, bottles, racks, pipette aids and the other equipment by spraying  
or swabbing with 70% (vol/vol) ethanol before all procedures.
M2
Preparation of M2 drops
Flushing
Wash #1
M2
Mouth-controlled 
pipette
Wash #2
Petri dish
Tweezers Syringe
uterus
Glass Pasteur pipette
Plastic tubing
Mouthpiece
mESC
derivation
M2
M2
Figure 3 | Overview of blastocyst-stage embryo collection. Embryos are 
flushed from the uteri at 3.5–3.75 d.p.c. by using M2 medium. Embryos are 
pooled and washed through a series of M2 drops by using a mouth-controlled 
pipette before plating for ES cell derivation. It is important to get rid of 
tissue debris before embryo plating. It also provides an opportunity to assess 
the stage and quality of embryos recovered for stem cell derivation. All 
procedures involving mice were approved by The Jackson Laboratory’s and 
Sloan-Kettering Institute’s Institutional Animal Care and Use Committees 
and were performed in accordance with NIH guidelines for the care and use 
of animals in research. 
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proceDure
preparation of MeF feeder plates ● tIMInG 1 d
1| One day before collecting embryos, thaw and plate inactivated MEFs onto four-well plates. The number of wells needed 
is dependent on the number of pregnant females used. The number of embryos received per female is highly variable, but it 
generally averages between six and eight. Blastocysts are plated in individual wells. Thus, for one female, 6–8 wells should 
be needed.
2| On the day of embryo collection, remove the MEF medium and rinse the four-well feeder plates with PBS. Replace  
the medium with either KOSR ES medium (variant A; see Step 10A, permissive strains) or serum-free ES medium (variant B; 
see Step 10B, nonpermissive strains). Return the plates to the incubator until the embryos are gathered.  crItIcal For 
permissive strains (129, B6) and for most of the nonpermissive strains listed in table 1, use KOSR ES medium for  
derivation (variant A; Step 10A). However, if you are deriving ES cells from a known nonpermissive strain such as NOD or  
a NOD-derivative strain, use serum-free ES cell medium (variant B; Step 10B). If the strain has not been previously  
characterized as nonpermissive or permissive, follow Step 10A initially and then repeat with Step 10B if the first attempt  
is unsatisfactory.
collecting e3.5 blastocysts ● tIMInG 15 min per pregnant female
3| Remove the uterus of a 3.5-d.p.c. pregnant mouse. Trim away the excess fat.
4| With a 5-ml syringe, collect 4 ml of M2 medium and attach a 27-G needle. While securing the uterine horn with forceps, 
insert the needle and flush the uterine horn with 2 ml of M2 medium into a Petri dish. Repeat this process with the second 
uterine horn (Fig. 3).
5| By using a mouth pipette or alternative micropipetting aid, collect the flushed embryos and wash through several drops 
of M2 before placing into a final drop of M2 medium (Fig. 3).
6| If embryos are not fully expanded, blastocysts with clearly discernible blastocoels (Fig. 1, E 4.0), culture the embryos 
overnight in a 35-mm dish of KSOM at 37 °C, 5% CO2. If blastocysts are fully expanded at the time of collection, continue to 
Step 5.
 crItIcal step If the blastocysts are not fully expanded when proceeding to Step 5, the percentage of embryos that hatch 
and attach to the feeders layers after plating may be very low (>50%). Embryos may also be collected at 3.75 d.p.c. to ensure 
a higher percentage of expanded blastocysts.
 crItIcal step Traditional mESC derivation protocols recommend the removal of the zona pellucida before plating. 
Although this step is unnecessary (viable embryos will hatch naturally under appropriate culture conditions) and can lead to 
embryo loss, there are some scenarios that may warrant zona removal. For a detailed protocol on zona removal by using acid 
Tyrode’s solution, see Nagy et al.27.
plating and early culture ● tIMInG 7–9 d
7| By using a mouth pipette (or alternative micropipette aid), plate blastocysts in either KOSR ES medium (see Step 10A) 
or serum-free ES medium (see Step 10B), one blastocyst per well of a four-well MEF feeder plate (Fig. 4, day 1) containing 
the appropriate medium for derivation.
8| Incubate the plates at 37 °C, 5% CO2. Do not disturb the plates for 48 h to allow for the blastocysts to hatch and  
attach to the feeder layer. The majority (80–90%) of blastocysts should hatch and attach to the feeder layer. On day 3 after 
plating, replace half the medium with fresh medium, by using either KOSR ES medium or serum-free ES medium depending 
on the desired experimental variant (Step 10A or Step 10B). Continue to feed the cells in this manner every other day until 
disaggregation. After the initial 48 h of incubation, monitor the growth of the outgrowth under a microscope daily (Fig. 4, 
days 2 and 3). If outgrowths are prominent 1 week after plating, proceed to the next step. If not, wait for 1 or 2 more days 
before proceeding to Step 9. Do not allow the outgrowths to grow so large that the center becomes dark. (Note that dark 
areas in outgrowths shown in Figure 2 are also depleted of NANOG).
? trouBlesHootInG
9| Disaggregate outgrowths mechanically (option A) or enzymatically (option B).
(a) Mechanical disaggregation
 (i)  By using a mouth pipette, transfer the outgrowth onto a new feeder-covered four-well plate in either FBS ES medium 
(for variant A; Step 10A) or serum-free ES medium (for Step 10B). 
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 crItIcal step At this step, if you are following 
variant A (see Step 10A), outgrowths are now moved 
from KOSR ES medium to FBS ES cell medium. If you 
are following variant B (see Step 10B), continue  
culture in serum-free ES medium.
 (ii)  By using tweezers that have been sterilized with 70% 
(vol/vol) ethanol, break up the outgrowth into small 
fragments.
 (iii)  Pipet the fragments several times with the pulled 
pipette to achieve further disaggregation.
 (iv)  Replace the medium with the appropriate medium,  
as described in Step 9A(i) above, and observe the 
wells daily. Once the colonies have emerged  
(2–3 d later), enzymatically passage 1:1 as described 
in option B. The goal is not to reach confluency, but 
rather to dissociate cells before large colonies become 
dark. The incipient ES cell line is now at P1  
(passage 1). Continue to passage as described in  
option B, and increase the passage number by  
1 with each subsequent exposure to trypsin and  
carefully track the passage number by labeling  
the plates and tubes. See Step 10 for details on  
ES cell passage.
(B) enzymatic disaggregation
 (i)  Carefully wash the wells with 500 µl of PBS.
 (ii)  Aspirate the PBS and add 100 µl of 0.05% (wt/vol) 
trypsin to each well. Incubate the cells at 37 °C  
for 5 min.
 (iii)  By using a mouth-controlled pipette, disaggregate the outgrowth by pipetting up and down vigorously  
several times.
 (iv)  If you are following variant B, add 100 µl of defined trypsin inhibitor to inactivate the trypsin. Pipet by  
gentle trituration. 
 crItIcal step This step is not necessary if you are following variant A, as the FBS in the medium inactivates  
the trypsin.
 (v)  Add 500 µl of either FBS ES medium (for variant A) or serum-free ES medium (for variant B). Transfer onto a new 
feeder-covered four-well plate. 
 crItIcal step At this step, if you are following variant A, outgrowths are now moved from KOSR ES medium  
to FBS ES cell medium. If you are following variant B, continue culture in serum-free ES medium.
 (vi)  The incipient ES cell line is now at P1 (passage 1). Increase the passage number by 1 with each subsequent  
exposure to trypsin and carefully track the passage number by labeling the plates and tubes. See Step 10 for details  
on ES cell passage.
 (vii)  Replace the medium with appropriate medium, as described in Step 9B(v), and observe daily. ES cell colonies will 
form, and they should be visible 3–4 d after disaggregation.
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Figure 4 | Overview of ES cell derivation process. Blastocyst-stage embryos 
are plated on mitotically inactivated MEFs and allowed to hatch from the 
zona pellucida. Shown here are transgenic embryos carrying a GFP reporter 
cassette driven by the Nanog promoter (Nanog:GFP). By days 2–3, hatched 
embryos attach to the feeder layer, and over the next several days (4–9) 
the Nanog-positive ICM forms a large Nanog-positive outgrowth from which 
mESCs are extracted by mechanical disaggregation and/or trypsinization. 
Scale bars, 50 µm. All procedures involving mice were approved by The 
Jackson Laboratory’s and Sloan-Kettering Institute’s Institutional Animal 
Care and Use Committees and were performed in accordance with NIH 
guidelines for the care and use of animals in research. 
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es cell maintenance ● tIMInG 9 d
10| Replace the medium and observe the cells daily. Continue to use FBS ES cell medium if you are following variant A or 
serum-free medium if you are following variant B. Monitor the growth and morphology and take careful notes. Mixed  
differentiation within the first 1–2 passages is not unusual; however, continued culture should promote typical ES cell  
morphology (Fig. 5). If poor morphology persists after the first two passages, the incipient ES cell line may be unstable. 
Expect variable growth rates among emergent lines and be aware that unusually rapid growth could be indicative of  
karyotypic instability (for example, trisomy for chromosome 8 often results in unusually rapid growth in mESCs).  
In addition, be alert for signs of deterioration, which include vacuolated cytoplasm, detachment of cells from colonies  
and cellular debris in the medium. If deterioration continues through passages, discard the cell line. Finally, be aware of 
signs of contamination, including sudden change in pH, turbidity, small round particles (yeast) and filaments (fungi).  
Discard contaminated cell lines and quarantine the remaining lines if possible. After disaggregation, passage the  
cells 1:4 (seeding density is ~1–4 × 105 cells per cm2 or ~3–5 × 105 cells per well) onto a six-well MEF feeder plate  
(or 35-mm dish) according to option A if you are following variant A and according to option B if you are following  
variant B.
? trouBlesHootInG
(a) passaging cells, variant a, FBs es cell medium
 (i)  Rinse the cells with room-temperature PBS.
 (ii)  Add a quantity of 0.05% (wt/vol) trypsin to cover the cell layer, usually one-third of the amount used to culture  
the cells.
 (iii)  Return the cells to the incubator for 4–6 min. Observe cell dissociation with an inverted microscope, with occasional 
swirling.
 (iv)  As soon as the colonies begin to dissociate, inactivate the trypsin by adding an equal amount of ES cell medium.
 (v)  Collect the cells and then remove any remaining cells by rinsing the culture dish with additional ES cell medium.  
Collect both aliquots (trypsinized cells and the rinse) in one tube and create a single-cell suspension by gentle  
trituration with a pipette.
 (vi)  Centrifuge for 5 min at 150g at room temperature. Resuspend the pellet in 2.5 ml of ES medium (for a 35-mm plate), 
creating a single-cell suspension through gentle trituration.
(B) passaging cells, variant B, serum-free es cell medium
 (i)  Rinse the cells with room-temperature PBS.
 (ii)  Add a quantity of 0.05% (wt/vol) trypsin to cover the 
layer of cells, usually one-fifth to one-third of the 
amount used to culture the cells.
 (iii)  Return the cells to the incubator for 3–5 min. 
 crItIcal step Cells cultured in serum-free culture 
medium will dissociate more quickly in the presence  
of trypsin. Avoid unnecessary exposure to trypsin 
by continually observing cell dissociation with an 
inverted microscope.
 (iv)  As soon as colonies begin to dissociate, inactivate  
the trypsin by adding an equal amount of defined 
trypsin inhibitor.
 (v)  Collect the cells and then remove any remaining  
cells by rinsing the culture dish with serum-free  
ES medium. Collect both aliquots (trypsinized cells 
and the rinse) in one tube and create a single-cell 
suspension by gentle trituration with a pipette.
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Figure 5 | Emergent mESC morphology. Healthy, emergent mESC lines grow 
as tightly formed, refractile colonies throughout passaging (+++), and they 
have robust Nanog expression. Lines that show persistent differentiation, 
flat colony morphology or slow growth through early passaging (+ and 
+/−) are less desirable and are not likely to emerge as robust, germline-
competent mESC lines. Scale bars, 50 µm. All procedures involving mice 
were approved by The Jackson Laboratory’s and Sloan-Kettering Institute’s 
Institutional Animal Care and Use Committees and were performed in 
accordance with NIH guidelines for the care and use of animals in research. 
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 (vi)  Centrifuge the tube for 5 min at 150g at room temperature. Resuspend the pellet in 2.5 ml of serum-free ES medium, 
creating a single-cell suspension through gentle trituration.
11| Continue to culture the cells, replacing the medium with the appropriate medium (FBS ES medium for variant A and  
serum-free medium for variant B), and observe the cells daily. Once 70% confluency is reached (2–3 d later), passage  
cells 1:4 onto a 100-mm feeder-covered dish. Alternatively, if genotyping is required, cells can instead be passaged onto  
two 60-mm dishes, setting aside one for genotyping (Step 19C).
? trouBlesHootInG
12| Freeze some of the cells in culture when they reach 70% confluency. Change the medium the morning before a  
freeze to minimize stress on the cells. Follow the passaging protocol in Step 10 above and resuspend in 1 ml of the  
appropriate medium (FBS ES medium for variant A and serum-free medium for variant B). Count the cells by using either  
a manual or automatic cell counter. Centrifuge the cells for 5 min at 150g at room temperature. Resuspend the cells in  
cryopreservation medium at a concentration of 3 × 106 cells per ml. Add 1 ml of medium per cryovial. Transfer each vial to  
a CoolCell (or other container that will allow for a cool rate of −1 °C/min) and place it at −80 °C. After 24 h, transfer  
the cells to liquid nitrogen. The frozen cells are now at P3–P4 (see Step 9B(vi) regarding passage number assignment),  
depending on whether the initial disaggregation (Step 9) was enzymatic (P4) or mechanical (P3).
 crItIcal step It is best practice to freeze cells as soon as possible to create a stock of ultra-low-passage vials.
? trouBlesHootInG
 pause poInt Cells can now be stored in liquid nitrogen indefinitely. Carefully maintain these stocks and plan subsequent 
thaws and expansions to preserve low-passage vials.
esc characterization ● tIMInG ~3 weeks 
13| One day before seeding ES cells, thaw and plate mitotically inactivated MEFs. For the full characterization of one cell 
line, two 60-mm dishes and six wells on a 12-well plate are needed. In addition, for a full characterization, two gelatinized 
60-mm plates without feeders are needed. Incubate MEF feeder plates or dishes at 37 °C, 5% CO2.
14| The day after MEF plating, remove a vial of frozen ESCs from liquid nitrogen. Place the vial in a 37 °C water bath until 
the cells begin to thaw.
15| Sterilize the vial with 70% (vol/vol) ethanol and then transfer the cells to 10 ml of prewarmed (37 °C) medium in a  
15-ml conical tube.
16| Centrifuge the cells for 5 min at 150g at room temperature.
17| Resuspend the pellet in 5 ml of medium and create a single-cell suspension by gentle trituration with a serological 
pipette. Plate the cells onto a 60-mm MEF feeder plate.
18| Once the cells have reached 70% confluency, trypsinize the cells as detailed in Step 10, resuspend them in 4 ml of  
ES medium and divide them into four 1-ml aliquots in separate 15-ml conical tubes.
19| Seed the cells according to the instructions below and proceed with immunolabeling for markers of pluripotency  
(option A), mitotic chromosome counting (option B), DNA extraction for genotyping (option C) and pathogen testing  
(option D). We recommend that users perform all of these options to enable complete mESC characterization.
(a) Immunolabeling for markers of pluripotency ● tIMInG 5 h
 (i)  Add an additional 4 ml of ES medium to one of the 1-ml aliquots of cell suspension. Seed 0.5 ml of the resulting  
suspension into each of six wells of a 12-well plate MEF feeder plate.
 (ii)  Incubate the plate at 37 °C, 5% CO2 for 1–2 d to allow cells to reach 50% confluency. Change the medium on the 
morning of the prep.
 (iii)  Rinse the cells with room-temperature PBS.
 (iv)  Fix the cells in 4% (wt/vol) PFA for 20 min at room temperature.
 (v)  Wash the cells with PBS three times for 5 min each. 
 pause poInt Fixed cells may be kept at 4 °C in PBS for up to 2 weeks.
 (vi)  Incubate the cells in all wells with blocking buffer for 15 min on a rocking platform at room temperature.
 (vii)  Incubate the cells in primary antibody solution for at least 1 h at room temperature on a rocking platform (one well 
for each primary antibody, anti-OCT3/4, anti-NANOG and anti-SSEA1, and one well for each ‘no primary’ control option).
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 (viii)  Wash the cells with PBS three times for 5 min each.
 (ix)  Incubate the cells in appropriate secondary antibody 
solution (e.g., goat anti-mouse IgG Alexa Fluor 488, 
goat anti-rabbit IgG Alexa Fluor 488 or goat anti-
mouse IgM Alexa Fluor 488) for at least 1 h at room 
temperature on a rocking platform.
 (x)  Wash the cells with PBS three times for 5 min each.
 (xi)  Incubate the cells with DAPI for 10 min.
 (xii)  Wash the cells with PBS once for 5 min.
 (xiii)  Image the cells with an inverted epifluorescence microscope. Antibodies specific to NANOG and OCT3/4 should label  
the nuclei of ES cells, whereas SSEA-1–specific antibody will label the surface of ES cells. Proceed with ES cell  
lines that show maximum distribution of labeling, as shown in Figure 6 (optimal versus suboptimal). If desired,  
quantitative assessment of labeling may also be performed by using flow cytometry20. 
 crItIcal step Even robust, germline-competent mESCs are heterogeneous in their pluripotency marker  
expression, and in poorly performing mESC lines there can still be some pluripotency marker expression. Here, the 
goal of assessing pluripotency marker expression is to identify those lines with the most homogeneous and consistent 
expression of each maker, especially NANOG26.
(B) Mitotic chromosome counting ● tIMInG 6 h
 (i)  Take 1 ml of the cell suspension and add an additional 4 ml of ES medium (Fig. 7). Seed the cells onto a 60-mm  
gelatinized dish.
 (ii)  Incubate the dish at 37 °C, 5% CO2 for 1–2 d to allow the cells to reach 50–70% confluency.
 (iii)  Add 10 µl of 10 µg/ml colcemid to 5 ml of fresh, warmed ES medium.
 (iv)  Remove the spent ES cell medium from one of the cultures growing on a gelatinized 60-mm plate and add the  
colcemid-containing medium to the culture.
 (v)  Incubate the dish for 3 h at 37 °C.
 (vi)  Trypsinize the cells as detailed in Step 10.
 (vii)  Aspirate and discard the supernatant, leaving about 500 µl of medium in the tube. Gently pipet up and down to  
resuspend the pellet.
 (viii)  Set a water bath to 75 °C.
 (ix)  By using a P1000 pipette, add 5 ml of 0.56% (wt/vol) KCl to the cells slowly. 
 crItIcal step KCl should be added in a drop-by-drop manner to prevent lysis. Carefully invert the cells to mix.
 (x)  Incubate the mixture for 60 min at room temperature.
 (xi)  Centrifuge the tube for 5 min at 150g.
O
C
T
4
Optimal
N
A
N
O
G
S
S
E
A
-1
Sub-optimal
N
uc
le
i
a b
c
e f
d
Figure 6 | mESC characterization by immunolabeling of pluripotency 
biomarkers. The pluripotency markers OCT3/4, NANOG and SSEA-1 can 
be used to assess pluripotency in new mESC lines. (a–f) Heterogeneous 
labeling (b,d,f) is associated with suboptimal GLT when compared with 
lines that show optimal, consistent labeling (a,c,e) for these markers. Scale 
bars, 50 µm. All procedures involving mice were approved by The Jackson 
Laboratory’s and Sloan-Kettering Institute’s Institutional Animal Care and 
Use Committees and were performed in accordance with NIH guidelines for 
the care and use of animals in research. 
Derived ES cells
Colcemid 
treatment
+ harvest
Hypotonic 
treatment
+ fixation
Metaphase
spreading
+ DNA staining
Figure 7 | Karyotypic analysis of ES cells. mESC lines are treated with 
colcemid to arrest cells in metaphase. Cells are fixed and ruptured 
by hypotonic treatment and nuclei are spread on glass slides. Mitotic 
chromosomes are stained with DAPI, which is a DNA-intercalating dye that 
preferentially binds A-T–rich DNA, resulting in a reverse G-banding pattern. 
For genetic engineering, male mESC lines are preferable for breeding 
efficiency. The Y chromosome (arrowhead) stains homogeneously with DAPI, 
and it is clearly distinguishable from the other chromosomes, which show 
discrete banding patterns. All procedures involving mice were approved 
by The Jackson Laboratory’s and Sloan-Kettering Institute’s Institutional 
Animal Care and Use Committees and were performed in accordance with 
NIH guidelines for the care and use of animals in research. 
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 (xii)   Aspirate and discard the supernatant, leaving 1 ml of the hypotonic solution. Resuspend the pellet by  
gentle pipetting.
 (xiii)   In a drop-by-drop manner, slowly add 1 ml of 3:1 methanol:glacial acetic acid. Swirl the tube as the fixative is added.
 (xiv)   Centrifuge the tube for 5 min at 150g.
 (xv)   Aspirate and discard the supernatant, leaving 1 ml of fixative. Resuspend the pellet by gentle pipetting.
 (xvi)   Slowly add 3 ml of fixative, by swirling to mix.
 (xvii)   Centrifuge the tube for 5 min at 150g at room temperature.
 (xviii)  Repeat Step 19B(xiv–xvi) twice.
 (xix)   Resuspend the pellet in 1 ml of fixative. 
 pause poInt Cells may be stored in fixative at −20 °C for several years.
 (xx)   Steam a freshly cleaned slide over a water bath.
 (xxi)   Immediately pipet 75 µl of the cell suspension onto the steamed slide from a height of 6 inches. Tilt the slide and 
blow gently to disperse the cells.
 (xxii)  Place the slide on a hot plate to dry.
 (xxiii)   Store the slide for 24–48 h on a slide warmer at 37 °C.
 (xxiv)   Apply a drop of Vectashield hard-set mounting medium 
with DAPI to the slide, and then apply a coverslip.
 (xxv)   Acquire images of metaphase spreads at ×60  
magnification. Analyze at least 20 spreads per cell 
line by counting the total chromosome number and 
assessing sex chromosomes (XX or XY), as shown in 
Figure 7. Determine the percentage of spreads with 
40 chromosomes. For example, if 19 of 20 spreads 
have 40 chromosomes and a Y chromosome is  
observed in every spread, the cell line is 95% 
euploid, 40 XY. To select for mESC lines that will be 
used for genetic engineering, male lines are prefer-
able for maximum breeding efficiency.
(c)  Dna extraction for snp panel and/or genotyping  
● tIMInG 1 h
 (i)   Take 1 ml of the cell suspension and add an  
additional 4 ml of ES medium. Seed the suspension 
onto a 60-mm gelatinized dish. 
 crItIcal step For optimal and accurate  
mESC-specific SNP genotyping, it is important to 
exclude feeders.
Black ES cells Albino 
blastocyst
(host)
ES cell
derivation
ES cell
injection
Transfer to 
pseudopregnant 
female
Breeding of 
chimera with 
white mouse
Figure 8 | Germline testing of mESC lines. mESC lines are injected into 
host blastocyst embryos, and mESC contribution to resulting chimeras is 
assessed by coat color. In this example, mESCs derived from a nonalbino 
strain (e.g., C57BL/6J, genotype a/a, Tyr+/Tyr+) are injected into host 
blastocysts from an albino strain (e.g., C57BL-Tyrc−2J/J, genotype a/a, 
Tyrc/Tyrc). The resulting chimeras will have patches of fur that are albino 
(contributed by the host blast) and nonalbino (in this example, black (a/a) 
pigmentation is contributed by ES cells). Contribution from the mESC line 
is evidenced by the overall percentage of nonalbino coat color. Generally, 
high contribution by a male ES cell line will also produce predominantly 
male chimeras. Female chimeras are possible, but they are less productive. 
The male chimeras are then bred with an albino strain (in this case, a/a, 
Tyrc/Tyrc) to ensure that germ line transmission can be assessed by coat 
color. In this example, pigmentation is only possible in offspring that are 
a/a, Tyr+/Tyrc (black pups in image) where the wild-type Tyr and an a allele 
are contributed by sperm derived from the ES cell line. Albino offspring are 
a/a, Tyrc/Tyrc where the Tyrc allele and an a allele are contributed by sperm 
derived from the host blastocyst. Pups shown are from two litters, 7 and  
11 d postpartum. All procedures involving mice were approved by The 
Jackson Laboratory’s and Sloan-Kettering Institute’s Institutional Animal 
Care and Use Committees and were performed in accordance with NIH 
guidelines for the care and use of animals in research. 
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 (ii)  Incubate the cells at 37 °C, 5% CO2 for 1–2 d to allow 
the cells to reach 50–70% confluency.
 (iii)  Extract DNA from a confluent culture with a Qiagen 
DNeasy kit, according to the manufacturer’s instructions, 
and then perform PCR as needed for genotyping.
 (iv)  To confirm the genetic background of the established 
cell line, submit DNA to a SNP panel, e.g., the  
KBioscience mouse SNP panel28.
(D) pathogen testing ● tIMInG 2 weeks
 (i)  Take 1 ml of the cell suspension and centrifuge it 
again at 150g for 5 min at room temperature,  
wash the pellet in PBS and resuspend it in 5 ml of 
antibiotic-free ES medium. 
 crItIcal step Culture the cells in the absence of 
antibiotics for the remainder of the pathogen test.
 (ii)  Seed the cells on a 60-mm MEF feeder dish.
 (iii)  Incubate the cells at 37 °C, 5% CO2 for 1–2 d until 
they are fully confluent. Remove and reserve the 5 ml 
of used medium. 
 crItIcal step Contaminants can be harbored in 
the medium, and thus it is important that the used 
medium, in addition to the cells, be tested.
 (iv)  Trypsinize the cells as detailed in Step 10.
 (v)  Resuspend the cells in the used medium, by dividing 
them into three tubes: 0.5 ml for bacterial testing, 2 ml 
for fungal testing and 2.5 ml for Mycoplasma testing.
 (vi)  For bacterial testing, add the 0.5-ml aliquot from  
Step 19D(iv) to 4.5 ml of tryptose phosphate  
broth. Incubate the mixture at 37 °C for 48 h.  
Check for growth.
 (vii)  For fungal testing, inoculate a Sabouraud plate  
with the 2 ml of culture. Culture it for 14 d at room 
temperature. Check for growth.
 (viii)  For Mycoplasma testing, centrifuge the 2.5 ml of 
culture at 500g for 5 min at room temperature and 
aspirate until 200 µl of medium remains. Extract DNA 
by using a DNeasy kit according to the manufacturer’s 
instructions. Test for the presence of Mycoplasma  
by using a PCR-based detection method (e.g.,  
van Kuppeveld et al.29).
 (ix)  If desired, submit sample cells for a molecular mouse 
antibody production (MAP) test to screen for mouse 
pathogens in accordance with institutional policies.
Germline transmission (Glt) of parental lines  
● tIMInG 8 weeks
20| Thaw a well-characterized ES cell line onto a 60-mm 
MEF plate as detailed in Steps 14–17.
 crItIcal step To maximize the success of GLT, the mES 
cell line should robustly express pluripotency markers and 
have a stable euploid karyotype of at least 70%, 40 XY.
21| Allow the cells to reach 70% confluency.
22| Dissociate the cells with trypsin.
taBle 2 | Data collected to assess mESC suitability for chimera 
contribution and GLT.
Development
No. of embryos transferred 50
No. of pups born  9–25
% born   18–50%
Chimeras
No. of chimeras  3–14
% chimeras   30–60%
No. of male chimeras  2–14
% male chimeras     80–100%
Coat color contribution
100% 0–8
>80% 0–5
40–80% 0–7
<40% 0–8
Fertility
No. set up  2–14
No. productive  1–10
% productive   30–70%
GLT
No. of chimeras with GLT  1–10
% GLT     50–100%
Rates of GLT
100%  0–10
>50%  0–10
10–50%    0
<10%    0
Acceptable ranges are provided on the basis of our accumulated data from microinjection of 10,  
low passage (P6–P11), parental (mESCs that have not been genetically engineered) mESCs from  
a variety of strains, including BALB/cByJ, C3H/HeJ, PWD/PhJ, NOD/ShiLtJ and C57BL/6J. Each 
ES cell line was injected into 50 blastocyst stage host embryos from C57BL/6J or C57BL-Tyrc-2J/J 
strains. The percentage born is the number of viable offspring born divided by the number of  
embryos transferred and can vary substantially depending on the microinjection facility as well as 
mESC quality. The percentage of chimeras is the number of chimeras born divided by the total number 
born. The percentage of male chimeras is the number of chimeric males divided by the total males 
born. Coat color contribution is based on a subjective assessment of mESC contribution to the  
host embryo based on coat color in wean age animals. This assessment could vary based on  
microinjection facility and operator. The percentage of GLT is the number of animals demonstrating 
GLT divided by the number of productive animals. To assess fertility, chimeras are housed  
with proven breeders (typically as trios) at the age of 8–12 weeks and are kept for up to 12 weeks 
(to generate 20 offspring per chimera). Chimeras that do not produce offspring within this  
timeframe are considered nonproductive. GLT rate is the number of ES cell-derived offspring  
(by coat color) divided by the total offspring (~20).
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23| Inactivate the trypsin and add an additional 3 ml of medium to the dish.
24| Return the cells to the incubator for 20 min to allow feeder cells to settle to the bottom of the dish.
25| Carefully remove the supernatant to a 15-ml conical tube.
26| Centrifuge the mixture for 5 min at 150g at room temperature.
27| Wash the cells with PBS.
28| Centrifuge the mixture for 5 min at 150g at room temperature.
29| Resuspend the cells in 1 ml of medium buffered with 10 mM HEPES.
30| Deliver cells to the microinjection facility. Request host embryos from a strain that will allow for determination of mESC 
contribution by coat color, as depicted in Figure 8. For a review of mouse coat-color loci, see Jackson30.
 crItIcal step Microinjection of mESCs into host blastocyst embryos requires specialized equipment and expertise and 
is usually provided by a core facility. For laboratories interested in establishing in-house microinjection/chimera production 
capability, detailed protocols are available from a variety of sources, including Nagy et al.27).
31| Collect the relevant data for 50–100 injections, as shown in table 2. Generate ~20 offspring per chimera, assess  
GLT by using coat color as a guide (Fig. 8) and reference the data shown in table 2. Up to 60% of the viable offspring from 
microinjection of a robust, parental male mES cell line should be chimeric, and 80–100% of these should be male. Moreover, 
at least 50% of the chimeric males should have GLT rates of 50% or more.
? trouBlesHootInG
? trouBlesHootInG
Troubleshooting advice can be found in table 3.
taBle 3 | Troubleshooting table.
step problem possible reason solution
8 Blastocyst failure to 
attach or hatch
Blastocyst not fully developed Plate only fully expanded blastocysts
Unhealthy MEF feeder layer Verify that MEFs are seeded at correct density and test for 
ability to support ES cell viability and growth with an  
established mESC line
Embryos are unable to hatch from  
the zona pellucida
Dissolve the zona pellucida using acid Tyrode’s before  
plating the blastocyst onto a feeder layer
10–12 Differentiation Improper composition of culture 
media
Verify that media were made correctly and check dates on 
all media components
Blastocyst attachment to edge of 
feeder layer/well
Blastocysts should be placed in the center of the well to 
avoid attachment to the sides of the well. Dishes can be 
rotated clockwise and/or counterclockwise to swirl the 
embryos into the center of each circular well
Overgrowth of cultures Outgrowths and colonies should be dissociated before the 
center of the outgrowth becomes dark
Strain is nonpermissive Repeat the derivation according to variant B
(continued)
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taBle 3 | Troubleshooting table (continued).
step problem possible reason solution
10–12 Poor growth, and/or  
sudden change in media 
color, cloudiness in 
medium, presence of 
fungi, yeast, bacteria
Contamination Clean and sterilize the cell culture incubator and review 
proper aseptic technique. Discard all contaminated cultures 
and quarantine any cultures growing in the same incubator. 
Discard and replace all media
Excessive cell death, poor 
survival after passage
Improper composition of culture 
media
Ensure that media were prepared correctly and check all 
expiration dates. All culture media should be stored at 4 °C 
and should be protected from light. Media should be  
discarded and replaced after 1–2 weeks
Excessive exposure to trypsin Inhibit trypsin as soon as cells begin to dissociate
11 Poor post-thaw viability Improper storage conditions Cells should be initially frozen at −80 °C in a container that 
allows for a controlled freeze (1 °C per minute) and then 
rapidly transferred to liquid N2 after 1–7 d. Also, be sure to 
check the integrity of cryovials
Improper medium composition Verify that cryopreservation medium was made correctly
Poor handling Always minimize the exposure of thawed cells to the  
cryopreservation medium, which contains DMSO. DMSO is  
an effective adjuvant but is also toxic to cells at ambient 
temperatures. Cells require a slow freeze and a rapid thaw.  
To thaw rapidly, use a 37 °C water or bead bath. Sterilize  
the outside of the vial and immediately transfer thawed  
contents to medium immediately after thawing
31 GLT is not detected Selected breeding scheme does  
not allow for assessment of GLT by 
coat color
Verify that the coat color genotype of the ES cell line,  
the host blastocyst and breeder strain will allow for  
assessment of GLT by coat color. If the wrong strains have 
been selected, it may be possible to genotype offspring 
using strain-specific SNPs. Otherwise, select a different 
strain to breed chimeras or repeat with a different  
host blastocycst
Cells are karyotypically abnormal Verify the karyotype of the cell line;  
subclone or re-derive if necessary
Pluripotency is limited, cells have 
poor viability or poor proliferative 
potential
If a high-passage vial was used, choose  
a lower passage for testing. Alternatively (and more likely), 
this result may indicate that the mESC line is inadequate. In 
this case, test a different line from the same  
derivation, or repeat the derivation  
according to variant B
● tIMInG
Steps 1 and 2, preparation of MEF feeder plates: 1 d
Steps 3–6, collecting E3.5 blastocysts: 15 min per pregnant female
Steps 7–9, plating and early culture: 7–9 d
Steps 10–12, ES cell maintenance: 9 d
Steps 13–19, ESC characterization: 3 weeks (including all Step 19 options)
Step 19A, immunolabeling for markers of pluripotency: 5 h
Step 19B, mitotic chromosome counting: 6 h
Step 19C, DNA extraction for SNP panel and/or genotyping: 1 h
Step 19D, pathogen testing: 2 weeks
Steps 20–31, GLT of parental lines: 8 weeks
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antIcIpateD results
By using this protocol, we have produced germline-competent ES cell lines from a variety of mouse strains, including  
those thought to be nonpermissive, such as DBA20, PWD and NOD (A.C. and L.G.R., unpublished data). The careful selection 
of healthy, blastocyst-stage embryos, combined with minimal manipulations before plating promotes a high yield of ICM 
outgrowths from embryos that hatch naturally from the zona pellucida and adhere to MEF feeders. Under the derivation  
conditions described here, up to 90% of ICM outgrowths will yield incipient ES cell lines, with some variation depending  
on the strain background and the experience of the technicians. During the outgrowth phase, exclusion of serum from the 
derivation medium minimizes trophectoderm differentiation and 2i/LIF culture promotes expansion of the epiblast.
In incipient ES cell lines, we have found that serum-free 2i/LIF medium (variant B) promotes robust NANOG expression  
and, ultimately, higher yield of coat-color chimeras through germline testing20. Although serum-free culture conditions are 
typically used in feeder-free culture systems, we have found that the use of feeders promotes more efficient derivation (ratio 
of the number of embryos giving rise to ES cell lines/number of embryos plated) and also yields a higher percentage of  
adherent ES cell lines, which are more favorable for gene-targeting experiments. However, not surprisingly, MEF viability in 
the absence of serum is highly variable. This can be overcome with careful selection of low-passage feeder MEFs that have 
been previously tested for survival in serum-free conditions and careful monitoring of feeder layers during culture.  
In addition, in the context of a gene-targeting experiment, serum can be temporarily introduced during drug selection to 
promote MEF survival after electroporation. Given these complexities, if a particular mouse strain has not been previously 
characterized as nonpermissive (table 1), derivation of ES cells in the presence of serum (variant A) should be attempted 
first. If robust pluripotent, karyotypically stable ES cell lines are not achieved with variant A, then serum-free derivation 
should follow.
It is important to closely monitor the growth of incipient mES cell lines with careful observation of morphology and  
density, and to replenish the medium daily. The timing of passages is dictated by the confluency of the culture (and not  
convenience), and therefore it will vary from one incipient cell line to the next. Cell lines should be cryopreserved at P3–P4, 
and subsequent culturing and freezing should be carefully planned to ensure ample frozen stocks of low-passage cells. 
Generally, as the passage number increases, genomic stability and pluripotency decline. Moreover, there is emerging evidence 
(though still anecdotal) that although 2i/LIF conditions promote pluripotency, prolonged culture may promote aneuploidy; 
therefore, it is important to consider weaning newly derived, characterized mESC lines from 2i. With the exception of lines 
created by variant B, we maintain low-passage stocks in 2i/LIF and then create higher-passage working stocks that are 
weaned from 2i. To do this, cells are essentially brought through several passages with decreasing doses of 2i (e.g., dividing 
the dose by two at each passage), and then working stock vials are cryopreserved.
Before proceeding with germline testing or in vitro differentiation, newly derived ESC lines should be extensively  
characterized. mES cell lines should be free of Mycoplasma, bacteria, fungi and mouse pathogens. SNP paneling is  
recommended to confirm the strain of origin of mES cells, and karyotypic assessment should be used to determine sex  
and percentage euploidy. For gene targeting, male ES cell lines that are 70% euploid (40 XY) or higher are acceptable,  
but <90% is ideal. Karyotypic stability is stochastic in cultured cells, and it should be reassessed after extensive passaging, 
as in a gene-targeting experiment. Cell lines that have developed an unstable karyotype may be subcloned; however, given 
the efficiency with which ES cells can be derived, re-derivation is preferable. Finally, to ensure maximum developmental  
potential reflected in robust chimera contribution, highly euploid mESCs should robustly express well-accepted markers of 
the pluripotent state such as NANOG, OCT4, SOX2 and SSEA-1.
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AID stabilizes stem-cell phenotype by removing
epigenetic memory of pluripotency genes
Ritu Kumar1, Lauren DiMenna2, Nadine Schrode3, Ting-Chun Liu1, Philipp Franck1, Silvia Mun˜oz-Descalzo3,
Anna-Katerina Hadjantonakis3, Ali A. Zarrin4, Jayanta Chaudhuri2, Olivier Elemento5 & Todd Evans1
The activation-induced cytidine deaminase (AID; also known as
AICDA) enzyme is required for somatic hypermutation and class
switch recombination at the immunoglobulin locus1. In germinal-
centre B cells, AID is highly expressed, and has an inherent muta-
tor activity that helps generate antibody diversity2. However, AID
may also regulate gene expression epigenetically by directly dea-
minating 5-methylcytosine in concert with base-excision repair to
exchange cytosine3. This pathway promotes gene demethylation,
thereby removing epigenetic memory. For example, AID promotes
active demethylation of the genome in primordial germ cells4.
However, different studies have suggested either a requirement5
or a lack of function6 for AID in promoting pluripotency in soma-
tic nuclei after fusion with embryonic stem cells. Here we tested
directly whether AID regulates epigenetic memory by comparing
the relative ability of cells lacking AID to reprogram from a differ-
entiated murine cell type to an induced pluripotent stem cell. We
show that Aid-null cells are transiently hyper-responsive to the
reprogramming process. Although they initiate expression of plur-
ipotency genes, they fail to stabilize in the pluripotent state. The
genome of Aid-null cells remains hypermethylated in reprogram-
ming cells, and hypermethylated genes associated with pluripo-
tency fail to be stably upregulated, including many MYC target
genes. Recent studies identified a late step of reprogramming
associated with methylation status7, and implicated a secondary
set of pluripotency network components8. AID regulates this late
step, removing epigenetic memory to stabilize the pluripotent
state.
The path to pluripotency involves multiple steps that can be more or
less efficient, and this can be modelled in transcription-factor-induced
reprogramming9. Reprogrammed induced pluripotent stem cell (iPSC)
clones initially retain methylation patterns that may reflect an epige-
netic memory of the source lineage10,11. To test directly the function of
AID in reprogramming, we prepared tail-tip fibroblasts (TTFs) from
Aid-knockout or control siblingmice. Before reprogramming, the fibro-
blasts appeared morphologically identical (Supplementary Fig. 1a), and
were transduced equivalently with lentivirus encoding the four human
‘Yamanaka’ reprogramming transcription factors12: OCT4,KLF4, SOX2
and cMYC (OKSM; Supplementary Fig. 1b). Expression levels of exo-
genous humanOCT4 72h after infection (before induction of the endo-
genousmurine gene)were equivalent, showing that lack ofAIDdoes not
affect expression vector function (Supplementary Fig. 1c). Exogenous
transcription factor expression was subsequently equivalently repressed
in wild-type and Aid-null transduced cells (Supplementary Fig. 1d).
Using quantitative polymerase chain reaction with reverse transcription
(RT–qPCR) assays, transcript levels for Aid were not reliably detected
above background in wild-type TTFs. However, after 1 week of repro-
gramming, transcriptswere readilymeasured inwild-type cells, increasing
as much as tenfold during the reprogramming process (Supplementary
Fig. 2).
Initial reprogramming steps include the induction of proliferation
and a change in the morphology of fibroblasts to smaller and rounder
cells13. We found that cells lacking AID are initially hyper-responsive
to reprogramming factors.The change inmorphologywasmore rapid in
Aid2/2 cells, beginning at 2 days after transduction.After 4 days,Aid2/2
cells were rounded and smaller than Aid1/1 cells (Fig. 1a). A higher
fraction of Aid2/2 cells stained positive for SSEA1, an early marker
for pluripotency14 (Fig. 1b). At day 7, more Aid-null cells expressed
NANOG compared with controls (Fig. 1c), correlating with modestly
higher transcript levels for several pluripotency genes before the first
week of reprogramming (Fig. 1d). Consistentwith themolecular data, at
2 weeks the Aid-null cells consistently generated more early colonies
thanwild-type cells (sixfoldmore colonies onaverage over six independ-
ent experiments). Thus, Aid-null fibroblasts are hyper-responsive to
reprogramming, even though the growth curves for uninfected wild-
type and Aid-null cells were indistinguishable (Supplementary Fig. 3a).
Rather, the enhanced expression of pluripotency markers in Aid2/2
cells suggests that AID normally helps to stabilize the differentiated
state, creating a barrier to the initial process of reprogramming. When
the Aid2/2 fibroblasts were passaged before transduction, this hyper-
responsiveness was no longer seen (Supplementary Fig. 3b), suggesting
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Figure 1 | Cells lacking AID are initially hyper-responsive to transcription-
factor-based reprogramming. a,Aid1/1 andAid2/2 fibroblasts after 4 days of
OKSM transduction. Note the more rounded appearance of null cells. Original
magnification, 310. b, Cells positive for SSEA1 after 4 days of OKSM
transduction, determined by flow cytometry. c, Immunostaining with anti-
OCT4 and anti-NANOG antibodies after 1 week of OKSM transduction.
Original magnification,340. d, Relative transcript levels of pluripotency genes
determined by qPCR after 4 days of OKSM transduction. For each gene,
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that passive removal of epigenetic marks through DNA replication can
normalize the initial response to OKSM.
Although there were more cells, no obvious differences were
observed at 2 weeks in the morphologies of iPSC-like colonies derived
from Aid2/2 cells compared with Aid1/1 cells, and both stained pos-
itive for the pluripotency marker NANOG (Supplementary Fig. 4).
However, by 4 weeks the colonies derived from Aid2/2 fibroblasts
were flattened with less defined edges (Fig. 2a). We tracked individual
iPSC-like colonies and observed many Aid2/2 colonies that appeared
pluripotent at 3 weeks but showed a differentiated morphology at 4
weeks (Fig. 2b). At 3 weeks, the Aid2/2 colonies showed a ‘patchy’
NANOG pattern, and by 4 weeks most colonies were differentiated,
with few NANOG1 cells (Fig. 2c). This highly reproducible phenom-
enonwas never observed for colonies derived fromAid1/1 cells, which
retained their iPSC morphology and NANOG expression throughout
the 4 weeks (Fig. 2b, c). The colonies derived fromAid2/2 cells showed
a progressive decline in the frequency of cells expressing SSEA1
(Fig. 2d) and OCT4 (Fig. 2e). The same results were observed using
mouse embryonic fibroblasts (MEFs), as the Aid-null cells failed to
maintain a pluripotent iPSC phenotype (Supplementary Fig. 5). The
stabilization of pluripotency was equally effective in wild-type cells
(and ineffective in Aid-null cells) regardless of whether constitutively
expressed or doxycycline-inducible OSKM cassettes were used (Sup-
plementary Fig. 6a).
Using either wild-type or Aid-null cells, the expression of OKSM
using a doxycycline-inducible vector for only 6 days was insufficient to
generate pluripotent colonies. OKSM expression for 9, 12, 21 or 28
days was sufficient to generate pluripotent colonies, showing a ‘dose
response’ in the wild-type fibroblasts, but was equally ineffective for
generating stable pluripotent cells from Aid-null cells at the 4-week
time point (Supplementary Fig. 6b, c).When AIDwas expressed along
with OKSM during initial reprogramming stages, this failed to rescue
pluripotency (data not shown).However,whenOKSM-transducedAid-
null cells were secondarily infected with an AID-expressing retrovirus
after 1 week (Supplementary Fig. 7a, b), there was a partial but statist-
ically significant rescue of pluripotency markers stabilized at the 4-week
time point. Because the rescue was not complete we cannot rule out
additional molecular mechanisms, beyond AID, that also contribute to
the stabilization of pluripotency. Expression of AID in wild-type cells
further enhanced the stable expression of pluripotency markers at 4
weeks (Supplementary Fig. 7c). AsNanog is syntenic with theAid locus,
an independent set of experiments used fibroblasts derived fromanAid-
knockout strain in which the neoR gene was deleted15. These ‘clean’
knockout cells also failed toderive stable iPSCcolonies (data not shown).
It was previously reported that iPSCs derived from different cell
types retain an epigenetic memory of their somatic phenotype10,11.
We tested whether genome replication through passaging could sta-
bilize a pluripotent phenotype even in the absence of AID. We gener-
ated iPSC-like colonies and isolated 13Aid1/1 and 12Aid2/2 colonies
(clones) at 3 weeks that appeared pluripotent by morphology. After
three passages (p3) all the clones, regardless of genotype, retained iPSC-
like morphology and stained positive for OCT4 and NANOG (Fig. 3a).
However, between p7 and p10, 5 out of 12Aid2/2 clones failed to retain
pluripotency anddifferentiated (Fig. 3b).All 13Aid1/1 colonies and the
other 7 Aid2/2 clones that were stable beyond p10 retained pluripo-
tency until at least p50. All iPSC clones that retained morphology
beyond p10 formed embryoid bodies equivalently and could differenti-
ate into cells expressing smoothmuscle actin (mesoderm), bIII tubulin
(ectoderm) and a-fetoprotein (endoderm), regardless of Aid genotype
(Fig. 3c). In an independent set of experiments, wild-type and Aid-null
clones were picked and either maintained in culture as colonies or
passaged. The non-passaged wild-type-derived clones maintained a
pluripotent morphology, whereas the Aid-null cells differentiated.
With passaging, 60% of the Aid-null clones were able to maintain a
pluripotent morphology (Supplementary Fig. 8).
Thus, although AID is not essential for reprogramming, an import-
ant transition occurs at around 3 weeks that is assisted by AID to
stabilize the pluripotent phenotype.We considered whether the previ-
ously described DNA-demethylating role of AID might be at least
partially responsible for this phenotypic stabilization. We profiled
the epigenome by carrying out reduced-representation bisulphite
sequencing (RRBS) in Aid-null and control cells after 3 weeks of
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reprogramming. We observed global DNA hypermethylation in the
Aid-null cells (Supplementary Fig. 9a), whenwe considered either total
CpGs or differentially methylated regions (DMRs). DNA hypermethy-
lation occurs preferentially near RGYWmotifs (Supplementary Fig. 9b),
the characteristic DNA-targeting sites for AID (45% of the hypermethy-
lated CpGs). Notably, as AID targets gene bodies, the hypermethylated
regions are enriched in gene bodies, even thoughRRBS is biased towards
capturing CpG-rich promoter and enhancer regions (Supplementary
Fig. 9c).
Transcript profiles comparing the original, pre-transduced fibro-
blasts from Aid1/1 and Aid2/2 embryos closely match (Supplemen-
tary Fig. 10a). By contrast, many genes fail to be upregulated in the
mutant cells during reprogramming (Fig. 4a, b and Supplementary
Fig. 10b). The genes that fail to be upregulated during reprogramming
are highly enriched (P, 13 10210) in the gene set showing hyper-
methylation in Aid-null cells (Fig. 4c). Of note, genes that are upregu-
lated during reprogramming in both wild-type and Aid-null cells are
also enriched in hypermethylated genes (P, 13 10214), suggesting
that many genes overcome the loss of AID during reprogramming.
Among the set of hypermethylated genes, in Aid-null cells there is a
failure to upregulate a set of secondary pluripotency genes, including
Rex1 (also known as Zfp42), Gdf3, Dnmt3l, Cbx7, Zfp296, Dnmt1,
Apobec1 and Tet3 (Fig. 4d). This expression data correlates well with
the RBBS data, which was validated by MassArray bisulphite sequen-
cing (Supplementary Fig. 11), and is consistent with a failure of this
downstream network to be demethylated at late stages of reprogram-
ming. Comparing the gene set of hypermethylated underexpressed
genes to public embryonic stem (ES)-cell chromatin immunoprecipi-
tation and massively parallel DNA sequencing (ChIP-seq) data sets
revealed a marked enrichment of cMYC target genes in reprogram-
ming cells lacking AID (Supplementary Fig. 12). According to qPCR
data there was no difference in cMyc transcript levels in wild-type or
Aid-null cells at any point in the reprogramming process (data not
shown). Furthermore, enhanced levels of cMYC, achieved by retroviral
transduction starting at 1 week of reprogramming, failed to stabilize
pluripotency inAid-null cells (Supplementary Fig. 13), suggesting that
cMYC access to key target pluripotency genes (due to hypermethyla-
tion) rather than cMYC levels per semay be a limiting step for stabili-
zation of the network.
Individual iPSC-like clones were isolated at 2 weeks and expanded
to evaluate global methylation patterns for each individual clone.
Hypermethylation patterns in theAid-null clones were highly consist-
ent with data obtained from bulk colony analysis. On the basis of
genome-wide DNA methylation profiles (with the genome binned
for 100 kb regions), Aid-null or wild-type clones cluster according to
genotype (Supplementary Fig. 14a). Regions that were hypermethy-
lated in theAid-null bulk analysis tended to be hypermethylated in the
Aid-null clones (Supplementary Fig. 14b). In fact, 66% of bulk hyper-
methylated DMRs were also hypermethylated in DNA derived from
the isolated clones (P, 13 102151). Methylation differences found
previously for the secondary pluripotency genes were largely validated
by MassArray bisulphite sequencing of DNA (Supplementary Fig.
14c), and most of the hypermethylated genes were expressed in the
Aid-null clones at significantly lower levels compared with levels in
wild-type clones (Supplementary Fig. 14d).
Altogether, our results show that active demethylation through
AID-dependent cytosine deamination is important for stabilizing a
genetic network controlling stem-cell phenotype. AID is not essential
for reprogramming, because cells lacking AID can form stable plur-
ipotent iPSCs, either through a passive demethylation process facili-
tated by DNA replication, or perhaps through compensation from
related members of the APOBEC family16. A recent study suggested
that loss of AID affects transcription-factor-induced reprogramming
only by an early acute short hairpin RNA (shRNA)-dependent deple-
tion17, but did not report the ‘iPSC’ phenotype beyond 3 weeks, when
we show that Aid-null cells eventually fail to stabilize as pluripotent.
Unless passaged, Aid-null cells always fail to reprogram. RNA-seq
profiles of Aid-null cells after 4 weeks of reprogramming cluster with
fibroblast samples (data not shown), and qPCR analysis validates sig-
nificant upregulationof fibroblast-associated genes in theAid-null sam-
ples (Supplementary Fig. 15), consistent with an epigeneticmemory for
fibroblast fate that fails to be fully removed during reprogramming in
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the absence of AID. The function of AID for transition to a stable
pluripotent phenotype may be relevant during embryogenesis, as Aid-
knockout strains have small litters. We found that ES-cell lines could
be established from Aid-null blastocysts, and these appeared by mor-
phology and staining patterns to be normal (Supplementary Fig. 16).
However, the efficiency ofES-cell-linederivationwasmarkedly reduced
(17/28 embryos, 60.7%) compared with congenic wild-type embryos
(21/24, 87.5%; P, 0.03 by chi-squared analysis).
Although there is much promise for the use of iPSCs for disease
modelling and cellular therapies18, there remains concern aboutwhether
iPSC genomes are damaged through the process of reprogramming19–21.
AID, which has natural mutator activity, is activated during reprogram-
ming, and mediates demethylation in gene bodies including secondary
pluripotency genes that encode proto-oncogenes. Although inefficient,
we showed that iPSCs could be generated in the absence of AID, remov-
ing epigenetic memory marks through an AID-independent mech-
anism. Retaining epigenetic memory, in the absence of AID, might be
useful for promoting efficiency of differentiation towards parental lin-
eage fate. Furthermore, if AID-independent reprogramming lessens the
mutation load, it could provide a safer strategy for the generation of
iPSCs for cellular therapies.
METHODS SUMMARY
TTFswere prepared using 0.2% collagenase;MEFswere prepared from embryonic
day (E)13.5 embryos. Intracellular immunostainingwas performed after fixing the
cells with 4%paraformaldehyde. Surface stainingwas donewithout fixing the cells.
Complementary DNA was prepared using Superscript III and qPCR was per-
formed (primers listed in Supplementary Table 1) using SYBR green and a
Roche LightCycler 480 II. All data were from at least three independent experi-
ments. Enhanced RRBS was performed as described22 and bisulphite reads were
aligned to the bisulphite-converted mm9 genome using Bismark23. We achieved
very high coverage by sequencing one full Illumina lane (,200M, 51 bp reads) per
sample. For bulk colonies, the wild-type and Aid-null samples (at 3 weeks) were
analysed with RRBS that covered 1.96M and 1.82M CpGs, respectively, with at
least 103 coverage (with .1.62M CpGs in common between the two runs).
1.52M and 1.59M CpGs had$203 coverage in wild-type and Aid2/2 cells,
respectively. 1.17M and 1.32M CpGs had$503 coverage, respectively.
Differentially methylated CpGs were identified using the Fisher exact test with
Benjamini–Hochberg correction for multiple testing. DMRs were defined as con-
taining at least five differentially methylated CpGs and a total methylation differ-
ence of more than 10%. Paired-end RNA-seq libraries were constructed as
described24 and sequenced using an Illumina HiSeq2000. Reads were aligned to
mm9 using TopHat and gene expression levels were quantified using Cufflinks,
using upper-quartile and GC-content normalizations. Fold changes of 1.5 with
fragments per kilobase of transcript permillion fragmentsmapped (FPKM).5 in
at least one condition were used to derive differentially expressed genes.
MassArray EpiTYPER analysis was performed on selected regions identi-
fied as hypermethylated by RRBS. PCR primers (Supplementary Table 2) were
designed to probe amplicons using EpiDesigner (http://www.epidesigner.com/).
Bisulphite conversion and MassArray analysis were performed as previously
described22. Metadata for all RRBS experiments are given in Supplementary
Table 3.Methylation differences were calculated at each CpG and boxplot analysis
was performed at each interrogated region. All statistical analyses were performed
using the R software package.
Full Methods and any associated references are available in the online version of
the paper.
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METHODS
Summary. Intracellular immunostaining was performed after fixing the cells with
4% paraformaldehyde. Surface staining was done without fixing the cells. All data
were fromat least three independent experiments. EnhancedRRBSwas performed
as described22 and bisulphite reads were aligned to the bisulphite-converted mm9
genome using Bismark23. We achieved very high coverage by sequencing one full
Illumina lane (,200M, 51 bp reads) per sample. For bulk colonies, the wild-type
and Aid-null samples (at 3 weeks) were analysed with RRBS that covered 1.96M
and 1.82MCpGs, respectively, with at least 103 coverage (with.1.62MCpGs in
common between the two runs). 1.52M and 1.59M CpGs had$203 coverage
in wild-type and Aid2/2 cells, respectively. 1.17M and 1.32M CpGs had$503
coverage, respectively. Differentially methylated CpGs were identified using the
Fisher exact test with Benjamini–Hochberg correction for multiple testing. DMRs
were defined as containing at least five differentially methylated CpGs and a total
methylation difference of more than 10%. Paired-end RNA-seq libraries were
constructed as described24 and sequenced using an Illumina HiSeq2000. Mass-
Array EpiTYPER analysis was performed on selected regions identified as hyper-
methylated by RRBS. PCR primers (Supplementary Table 2) were designed to
probe amplicons using EpiDesigner (http://www.epidesigner.com/). Bisulphite
conversion and MassArray analysis were performed as previously described22.
Metadata for all RRBS experiments are given in Supplementary Table 3.
Methylation differences were calculated at each CpG and boxplot analysis was
performed at each interrogated region. All statistical analyses were performed
using the R software package.
Mice.AID-deficient (Aid2/2) mice were a gift from T. Honjo. Some of the repro-
gramming experiments were performed on the Aid2/2 and Aid1/1 littermates
derived by crossing Aid1/2 mice, and for some of the experiments wild-type
BALB/c mice were purchased from the Jackson Laboratory. Reprogramming
experiments were performed on tail fibroblasts obtained from seven Aid2/2 and
seven Aid1/1 age-matched mice (four littermates and three non-littermates,
each). We observed similar results when comparing littermates or the purchased
mice. Mice or embryos used for MEFs were genotyped by PCR. All animals were
maintained according to the guidelines for animal welfare of the Memorial Sloan-
Kettering Research Animal Resource Center.
Preparation of fibroblasts. For preparation of tail fibroblasts either whole tails or
tail tips were collected from age-matched adult Aid1/1 and Aid2/2 mice (age
range, 3–8 weeks). Tails or tail tips were minced using a razor blade/scalpel after
washing with PBS. For preparation of MEFs, Aid1/2 males and Aid1/2 females
were timemated and E13.5 embryos were collected. Embryos were washed several
times and extra care was taken to prevent maternal cross contamination. After
removing the head and all internal organs embryos were minced using a razor
blade/scalpel. Minced tails or embryos were washed twice with DMEM (Cellgro)
containing 10% FBS (Gemini Bio Products), 1mM L-glutamine (Cellgro),
100Uml21 penicillin (Cellgro) and 10mgml21 streptomycin (Cellgro), and disso-
ciatedusing0.2%collagenase fromClostridiumhistolyticum (Sigma) at 37 uCfor 4 h
(tails) or 2 h (embryos) with continuous shaking. Dissociated cells were filtered
through a 70-mm cell strainer (BD falcon) and washed two times with DMEM
containing 10% FBS and plated on 0.1% gelatin- (Cellgro) coated tissue culture
plates. Fibroblasts were cultured in DMEM containing 10% FBS, 1mM
L-glutamine, 100Uml21 penicillin and 100mgml21 streptomycin and media was
replaced daily. After passaging two times, fibroblasts were frozen inmedia contain-
ing 10%DMSO, 40% FBS and 50%DMEM.Generally, p2 fibroblasts were used for
the reprogramming experiments, unless indicated otherwise. Genotype was con-
firmed by PCR. Primers for wild type, F: 59-GGTCCCAGTCTGAGATGTA; R: 59-
CAACGTGGCGTCCAAACAGGC; for knockout, F: 59-CTGCCAAACCTGA
TGTCTTGA; R: 59-AACCAAGCCTATGCCTACAGC.
Production of lentiviruses and retroviruses. Reprogramming virus was pro-
duced by transfection of a single lentiviral stem cell cassette (STEMCCA) in
HEK293T cells using polyethylenimine (PEI) (Polysciences). STEMCCA (con-
stitutive) expresses all four human factors (OCT4, KLF4, SOX2, cMYC), using a
single elongation factor 1a (EF1a) promoter within a lentiviral vector using a
combination of 2A peptide and internal ribosome entry site (IRES) strategies.
Both constitutive and doxycycline-inducible STEMCCA vectors were used for
the reprogramming studies. For the doxycycline-inducible system, fibroblasts
were treated with doxycycline (1mgml21) starting 1 day after transduction for
2 weeks. Lentiviruses were produced using a five-plasmid transfection systemwith
STEMCCA transfected together with four expression vectors encoding the pack-
aging proteins Gag-Pol, Rev and Tat, and the G protein of the vesicular stomatitis
virus (VSV). Five vectorswere incubated inDMEMwith 0.06%PEI for 20min and
then transferred to the plates containing 80% confluent HEK293T cells.
Transfection was performed in FBS (10%) containing media. After 5 h media
was replaced with freshmedia. Viral supernatant was collected after 48 h and spun
at 3,000 r.p.m. to remove dead cells and filtered through a sterile syringe filter with
0.45mm polyethersulfone membrane (VWR international). Ectopic expression of
wild-typeAID or catalyticallymutant AIDwas achieved using retroviral vectors as
described previously25. Retroviruses were produced by co-transfecting the vector
with the packaging plasmid pCL-ECO in HEK293T cells. The cMYC overexpres-
sion experiments were achieved using retroviral vector pMXs-c-Myc (Addgene,
13375). pMXs-c-Myc was co-transfected with vector encoding VSVg in GP2-293
cells to collect functional virus.
Transduction with lentiviruses. Five-hundred-thousand fibroblasts were plated
in one well of a gelatin-coated 6-well tissue culture plate. After 6 h, 1ml of viral
supernatant containing 8mgml21 polybrene (Millipore) was added to the fibro-
blast-containing wells. For every experiment, Aid2/2 andAid1/1 fibroblasts were
infected at the same time with an identical titre of virus, prepared for each experi-
ment from the same batch. Viral supernatant was removed after 12 h of infection
and fresh media containing DMEM, 10% FBS, 1mM L-glutamine, 100Uml21
penicillin and 10mgml21 streptomycinwas added. After 1 daymedia was replaced
by mouse embryonic stem-cell (MES) media containing DMEM, 20% ES-cell-
compatible FBS (Gemini Bio Products), LIF (2% conditioned medium) and
1.53 1024M monothioglycerol (MTG; Sigma), 1mM L-glutamine, 100Uml21
penicillin and 10mgml21 streptomycin. Cells were maintained in the samemedia.
In some of the experiments cells were transferred to mitotically inactivated MEF
feeders after 2 days of transduction. Approximately 30,000–50,000 cells were
transferred to one well of a feeder-containing 6-well plate. Isolated iPSC colonies
were always cultured on feeders. All the cells were kept at 37 uC in a humidified
environment at 5% CO2.
Immunostaining. Immunostaining was performed on fixed cells (4%PFA in BBS
with 1mM CaCl2, 15min) washed and blocked for 30min in BBT-BSA buffer
(BBSwith 0.5%BSA, 0.1%Triton and 1mMCaCl2). Cells with primary antibodies
were incubated overnight at 4 uC at the following dilutions: anti-NANOG
(eBiosciences 14-5761, 1:100, 5mgml21) and anti-OCT4 (Santa Cruz 5279,
1:100, 2mgml21). Cells were washed and blocked in BBT-BSA and then incubated
with Alexa-conjugated secondary antibodies (1:500, from Molecular Probes).
Vectashield-DAPI was used as a mounting medium. Images were acquired using
a Zeiss LSM 510-Meta confocal microscope or a Zeiss epifluorescence microscope
with AxioVision software. For flow cytometric analysis cells were trypsinized,
fixed with 4% PFA for 20min, blocked for 1 h and then stained in suspension.
SSEA1 (Santa Cruz, 1:100) staining was performed on unfixed cells. Cells were
analysed on a BD-Accuri C6 flow cytometer (BD Biosciences) using CFlow Plus
software.
RT–qPCR. Cells were trypsinized and collected in Trizol reagent (Life technolo-
gies). Total RNA extraction was done using the RNeasy Mini Kit (Qiagen). The
cDNA was synthesized using the SuperScript III First-Strand Synthesis System
(Invitrogen). RT–qPCR was performed on three experimental replicates using
SYBR green Master I (Roche). Data were generated on a LightCycler 480 II
(Roche) and analysed using LightCycler 480 software. qPCR data was calculated
based on the mean of three experimental replicates. All quantifications were
normalized to an endogenous Gapdh control. The relative quantification value
for each target gene was compared to the calibrator for that target gene. All the
primers used for qPCR spanned introns (Supplementary Table 1).
In vitro differentiation. For embryoid body formation, iPSCs were passaged two
times on feeder-free gelatin-coated culture dishes. 53 105 iPSCs were plated on a
10-cm low attachment dish. Embryoid bodies were cultured for 6 days in MES
media without LIF, and media was changed every other day. For mesodermal
differentiation, embryoid bodies were replated on gelatin-coated dishes and cul-
tured for another 7 days in the same media. For neural differentiation, embryoid
bodieswere cultured inmedia containingDMEMF-12 (Cellgro), 0.5%N2 (Gibco)
and 0.5% B27 (Gibco) supplements, 1mM L-glutamine, 1% non-essential amino
acids (Gibco) and 1.53 1024Mmonothioglycerol for another 3 days, after which
embryoid bodies were seeded onto gelatin-coated disheswith the samemedia, plus
10mM retinoic acid (Sigma) for another 4 days. For endoderm differentiation,
embryoid bodies were replated onto gelatin-coated dishes in MES media lacking
LIF but containing 0.5% FBS and 50ngml21 Activin (R&D) for 7 days. For all
differentiation cultures, media was changed daily.
ES-cell derivation from blastcyst-stage mouse embryos. Aid2/2 males and
Aid2/2 females (or congenic wild-type pairs as controls) were time mated and
E3.5 blastocyst-staged embryos were collected inM2media according to standard
protocols26. Embryos were placed on mitotically inactivated MEFs27 in knockout
DMEM (Gibco) containing 15% knockout serum replacement (KSR; Gibco), 2mM
L-glutamine, 0.1mM b-mercaptoethanol, 0.1mM non-essential amino acids, 1mM
sodiumpyruvate, 100Uml21penicillin and100mgml21 streptomycin, 1,000Uml21
LIF, 1mMPD0325901 (ERK inhibitor) and 3mMCHIR99021 (inhibitor of GSK3B).
After embryos attached, media was replaced every other day. After 10–11 days an
outgrowth could be observed and was dissociated in 0.25% trypsin/EDTA using a
mouth-controlled drawn glass pipette. Trypsin was inactivated by adding knockout
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DMEM(Gibco) containing 15%ES-cell-compatible FBS, 2mML-glutamine, 0.1mM
b-mercaptoethanol, 0.1mM non-essential amino acids, 1mM sodium pyruvate,
100Uml21 penicillin and 100mgml21 streptomycin, 1,000Uml21 LIF, 1mM
PD0325901 and 3mMCHIR99021. From this point onwards the culture was main-
tained in the samemedia onmitotically inactivatedMEFs. Media was replaced every
other day. After 3–5 days ES-cell-like colonies were observed and passaged at 70%
confluency. Stable ES-cell lines were validated by passaging a minimum of ten times
without loss of pluripotent morphology or marker expression.
Genomic analysis. RRBS was performed as described22 and bisulphite reads were
aligned to the bisulphite-convertedmm9usingBismark23.Differentiallymethylated
CpGs were identified using the Fisher exact test with Benjamini–Hochberg correc-
tion for multiple testing. We defined DMRs as regions containing at least five
differentially methylated CpGs, where contiguous differentially methylated CpGs
are separated by 250 bp or less, and forwhich the totalmethylation change between
wild-type and Aid-null cells is 10% or more (calculated using all CpGs within the
considered region including those thatwere not called as differentiallymethylated).
The distribution of DMR lengths was as follows. For hypermethylated DMRs,
average, 222 bp; median, 190 bp; minimum, 10bp; maximum, 4,081 bp. For the
lower number of hypomethylated DMRs, we observed the following statistics:
average, 229 bp; median, 188 bp; minimum, 19bp; maximum, 1,250bp. Paired-
end RNA-seq libraries were constructed as previously described24 and sequenced
using an Illumina HiSeq2000. Reads were aligned to mm9 using TopHat and gene
expression levels were quantified using Cufflinks, using upper-quartile and GC-
content normalizations. Twofold changes with FPKM. 5 in at least one condition
were used to derive differentially expressed genes. All statistical analyses were
performed using the R software package. The meta-data for all RBBS data are
provided in Supplementary Table 3.
Quantitative DNA methylation analysis by mass spectrometry. The level of
DNA methylation for specific genes was measured using a MALDI-TOF mass
spectrometry based method (EpiTYPER; Sequenom) as previously described28.
Briefly, 1mg of DNAwas treated with sodium bisulphite using the EZmethylation
kit (Zymo-Research). The treatment converts non-methylated cytosines into ura-
cil, leaving methylated cytosines unchanged. PCR amplification, addition of SAP
solution and Transcription/RNase A cocktails were performed according to the
protocol provided by Sequenom and the mass spectra were quantified by the
EpiTYPER analyser. Amplicons probed are given in Supplementary Table 2.
25. Vuong, B. Q. et al. Specific recruitment of protein kinase A to the immunoglobulin
locus regulatesclass-switchrecombination.Nature Immunol.10,420–426(2009).
26. Nagy, A., Gertsenstein, M., Vintersten, K. & Behringer, R.Manipulating the Mouse
Embryo: A Laboratory Manual 3rd edn (Cold Spring Harbor, 2003).
27. Joyner,A.L.GeneTargeting:APracticalApproach2ndedn(OxfordUniv.Press,2000).
28. Ehrich, M. et al. Quantitative high-throughput analysis of DNA methylation
patterns by base-specific cleavage andmass spectrometry. Proc. Natl Acad. Sci.
USA 102, 15785–15790 (2005).
RESEARCH LETTER
Macmillan Publishers Limited. All rights reserved©2013
 
 
 
Abbreviations used in the text 
 
5hmC – 5-hyroxymethycytosine 
5mC – 5-methylcytosine 
AFP – Alpha-fetoprotein 
AID – Activation induced cytidine deaminase 
APOBEC1 - Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 
CBX7 - Chromobox 7 
DMR – Differentially methylated regions 
DNMT1 - DNA methyltransferase (cytosine-5) 1 
DNMT3L - DNA (cytosine-5-)-methyltransferase 3-like 
EB – Embryoid bodies 
ESC – Embryonic stem cells 
FPKM - Fragments per kilobase of exon per million fragments mapped 
GC- Germinal Center 
GDF3 - Growth differentiation factor 3 
iPSC – Induced pluripotent stem cells 
KLF4 - Kruppel-like factor 4 
MYC- myelocytomatosis oncogene 
neoR – Neomycin resistance 
OCT4 - Octamer-binding transcription factor 4 
RRBS – Reduced representation bisulphite sequencing 
SMA – Smooth muscle actin 
SOX2 - SRY-box containing gene 2 
SSEA1 – stage-specific embryonic antigen 1 
TET3 - Tet methylcytosine dioxygenase 3 
TF – Transcription factor 
TSS – Transcriptional start site 
TTF – Tail tip fibroblast 
ZFP296 - Zinc finger protein 296 
βIII TUB – beta-III tubulin 
UTF1 - Undifferentiated embryonic cell transcription factor 1 
KLF2 - Kruppel-like factor 2 
ERAS - ES cell-expressed Ras 
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Supplemental Figures  
 
 
 
 
Supplemental Figure S1. AID-null fibroblasts appear normal in culture, are equally 
transduced by the reprogramming vector, and silence reprogramming factors equivalent 
to wildtype cells. a, Tail-tip fibroblast cultures derived either from wildtype or knockout AID 
mice. There are no discernable morphological differences in these cultures. b, Fluorescent 
images demonstrating equivalent transduction and expression of mCherry from the lentiviral 
expression vectors used for TF-induced reprogramming. c, Percentage of wildtype or AID-null 
cells positive for exogenous human OCT4, measured by flow cytometry, three days after 
transduction with the reprogramming vector. Bars show the average of three independent 
experiments, and there is no significant difference. This demonstrates that lack of AID does not 
impact expression vector function. d, Relative expression of exogenous human OCT4 gene 
transcripts in wildtype and AID-null fibroblasts after 1, 2, 3, or 4 weeks of reprogramming 
following OSKM transduction. Shown are averages of the mean +/- standard error from three 
independent experiments, which shows no statistical difference at each time point. 
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Supplemental Figure S2. AID is up-regulated in wildtype cells during the reprogramming 
process. Shown are qPCR results from a representative reprogramming experiment evaluating 
the expression levels for AID at 1, 2, 3, or 4 weeks. The black bars indicate levels of AID 
transcripts in the wildtype cells transduced with lentivirus, relative to the levels detected at 1 
week, given an arbitrary value of 1. AID transcripts were not detected in fibroblasts prior to 
induction or reliably measured prior to 1 week. Nor were they detectable in knockout cells, as 
expected. 
  
WWW.NATURE.COM/NATURE | 3
 
 
 
 
 
Supplemental Figure S3. Hyper-responsiveness to reprogramming is not due to 
enhanced proliferation of AID-null fibroblasts and passaging results in loss of this 
phenotype. a, Growth curves were plotted for AID-null and wildtype fibroblasts as indicated. 
25,000 fibroblasts were plated and counted each day for 4 days. Each count occurred 24 hr 
following the previous count. Data represents mean of three individual experiments +/- standard 
deviation. There was no statistically significant difference in the growth rate of AID-null and 
wildtype fibroblasts. Eventually both sets of TTFs undergo senescence. b, Compared to the 
experiments represented in Fig. 1 using p2 primary fibroblasts, cells were passaged an 
additional four times prior to transduction. Plotted is the percentage of SSEA1 positive cells four 
days after transduction of the OKSM vector in AID+/+ or AID-/- fibroblasts.  The left panel is a 
staining control. 
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Supplemental Figure S4. AID wildtype and null cells generate NANOG+ iPSC-like colonies 
at 2 weeks of reprogramming. Shown are representative iPSC-like colonies after 2 weeks of 
reprogramming. Brightfield phase images are on the left. Both the wildtype and AID-null cells 
are positive for NANOG at this point in the process. 
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Supplemental Figure S5. AID stabilizes pluripotency during reprogramming of mouse 
embryonic fibroblasts. Shown is a representative flow cytometry experiment quantifying the 
relative percentage of SSEA1 positive cells in AID+/+ and AID-/- cells after 1, 2, 3 or 4 weeks, 
following OSKM transduction. Equivalent results were obtained in three independent 
experiments. In each case the paired cells from a common stock were transduced at the same 
time with a common viral preparation. 
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Supplemental Figure S6. AID-null cells fail to stably reprogram regardless of constitutive 
or inducible OSKM expression. a, Shown are results from a representative experiment 
comparing directly the relative percentage of SSEA1 positive cells obtained after 4 weeks of 
transduction using either constitutive or doxycycline-inducible OSKM STEMCCA lentiviruses, as 
indicated. b, AID+/+ and AID-/- fibroblasts were transduced with doxycycline inducible 
reprogramming vectors. As indicated in the schematic (top) doxycycline was added one day 
after infection, replenished daily with media change, and was withdrawn after 6, 9, 12, 21 or 28 
days. Colonies were stained with anti-NANOG antibody at day 28 (examples shown below). 
Withdrawal of doxycycline at different time points failed to stabilize AID-null colonies, suggesting 
that aberrant silencing or continuous expression of reprogramming factors has no role in the 
destabilization of AID-null colonies. c, In contrast to the AID-null cells, there is a progressive 
increase in the number of NANOG positive colonies correlating with extended period of 
doxycycline treatment in the transduced wildtype cells. 
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Supplemental Figure S7.   Partial rescue of pluripotency can be achieved by ectopic 
expression of wildtype AID in AID-null fibroblast. a, Shown is a schematic of experimental 
strategy. After 1 week of transduction with the reprogramming vector, AID-null or wildtype 
fibroblasts were infected with retroviral vectors encoding wildtype AID, catalytically mutant AID, 
or control empty vector. Each of these vectors also expressed EGFP. After 48hrs of infection 
(day 9) EGFP+ cells were sorted and replated on gelatin-coated dishes with mouse ESC media.  
After culturing for an additional 3 weeks (4 weeks total after initial transduction with 
reprogramming vectors) cells were analyzed for OCT4 expression by flow cytometry. b, 
Western blotting experiments demonstrate equivalant expression of wildtype and catalytically 
mutant AID 48 hr after retroviral infection. Beta Actin serves as a loading control. c, Shown is 
the percentage of OCT4 positive cells quantified by flow cytometry. Ectopic expression of 
wildtype AID in AID-null cells resulted in a statistically significant increase in the percentage of 
OCT4 positive cells (left set, **p<0.01). Overexpression of AID in wildtype fibroblasts also 
resulted in an increase in OCT4 positive cells (right set, *p<0.05). Data represents mean of 
three individual experiments +/- standard deviation. The same results were obtained when 
SSEA1+GFP+ cells were sorted at day 9. 
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Supplemental Figure S8. Passaging is required for some AID-null clones to stabilize 
pluripotency. a, Morphology of colonies derived from wildtype or AID-null fibroblasts isolated at 
two weeks post-transduction. b, Morphology of isolated colonies at 3 weeks (one week after 
they had been isolated), when they were not passaged. Note the loss of characteristic iPSC 
morphology in the AID-null cells. c, Relative percentage of clones that remained pluripotent or 
differentiated, with or without passaging.  
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Supplemental Figure S9. Gene bodies are hyper-methylated in AID-null cells during the 
reprogramming process. Results shown in these figures were obtained after performing 
reduced representation bisulfite sequencing (RRBS) of wildtype and AID-null cells at the 3 week 
time point. Short bisulfite converted reads obtained by RRBS were aligned to the bisulfite 
converted reference mouse genome (mm9) using the Bismark program. a, >1.8-1.9M CpGs 
were covered with 10 or more reads (>10X) in each experiment. Globally, the total fraction of 
methylated CpGs was increased from 21.88% to 23.69% in AID-/- cells. When only counting 
CpGs not localized to CpG islands, the increase was even further pronounced (38.68% to 
43.94% in AID-/-).  These numbers were obtained by dividing the total number of non-converted 
CpGs in bisulfite treated reads to the total number of CpGs. Compared to the wildtype cells, the 
AID-null cells show considerably more hyper-methylated CpGs. In this analysis, differential 
methylation was evaluated using Fisher exact tests comparing methylated vs total CpGs read 
counts in wildtype (WT) vs null (AID-/-) and further adjusted for multiple testing, controlling the 
false discovery rate to 20%. Similar results were obtained at more stringent thresholds (not 
shown). Correspondingly, when we identified differentially methylated regions (DMRs) we 
observed vastly more hyper-methylated regions (Hyper) than hypo-methylated regions (Hypo). 
DMR were identified as described in Methods. b, Characteristic for AID is the preferred 
localization of hyper-methylated CpGs sites near (< 5 bp away) an RGYW hot-spot sequence, 
which is the known DNA recognition sites of AID (R=A/G, Y=C/T, W=A/T). In this figure, the 
fractions of differentially methylated CpGs were compared using Chi-square tests. c, (left) A 
larger fraction than expected of hyper-methylated regions in AID-/- vs WT (yellow) is located in 
gene bodies (exons and introns). The grey bars indicate the fraction of RRBS covered regions 
in each genomic compartment in the mouse genome (RRBS is biased towards CpG islands, 
hence the increased coverage of promoter regions that frequently contain or overlap with CpG 
islands). In contrast, hypo-methylated regions (right) are biased more to promoter regions. 
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Supplemental Figure S10. Plots showing gene expression profile in AID-null and wildtype 
cells obtained by RNA-seq analysis. a, Plots show expression levels (FPKM, log2-
transformed) from RNA-seq data in pre-transduced fibroblasts. FPKMs were calculated using 
TopHat for alignment and CuffLinks for quantification, as described in Methods. Each dot in 
these figures represents a gene. With a cut-off of 2-fold (red lines) and considering only genes 
expressed above 5 (FPKM) in at least one of the samples, 76 genes are relatively activated in 
wildtype cells, and 355 are relatively activated in AID-null cells. b, Plots show expression levels 
(log2 FPKM) from RNA-seq data from cells taken at 3 weeks of the reprogramming process 
relative to expression levels in pre-transduced fibroblasts. With a cut-off of 2-fold and requiring 
an FPKM of at least 5 in one sample, 3,133 genes are activated in wildtype (WT) cells, but only 
2,373 are activated in AID-null cells. In contrast, the number of down-regulated genes is 
approximately the same in WT and AID-null cells. 
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Supplemental Figure S11. MassArray validation of hyper-methylated regions in AID-null 
cells. MassArray analysis was performed on DMR regions identified by RRBS and located 
within each of the secondary pluripotency genes. For each CpG within each region, the wildtype 
methylation level was subtracted from the AID-null methylation level, and the CpG differences 
were plotted using boxplots. As shown in this panel, the vast majority of CpGs from regions 
identified as hyper-methylated by RRBS are also hyper-methylated according to the MassArray 
analysis. 
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Supplemental Figure S12. cMyc target genes fail to be up-regulated during 
reprogramming of AID-null cells.  The chart represents the level of overlap between genes 
that fail to be up-regulated in AID-null cells relative to wildtype cells during reprograming and 
genes that are bound by core pluripotency factors in ESCs, identified through publicly available 
ChIP-seq datasets (Chen et al. Cell 133, 1106-1117, 2008). Genes that fail to upregulate in AID-
null cells were defined as those that upregulate 2-fold or more during reprogramming in WT 
cells, but not in AID-null cells. For this analysis, ChIP-seq reads were downloaded from 
GEO/SRA, aligned to the mm9 genome using BWA; peak calling was performed using 
ChIPseeqer (Giannopoulo & Elemento. BMC Bioinformatics 12, 277, 2011). Peak annotation 
was performed using RefSeq genes using the ChIPseeqerAnnotate program. Overlap was 
assessed using the hypergeometric distribution. Significance of enrichment (negative log10 
hypergeometric p-value) is graphed on the Y-axis. Of note, all p-values were significant; 
however the overlap with cMyc target genes was vastly more significant than the other overlaps 
(even though other factors e.g. Klf4 have more target genes). 
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Supplemental Figure S13. Forced cMYC expression is not sufficient to rescue AID-
dependent pluripotency. a, As indicated in the schematic, 1 week after transduction with 
reprogramming vectors, transduced AID-null cells were infected with a cMYC-expression vector. 
b, Western blotting experiments demonstrate over-expression of cMYC in AID-null cells. c, 
However, no difference was observed in the percentage of OCT4 or SSEA1 positive cells at 4 
weeks, as measured by flow cytometry.  
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Supplemental Figure S14. Methylation studies and gene expression profiling of individual 
clones confirms a role of AID in stabilizing induced pluripotency through DNA 
demethylation. a, Isolated clones of iPSCs derived from AID-null or wildtype cells cluster with 
their own genotype according to methylome. Cluster dendograms are based on genome-wide 
DNA methylation patterns determined by RRBS global analysis. Briefly, the genome was binned 
in 100 kb windows and DNA methylation levels were evaluated in each window, for each clone. 
Methylation levels were obtained by averaging the methylation levels of all CpGs within each 
100kb window. Average linkage hierarchical clustering of the clones was then performed using 
their methylation profiles and 1 – Pearson correlation as distance. b, Changes in methylation at 
the genome-wide level identified in bulk reprogramming cultures of wildtype or AID-null cells are 
validated in isolated clones. Following RRBS of DNA from 3 randomly isolated clones derived 
(each) from AID-null or wildtype fibroblasts, the average methylation (KO/WT) ratio (log2-
transformed) was determined at all differentially methylated regions identified in bulk colonies. 
Hyper-methylated regions identified in the bulk samples (n=5,341) tend to be hyper-methylated 
in the knockout clones compared to wildtype clones, indicated by the rightward shift of the area 
under the curve (p<1e-151, paired Wilcoxon test). c, MassArray bisulfite sequencing validates 
hyper-methylation phenotype of most secondary pluripotency genes. Analysis was carried out 
as in Fig. 4e, except using DNA from isolated wildtype or AID-null reprogrammed clones, 
isolated initially 2 weeks into reprogramming, and evaluated at approximately 3 weeks. Shown 
is the average for three AID-null clones compared to the average for three wildtype (WT) clones. 
6 of the 9 genes validated at the clonal level. That 3 of 9 did not might reflect the passaging of 
these cells required to generate sufficient materials. d, qPCR analysis of hyper-methylated 
secondary pluripotency genes showed significantly lower expression levels in AID-null clones 
compared to wildtype clones (*p<0.05, **p<0.01, ***p<001). 12 individual clones were picked 
from AID-null or wildtype cells 2 weeks following initiation of reprogramming in two separate 
experiments, and evaluated at approximately 3 weeks.  
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Supplemental Figure S15. Fibroblast-associated genes are expressed at relatively high 
levels in AID-null cells that are failing to stabilize pluripotency after 4 weeks of 
reprogramming. Shown are the relative expression levels of several fibroblast-associated 
genes in AID+/+ and AID-/- fibroblasts quantified by qPCR 1, 2, 3 or 4 weeks following OSKM 
transduction. Data is derived from three independent experiments and represents mean +/- 
standard error (*p,0.05, **p<0.01). 
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Supplemental Figure S16. Embryonic stem cells can be derived from AID-/- embryos, 
although less efficiently compared to wildtype embryos. a, Representative phase contrast 
image of ES cell colonies derived from an AID-/- blastocyst. Without exception, AID–null ESCs 
show characteristic ESC morphology with sharp-edged, round colonies shown here at passage 
9 following derivation. b, Representative immuno-staining of an AID-/- ESC colony stain positive 
for pluripotent markers using with anti-OCT4 and anti-NANOG antibodies, and do not express 
the differentiated lineage marker GATA6, using anti-GATA6 antibodies. These representative 
colonies were stained at passage 6 after derivation, and all clones are stable for pluripotency 
markers beyond passage 10. 
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Supplemental Table ST1. Primers used for qPCR analyses. 
 
  
 
 
Primer sequence (Forward) Primer sequence (Reverse) Accession 
number 
mAid GCCACCTTCGCAACAAGTCT CCGGGCACAGTCATAGCAC NM_009645 
mNanog GGACAGGTTTCAGAAGCAGAAG ACCATTGCTAGTCTTCAACCAC NM_028016 
mOct4 ACCTCCTCTGAGCCCTGTGCC CACCTTTCCAAAGAGAACGCCCA NM_013633 
mSox2 GCGGAGTGGAAACTTTTGTCC CGGGAAGCGTGTACTTATCCTT NM_011443 
mKlf4 TGCCAGACCAGATGCAGTCAC GTAGTGCCTGGTCAGTTCATC NM_010637 
mUtf1 GTCCCTCTCCGCGTTAGC GGGGCAGGTTCGTCATTT NM_009482 
mKlf2 CTAAAGGCGCATCTGCGTA TAGTGGCGGGTAAGCTCGT NM_008452 
mEras GCCCCTCATCAGACTGCTAC GCAGCTCAAGGAAGAGGTGT NM_181548 
mCbx7 TGCGGAAGGGCAAAGTTGAAT ACAAGGCGAGGGTCCAAGA NM_144811 
mGdf3 GGGCCTCGCAGGACTTATG TGGTCGCAGGTTATAGTAGGAC NM_008108 
mZfp296 CGAGGGACATGCCCATATCG GGCGGTCGGAAGACTTAGAAC NM_022409 
mRex1 ACAAGGCGAGGGTCCAAGA TATGACTCACTTCCAGGGGGCACT NM_009556 
mApobec1 ACCACACGGATCAGCGAAAC GGGGTAGTTGACGAAATTCCTC NM_001134391 
mDnmt1 CCGTGGCTACGAGGAGAAC TTGGGTTTCCGTTTAGTGGGG NM_001199431 
mDnmt3l TGGAGACTTCCGACAGCTCTA AGGGCTGGGGAGGATTTCA NM_001081695 
mTet3 TGCGATTGTGTCGAACAAATAGT TCCATACCGATCCTCCATGAG NM_183138 
mcMyc GATCAGCTCTCCTGAAAAGA TCGAGGTCATAGTTCCTGTT NM_001177352 
hOCT4 TGGGCTCGAGAAGGATGTG GCATAGTCGCTGCTTGATCG NM_002701 
hKLF4 CCCAATTACCCATCCTTCCT ACGATCGTCTTCCCCTCTTT NM_004235 
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Amplicon Sequence 
Rex1 GGGTGCAAGAAGAAGCTGAGGGATAAAACCGCCCTGAGGAAGCACATGCTTGTCCACG
GGCCCCGGCGGCACGTGTGTGCAGAGTGTGGCAAAGCCTTCA 
Dnmt1 CCAAGGTGGCTGTCAAGTGGTGCGATGCATGTTTGAGCAAATAGAATTGATTAAAATAGA
TTTAAAATGGCACTCGTCTGGCTTTGTGTCTACCAGGCATCT 
Dnmt3l GGGAGAAAGGCTAAGCCCCTACTCACCTGAAGGAAGCGGGTAGTTGTCTCTTGGTCATC
CTCAGTCAGCAGCAGATTGTCCATGAATATCCAGAAGAAGGGC 
Zfp296 CAGCAGTGGCAGTGGTGGCGCCAGTTGAAAGCAAGCCCCCTCCAGTGAGCAGTGCTGC
CCGGCGGAGCCCCACCTGTGATGTGTGCAAGAAGACCCTCAGCTCTTTCAGCAACCTCA
AGGTCCACATGCGTTCCCACACTGGTGAGCGACCCTACTCCTGTGACCAGTGTTCCTAT
GCCTGCGCTCAGAGCAGCAAGCTCAACAGACACAAGAAGACCCATCGGCAGCTGGCAC
CCGGGAGCCCCTCCACTTCTGCC  
Apobec1 CCCTGCAGGTGGCTGTGGGCACACCTGAGGAAACAAAGTCCGGCACACAGCTGGCAGA
AGCCATCGCAGCAACATAAGCTCCCGAGGAAGGCGTCCAGAGACAGAGCAAGATGAGTT
CCGAGACAGGTAAAGGGATGCCGGGTTCTAGCAAGGTGTTGAGTTGA 
Gdf3 AAATTAAATTCTGCTAAACCGGCACCGCGGTAGTTAGACTAGCGTGGAGAGGTGATAAGA
ACACGTGCCTTCCTCTGGGCTGATCTTGGAACCAAGACAGAATGTGCAAGATCCAAGGC
CAGACTCCGGCCAGCCATGGTGTCCATCTGTATCCTCCTCCCTGCTCCACAGCACCCAC
TTGAGATTTTTCTCTGATAAACCCTCGGGTTCCTTACCCTGGTCTGGGAGAAGCTGAAGC
AGGTTCCCACGAACACCCAGCTCCTTCACGTAGCATAAGTCCTGCGAGGCCCCACTGGC
TGCAGCGGCTTCTCGAGCCCGGATGATTTTCCTTA 
Cbx7 GTGTGCATGTTGGGGTGTCCGGATGTGTTCATGGGCATCTCTACACAGGCCAATGGCAG
GGAGACAGCACACTCGGAGGAGGCTTGGTGGGCAGCCTCTTCCCTGGTCCAGCCCGTG
CCGGTTGTCCTGATCCTGTCCCCGGTGGCCAAGGCCGGCCTCTGTGTCCCACCACAAG
GCTGGAGTGGAAAGTTCATAGTAAAGACCCACGGCAAGGGACAGGGAAGGGACACCAC
CAGAAAGCTGGGGTGACTGCCTGAGGCAAGGTCTGGACCTCCTGGGCTCCTCCGGCTC
CACGGATCAGCCTCTG  
Snai1 TGGCTGTGCTTGGGCTGACCGGGCCCTGTCCAGGCCTTCCTAACCCTGCTGGTATCTCT
CCCCAGGTGAGAAGCCATTCTCCTGCTCCCACTGCAACCGTGCTTTTGCTGACCGCTCC
AACCTGCGTGCCCACCTCCAAACCCACTCGGATGTGAAGAGATACCAGTGCCAGGCCTG
TGCCCGAACCTTCTCCCGCATGTCCTTGCTCCACAAGCACCAAGAGTCTGGCTGCTCCG
GAGGCCCTCGCTGACCCTGCTACCTCCCCATCCTCGCTGGCATCTTCCCGGAGCTCACC
CTCCTCCTCAC 
Tet3 1)TTTCCCTCCGGGTTTTTTCCGCTTGCCCGTCGGCTCGGCTCATTTCCCAGGACACAGC
AAAGTGGTAGGCATTTAGTAAACCGTCTGCCAAATGAAGGGGCTGTAGAAACCCCAGCC
CAGCAGGCTGCTCCACACCCTTCTCTAACACTCAAACGGACAGACTTACCGACACAATCG
CAGGTAGGGAACTCGGACTGAGCCTTCTTGGCCGGTGTGTCCAGCAGACTCTTAGTAGG
TGTGTCTAGGTACTTTAGAGGTGACTCCAAGAAGCCACTGAGGGTTGGTGTGAGTGGGT
TCTCAGCCTTGGTGGGCGTGGCCTCCTGTCCCCCCTCTTCTGAATGGAAGCAGGTAGTT
GAGAGCACAGTCACGGCCCCTGAGGACTCGATCTTGATCTTCTTGGGGGAGCGGGTGG
CAAAAGGGCTCTCCGGAGCTGGGAGACATGTTGATTGGTTTTCAGGTTCTTGAATGGGC
ACCGAAGGTGGGCCGGGAAGCCCAAAGCTATCCCCAAATTCAGCCTCAAATTGCCGGAT
GAGCTCCTCCAGCTTGTCATCGGCAGGGGGAAGGGGGCCACCAGTGGAGCCTGACTGC
AGGGCTACCATGGGGCTGGGGGATCTCATTTCCTGAGTAGGGGGCAGCAGGCTGTCCC
CGGAGGGACTAGGTGCAAATAG  
 
2)TGGGACTGGGAGGCTGCCTCAGGCCCCACTCACGCTGCTCGTCTGGAAGATGCCCAC
GACCTGGTGGCCTTTTCGGCCGTGGCCGAAGCTGTGTCATCTTACGGGGCCCTTAGTAC
CCGGCTCTATGAAACCTTCAACCGTGAGATGAGTCGTGAGGCTGGGAGCAACGGCAGG
GGCCCCCGGCCTGAGAGCTGCTCTGAGGGCAGTGAAGACCTGGACA 
 
Supplemental Table ST2. Shown are the amplicons that were sequenced by MassArray 
analysis to validate the RRBS data. Note that two replicons were probed for Tet3. 
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Sample 
Number of 
Reads 
Number of 
Unique 
Aligned 
Reads 
Alignment 
rate 
Number  
of CpGs 
covered 
Mean CpG 
coverage 
Conversion 
rate 
AID-null 
clone 1 156476796 102307140 65.40% 3111280 77.75 99.65% 
AID-null 
clone 2 154731507 102016359 65.90% 3536375 66.74 99.70% 
AID-null 
clone 3 165603203 111544028 67.40% 4214110 72.05 99.46% 
WT  
clone 1 158138041 105320482 66.60% 3408245 84.65 99.57% 
WT  
clone 2 155146448 104404463 67.30% 2933321 96.77 99.56% 
WT  
clone 3 159087745 107087549 67.30% 3641092 80.52 99.57% 
AID-null 
 3 wks 164635077 108625223 66.00% 1822333 161.98 99.50% 
WT 3 wks 157653137 106427858 67.50% 1965414 134.04 99.70% 
AID-null 
starting 
fibroblasts 
152209632 98631148 64.80% 2629236 86.21 99.81% 
WT  
starting 
fibroblasts 
153679092 99364775 64.70% 2782197 84.69 99.81% 
 
 
Supplemental Table ST3. Meta-data for the enhanced RRBS analysis on individual AID-null or 
wildtype (WT) clones or bulk colonies evaluated three weeks after reprogramming was initiated, 
or in starting fibroblasts. 
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3.  DISCUSSION 
3.1. TOOLS FOR STUDYING PREIMPLANTATION DEVELOPMENT 
TISSUE CULTURE MODELS 
To understand how tissues and organs function individually and in 
concert with each other it is imperative to understand how these highly 
functional units arise during development. An important branch of research in 
this direction is the investigation of the function and roles of individual genes 
and gene regulatory networks in different tissues. This has long been 
achieved by reverse genetics, deleting single or multiple genes to infer their 
original function and possible interactions with other factors. These studies 
rely on the availability or generation of suitable animal models for direct in vivo 
analysis. In many instances, specific tissues have to be isolated for further 
study, which is often technically difficult and/or quantitatively insufficient. For 
this reason cell culture models have been developed for many cell types. 
These are essential for high-throughput and quantitative biochemical assays. 
The in vitro culture of stem cells has proven especially useful for the study of 
development, as they can be kept in culture indefinitely. Importantly, stem 
cells hold the developmental potential to differentiate into various cell types, 
thereby recapitulating differentiation processes observed in vivo, making them 
suitable for the safe testing of drugs and other therapies.  
Biochemical studies of preimplantation development are challenging 
due to the small size of these early embryos and their lineage compartments. 
Embryos at the late blastocyst stage reach a size of 100-200 cells and 
encompass two extraembryonic lineages, the TE and the PrE, as well as the 
embryonic lineage, the pluripotent EPI (see Introduction p. 5-7). Not only is 
the isolation of these lineages highly difficult but they also yield cell numbers 
for downstream biochemical applications. Stem cell culture models have 
therefore been successfully established for all three lineages. To gain insight 
into the second cell fate decision and the nature of the resulting lineages, 
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embryonic stem (ES) cells are derived from the EPI and extraembryonic 
endoderm stem (XEN) cells are derived from the PrE. 
ES CELLS  
The first successful in vitro culture of mouse ES cells was established 
in 1981 (Evans and Kaufman, 1981; Martin, 1981). Ever since, ES cell biology 
and methods to derive and maintain these cells have been studied 
extensively. Derivation efficiency has been a major problem for researchers in 
the field. Implementations of highly technical methods like isolation of the ICM 
and improvements in ES cell culture, such as addition of LIF, have improved 
ES cell derivation over the years (see Introduction p. 26-29). The 
development of the 2 inhibitor (2i) culture conditions, utilizing inhibitors 
against the differentiation promoting FGF/ERK pathway and GSK3, has 
caused a leap in the understanding of the nature of pluripotency and the 
maintenance of ES cells in a state of so called naïve pluripotency (see 
Introduction p 28).  
We have developed a protocol for the derivation of ES cells, taking 
advantage of the 2i system (Publication III). Using this protocol we achieved 
derivation efficiencies of 60% - 99%, including for previously considered non-
permissive strains such as NOD or DBA. Combining the pluripotency 
promoting properties of 2i during the blastocyst outgrowth phase with the 
growth enhancing effects of serum during the colony-forming phase could be 
the decisive factor for the success of this protocol. Culture in 2i would thereby 
select for stably pluripotent epiblast cells inside the ICM early on, when it is 
imperative to allow only pluripotent EPI cells rather than PrE or TE cells to 
grow. Once this EPI outgrowth is disaggregated, cells are growing in single-
cell culture and are therefore highly sensitive. Addition of nutrient and growth 
factor rich serum at this stage could enhance their survival and proliferation 
capacity.  
The described protocol allows for routine, highly efficient and 
straightforward ES cell derivation, without the requirement of immunosurgical 
removal of TE or addition of other factors and produced germ line competent 
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ES cells possessing normal karyotypes. Our protocol has since been 
employed successfully in several studies (Bangs et al., 2015; Li et al., 2014; 
Schrode et al., 2014; Wen et al., 2014; Xenopoulos et al., 2015) and has 
allowed various laboratories the ready derivation of ES cell lines from a 
multitude of mouse models (unpublished data, students of the CSHL mouse 
genetics course 2013). Considering the high success rate, it could be 
imagined that this protocol or slight variations of it can be used for the 
derivation of ES cells from other species, as has been achieved similarly for 
rat and naïve ES cells from human (Buehr et al., 2008; Li et al., 2008; Ware et 
al., 2014). 
Our protocol makes ES cell derivation more feasible, even for less 
experienced researchers. This could encourage the study of cell culture 
models in parallel to in vivo studies, facilitate the investigation of factors 
influencing the pluripotent state as well as differentiation processes, and allow 
the ready utilization of ES cells where in vivo studies are not suitable.  
As mentioned above, ES cells are mostly used to model differentiation 
into somatic tissues to study development, organ function and disease. The 
study of preimplantation development however exploits the high degree of 
similarity of ES cells to the pluripotent epiblast in the blastocyst stage ICM. 
This cell culture system has advanced the understanding of the mechanisms 
and processes involved in the second cell fate decision, which cannot be 
otherwise studied in vivo. For instance, the effect of FGF/ERK signaling on 
the second cell fate decision has been hypothesized through reverse genetics 
but the mechanism through which this takes place, the transcriptional 
repression of Nanog, was confirmed in ES cells (see Introduction p. 19).  
XEN CELLS 
The derivation of XEN cells as a model for PrE development has only 
recently been achieved (Kunath, 2005). It is therefore a comparatively novel 
stem cell type, whose derivation and utilization is still in a phase of trial and 
optimization. We have created a collection of protocols for the derivation of 
XEN cells from blastocysts as well as ES cells (Publication II). XEN cells can 
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be derived from blastocyst outgrowths using ES or TS derivation conditions, 
i.e. in the presence of LIF or FGF4/Heparin respectively (see Introduction, p. 
31). This intriguing observation hints at imbrication of pathways acting during 
preimplantation development and a more complex picture of regulation of the 
second cell fate decision.   
For ES derivation conditions, LIF is added to the culture. In ES cells 
LIF acts through the JAK/STAT3 pathway to promote self-renewal (see 
Introduction p. 27). However, LIF also activates the MEK/ERK pathway, which 
is necessary for PrE development (see Introduction p. 15-16). This might 
explain how PrE cells are maintained in blastocysts and their outgrowths 
when cultured in LIF containing media. Slight modulation of the derivation 
protocol must then be used to obtain XEN cells rather than ES cells under 
these conditions. Longer culture phases before disaggregation of the 
outgrowth might provide additional time to fully establish the PrE. Gentle 
dissociation may also favor XEN cells. Epithelialized PrE cells tend to 
proliferate to encompass EPI cells when culturing isolated ICMs of the 
blastocyst stage (Handyside, 1978; Rossant, 1975). By creating several 
partial outgrowths through light disaggregation the overall surface for PrE 
cells to proliferate on is increased, potentially favoring their propagation over 
ES cells. 
For TS derivation conditions, FGF4 and Heparin are added to the 
derivation media since MEK/ERK signaling is promoting TE proliferation (see 
Introduction p. 9). As discussed above, FGF/ERK signaling also plays an 
important role in PrE formation. This could explain why TS derivation 
conditions are also supportive for the derivation of XEN cells. However, since 
FGF signaling has a proliferative effect on TS cells they might be more likely 
to outcompete XEN cells in these culture conditions. Accordingly, we found 
that XEN derivation efficiencies are higher using ES conditions than TS 
conditions. Active ERK signaling needed for PrE formation might be 
sufficiently provided by LIF and through FGF4 secreted by EPI cells. 
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Moreover, exogenous FGF4 does not enhance reprogramming of ES cells to 
XEN cells through Gata6 overexpression (Wamaitha et al., 2015). 
XEN cells can also be derived by overexpression of the master 
regulator Gata6 in ES cells, underscoring the relevance of this transcription 
factor for PrE lineages (see Introduction p. 13). Interestingly, this conversion 
is also possible by treatment with growth factors such as retinoic acid 
supplemented with activin A (Cho et al., 2012). Activins are members of the 
transforming growth factor beta family and signal via Smad2 to activate 
downstream transcription factors (Abe et al., 2004). Interestingly, it has been 
suggested that Smad2,3 signaling is involved in parietal endoderm formation 
(Roelen et al., 1998), which could elucidate the supporting effect of Activin on 
XEN cell conversion from ES cells. Retinoic acid on the other hand has 
previously been shown to facilitate PrE formation in ES cells and embryoid 
bodies (Capo-Chichi et al., 2005; Mummery et al., 1990; Rohwedel et al., 
1999). Indeed, retinoic acid might positively regulate Bmp2 (Heller et al., 
1999; Rogers et al., 1992), which in turn can activate Gata4 in heart 
development (Arceci et al., 1993; Ghatpande et al., 2006; Kostetskii et al., 
1999). Overexpression of Gata4 in ES cells, similarly to Gata6, has been 
shown to lead to XEN cell conversion (Fujikura et al., 2002). Accordingly, 
activation of Gata4 through retinoic acid could explain its ability to convert ES 
cells to XEN cells.  
As mentioned before, XEN cells are a comparatively recent stem cell 
type and are not fully characterized. Different ways to derive them efficiently 
will help further understand their biology and facilitate their use as a stem cell 
model (reviewed in (Moerkamp et al., 2013)). For instance, they represent an 
interesting tool for the study of X-inactivation, since the paternal X 
chromosome remains silenced in the PrE endoderm and its derivatives, in 
contrast to the EPI (Kunath, 2005; Okamoto et al., 2004). 
Our protocol has proven useful in several studies (Bangs et al., 2015; 
Blij et al., 2015; Kropp et al., 2014; Loh et al., 2015; Lou et al., 2014; Lu et al., 
2015; Merzouk et al., 2014), including very recent work investigating the role 
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and possible functions of Gata6 in extraembryonic endoderm development 
(Wamaitha et al., 2015). 
LIMITATIONS FOR THE USE OF STEM CELL MODELS 
While the use of cell culture models to study the second cell fate 
decision can be useful, it is important to keep in mind that these cells likely do 
not fully recapitulate the in vivo state. The maintenance of cells in culture 
might introduce expression artifacts that do not exist in vivo at the putative 
stage. Additionally, cultured cells lack the context of their in vivo environment, 
which is essential for effects of local signaling and cell-cell contacts.  
Both ES and XEN cells resemble closely derivatives of the EPI and PrE 
rather then these early lineages themselves. ES cells have recently been 
found to closest resemble the E4.5 EPI, shortly before implantation (Boroviak 
et al., 2014). At this stage in vivo, the EPI lineage is fully specified and has 
lost its plasticity to convert to the PrE lineage (see Introduction p. 21-22). ES 
cells therefore may not be suitable for modeling earlier phases of the second 
cell fate decision. Similarly, XEN cells are thought to represent the parietal 
endoderm (PE) lineage (Brown et al., 2010; Kunath, 2005), which is specified 
after implantation from PrE cells that undergo epithelial to mesenchymal 
transition and migrate along the basement membrane of the trophectoderm 
layer to eventually form the parietal yolk sac (Kadokawa et al., 1987). XEN 
cells might therefore have undergone dramatic changes from their lineage of 
origin, the PrE. 
SINGLE CELL ANALYSIS OF INTACT EMBRYOS 
Tissue culture models have proven very useful and have allowed 
biochemical studies that are not achievable in vivo. However, their application 
has limitations. As discussed above, cells in culture might not faithfully 
recapitulate many aspects of cells growing in vivo necessitating careful 
interpretations of the results obtained in cell culture experiments.  
These issues are well recognized in the field and in recent years new 
steps have been taken to find solutions. Several groups have created 
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methods to isolate single cells from early embryos and perform single cell 
gene expression analysis, including RT-PCR and microarrays (Boroviak et al., 
2014; Guo et al., 2010; Ohnishi et al., 2014; Xue et al., 2013). These analyses 
have proven a useful tool to analyze transcriptional controls of genes through 
mRNA levels and produced considerable amounts of new information. It will 
be interesting to see similar work in null mutant embryos for genes important 
in the second cell fate decision as was done by Ohnishi et al. (Ohnishi et al., 
2014). However, transcriptome analysis does not provide a readout for protein 
levels, which can differ due to post-transcriptional and post-translational 
regulation. Unfortunately, biochemical assays to measure protein levels, such 
as Western Blotting, require substantial cell numbers for their completion. 
These limitations could be overcome using FACS (Fluorescence Activated 
Cell Sorting), which could be adopted to isolate single cells for the 
quantification of protein levels. 
It is increasingly evident that the in vivo context can play crucial roles in 
biological processes, especially during development. During preimplantation 
development, neighboring cells seem to influence each other through 
secretion of FGF4 and how cells react differentially to signaling from their 
neighbors still remains elusive. Additionally, cells acquire their fate in a 
seemingly random fashion inside the ICM. Therefore, retaining spatial 
information is essential. Fixation of whole embryo samples followed by 
immunohistochemistry and confocal microscopy has been used widely to 
study development. This methodology retains all spatial information and 
readily informs about the presence of a protein. However, it generally only 
provides binary information about the absence or presence of a protein of 
interest since it is not possible to quantitatively assess differing fluorescence 
levels by eye.  
To achieve unbiased, high throughput single cell quantitative protein 
expression measurements while retaining spatial information, we created a 
semi-automated pipeline (Publication I, Figure 1 A, B). MINS (Modular 
Interactive Nuclear Segmentation) was used to perform highly accurate 
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nuclear segmentation on 3D microscopy images of preimplantation embryos 
(Lou et al., 2014). The resulting data comprised fluorescence intensity 
measurements of all nuclei in the embryo as well as positional information of 
all cells. To ensure faithful analysis we computationally corrected for variation 
of fluorescence intensities caused by tissue depth and created a threshold for 
unbiased assignment of cell fates. In this way, we were able to analyze the 
entire ICM, taking into account all cells within each embryo analyzed. 
To gain a holistic picture of the processes and mechanisms governing 
development it will be important to utilize methods determining both single cell 
transcriptional activity as well as protein level analysis (reviewed in (Saiz et 
al., 2015)). 
3.2.  THE SECOND CELL FATE DECISION: TO BE OR NOT TO BE 
PLURIPOTENT 
BREAKING SYMMETRY IN THE ICM 
After specifying the TE at the morula stage, the ICM comprises a rather 
homogenous population of totipotent cells, coexpressing factors important for 
the imminent second cell fate decision. Starting around the early blastocyst 
stage, expression of the transcription factors Gata6 and Nanog becomes 
increasingly heterogeneous until they display mutually exclusive expression 
with Gata6 marking the PrE and Nanog the EPI. What causes the initial 
disruption of balanced co-expression is yet unknown and poses an important 
question in the field. Several interesting ideas have been brought forward to 
answer this question, mostly falling into one of two basic assumptions: 
predetermination of blastomeres versus stochastic adoption of cell fate 
through transcription factor heterogeneities (see Introduction p. 20). A 
satisfying and reproducible answer has not yet crystallized. 
STOCHASTIC DIFFERENTIATION IN THE ICM 
To gain more insight into this question we utilized our computational 
analysis pipeline for GATA6 and NANOG and determined cell fates inside the 
ICM. Since our approach allows for retention of spatial information we were 
3.  Discussion 
 128 
able to calculate the Pearson’s correlation coefficient as a function of cell-cell 
distance (Publication I, Figure 1 and Figure S1). We found that there was no 
correlation in the spatial pattern of cell fates at the early blastocyst stage. 
Instead correlation started to emerge at the mid blastocyst stage, with 
neighboring cells having a slightly higher chance to exhibit the same fate. 
These results could be explained if early lineage biases result from stochastic 
cell-autonomous fluctuations. Some of these progenitors could then 
proliferate, thereby explaining the slightly higher chance of adjacent cells 
displaying the same identity later on. 
Indeed, cellular noise, often in the form of transcriptional heterogeneity 
or fluctuation due to the unsynchronized phases of biochemical reactions or 
epigenetic mechanisms, can lead to bimodal states. Studies showed that 
controlled transcriptional noise in a reporter gene can lead to cellular 
variability in bacteria and yeast, with the latter generating bistable protein 
expression states (Blake et al., 2003; Ozbudak et al., 2002). In C. elegans 
intestinal specification was shown to be highly regulated. However, 
incompletely penetrant mutations for loss of intestinal cells caused broadly 
heterogeneous expression of a downstream gene in the gene regulatory 
network, leading to a threshold dependent allocation of cell fates (Raj et al., 
2010). In mouse, heterogeneity in expression levels of a gene in 
hematopoietic progenitor cells could account for stochastic priming for cell 
fate decisions (Chang et al., 2008). These examples demonstrate how cellular 
noise is able to create lineage biases. These biases alone, however, cannot 
create bistable states. Instead, the fate decision has to be stabilized once the 
bias is created (reviewed in (Ferrell, 2002)). EPI and PrE fates could thus be 
biased in a stochastic fashion through transcriptional noise, with their fates 
subsequently being stabilized by feedback loops, possibly involving FGF 
signaling. Further considerations of how this could be achieved are discussed 
below (see Discussion p. 138, “Possible mechanisms for 
GATA6/NANOG/FGF interplay”). 
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RELATIVE PROTEIN LEVELS AND LINEAGE CHOICE 
If, as discussed above, a threshold has to be reached to ensure 
lineage bias, relative protein levels might be critical for lineage allocation. We 
inferred the nuclear concentration of NANOG and GATA6 from fluorescence 
intensity levels in ICMs of Gata6 wildtype and heterozygous embryos. We 
found that heterozygous embryos, displaying lower levels of GATA6, had 
overall fewer PrE cells. This result was independently confirmed by 
Bessonard et al. (Bessonnard et al., 2014). Interestingly we were also able to 
demostrate that lineage specification of the PrE was retarded in Gata6 
heterozygous embryos in comparison with wildtype embryos (Publication I, 
Figure 4). These results demonstrate the importance of protein levels for the 
second cell fate decision. Lower levels of GATA6 could conceivably require 
more time to reach the threshold needed to overcome pluripotency and fewer 
cells would succeed in this process. In this scenario, GATA6 and NANOG are 
stably coexpressed in the early ICM until stochastic fluctuations lead to one of 
the two proteins reaching a required threshold level, required to establish a 
lineage bias. As discussed above, this bias could then be reinforced through 
FGF signaling or other mechanisms. It would be interesting to test to what 
extent NANOG levels play a role, and if lower levels of NANOG would 
concomitantly lower the threshold requirement for GATA6. Analysis of the 
relative versus absolute protein levels would allow the determination of 
relevance of the relative concentration of these two proteins and could be 
carried out in a compound allelic Gata6;Nanog series. 
 
It is important to note that both, the analysis of cell fate correlation, as 
well as protein levels were carried out from still images of fixed embryos. To 
confirm the inferred results and gain more insight into these processes time 
lapse imaging of live embryos with subsequent correlation and level analysis 
would be necessary.  
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PARALLELS BETWEEN SOMATIC CELL REPROGRAMMING AND 
EPI/PRE CELL FATE CHOICE 
A possible way to generate expression heterogeneity in order to create 
the phenotypic differences described above is through epigenetic regulation 
(Wong, 2005). ES cells are thought to maintain a metastable state, ready for 
differentiation cues, through epigenetic regulation. Similarly, such epigenetic 
states could play a role in breaking symmetry in the ICM or in reinforcement of 
the fate decision.  
An important epigenetic mechanism to silence genes during 
differentiation is DNA methylation. During preimplantation development, this is 
one possible mechanism to establish lineage boundaries. For instance Elf5, 
which together with Cdx2 and Eomes promotes TE development, is silenced 
through DNA methylation in ES cells but hypomethylated and thereby active 
in the TS cells. Similarly, based on cell culture models, the pluripotency 
marker Stella is speculated to be hypomethylated in ICM cells but gets 
methylated and silenced in the EPI upon implantation (Hayashi et al., 2008). 
In some instances such repressive DNA methylation marks have to be 
removed. The highly methylated zygote undergoes massive demethylation 
before the first cell fate decision to open chromatin and thereby increase 
plasticity (see Introduction p. 24). Similarly, during reprogramming of somatic 
cells to iPS cells the epigenetic landscape of the somatic cell needs to be 
reprogrammed as well to create an open, pluripotent state (Huangfu et al., 
2008; Mikkelsen et al., 2008; Shi et al., 2008). In general, active DNA 
demethylation might allow for dynamic regulation of the epigenetic state of 
regulatory genes in response to differentiation cues. 
We tested the involvement of the DNA demethylation promoting 
deaminase AID during fate reversion by reprogramming Aid null mutant 
fibroblasts to iPS cells (Publication IV). Interestingly we found that mutant 
fibroblasts displayed enhanced response to the process of reprogramming, 
through faster change in morphology, activation of pluripotency markers and 
numbers of colonies. AID could be permissive for the expression of fate 
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specific genes and in its absence the differentiated state becomes 
destabilized. However, the so acquired pluripotent state proved unstable and 
AID null mutant iPS cells were unable to retain pluripotency over time and 
instead differentiated. We also found that secondary pluripotency genes were 
hypermethylated in these cells. It could be speculated that AID is important 
during a later phase of reprogramming to activate secondary pluripotency 
genes. AID null cells also failed to upregulate Dnmt1, which is responsible for 
methylation of newly synthesized DNA strands and its exclusion from the 
nucleus causes DNA demethylation in the early embryo (Bestor, 2000; Howell 
et al., 2001). Interestingly, when passaging AID null iPS cells a small 
population was able to retain pluripotency. This observation together with the 
lack of DNMT1 in these cells could suggest that DNA replication through 
passaging caused sufficient passive demethylation in some cells to 
compensate for the absence of AID.  
Our results support reports of AID involvement in iPS reprogramming, 
possibly through demethylation of pluripotency gene promoters (Bhutani et al., 
2013; 2010). However, a recent study, attempting reprogramming of Aid null 
mutant fibroblasts, found no differences in efficiency or maintenance of 
pluripotency in these cells compared to wildtype (Shimamoto et al., 2014). 
This discrepancy could be explained by strain differences of the parental mice 
(Shimamoto: C57BL6, Kumar: BALB/c). Mouse strains differ in their genetic 
background, which can lead to phenotypical variations and can have dramatic 
effects for ES cell derivation (Baharvand and Matthaei, 2004; Erickson, 1996; 
Kawase et al., 1994; Simpson et al., 1997; Suzuki et al., 1999). It is possible 
that the establishment of pluripotency as well as epigenetic regulation during 
iPS cell reprogramming is similarly strain dependent. iPS reprogramming in 
wildtype as well as Aid null mutant fibroblasts from different mouse strains 
should be performed to gain a clear understanding of the role of AID in the 
maintenance of the pluripotent state. 
ES cells derived from Aid null mutant blastocysts displayed normal 
morphology and marker expression. However, derivation efficiency was 
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reduced in Aid null compared to wildtype embryos. One could speculate that 
AID plays a role during a phase of ICM to EPI development, analogous to the 
late phase in iPS reprogramming. Either way, the varying effects of Aid 
deletion on the maintenance of pluripotency suggest that another mechanism 
must be in place, potentially cooperating with AID in active demethylation. 
Interestingly, computational modeling when used to explain the 
mechanisms of fate reversion through iPS reprograming reveals interesting 
parallels between fate reversion and bimodal cell fate choice as described for 
PrE/EPI (Chang et al., 2008; MacArthur et al., 2008). For both, cells seem 
inherently robust to reprogramming/differentiation respectively, but 
amplification of transcriptional noise from several factors and transcriptional 
feedback loops may be sufficient to trigger activation of the 
pluripotency/differentiation program. This explains the stochastic behavior of 
both, reprogramming and PrE/EPI cell fate choice. It also seems that both 
require higher expression levels of the relevant genes to overcome a 
necessary threshold, similar to what could be the case for the second cell fate 
decision. 
 
SEGREGATING PRIMITIVE ENDODERM AND EPIBLAST 
GATA6 GOVERNS PRIMITIVE ENDODERM FATE 
Once gene expression homogeneity in the ICM is broken, cells 
progressively commit to their respective lineages. For the PrE this means 
significant changes and entails the activation of genetic programs, including 
the activation of transcription factor cascades and signaling pathways, which 
will eventually lead to the cells’ transition to an epithelial extraembryonic 
endoderm identity (see Introduction p. 10, 15). A good candidate for master 
regulator of this process seemed to be Gata6, since its ectopic expression in 
ES cells is sufficient for their trans-differentiation to a PrE like state (Fujikura 
et al., 2002; Shimosato et al., 2007). However, the Gata6 null mutant was 
reported to be postimplantation lethal with defects in PrE derivatives, which 
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suggested a less major role for Gata6 in the regulation of PrE formation ((Cai 
et al., 2008; Koutsourakis et al., 1999; Morrisey et al., 1998b), see 
Introduction p. 13). However, genotyping in these embryos was performed 
using in situ hybridization, which lacks the accuracy of PCR approaches. 
To gain a definite understanding of the role of GAT6 in preimplantation 
development we performed a more extended analysis on a Gata6 wildtype, 
heterozygote, and null mutant allelic series to determine the role of GATA6 
during the second cell fate decision. In order to gain a comprehensive picture 
of the phases that make up the second cell fate decision, embryos of various 
stages were obtained from Gata6 heterozygous (source: (Sodhi et al., 2006)) 
intercrosses at sequential time points after mating. No Gata6 null mutant 
embryos could be recovered after implantation (E5.5, see also Publication I: 
Table S1), which pointed to Gata6 null mutants being peri-implantation rather 
than postimplantation lethal as previously suggested (see Introduction, p. 13). 
Subsequently, we analyzed large numbers of embryos during the three 
phases of the second cell fate decision using immunohistochemistry. GATA6 
protein was indeed absent and instead all ICM cells ectopically expressed 
NANOG. Additionally, markers for the maturation of the PrE, i.e. SOX17, 
PDGFRA and GATA4, as well as markers for the lineage’s polarization and 
epithelialization, DAB2 and aPKC, could not be detected in Gata6 null mutant 
embryos (Publication I, Figures 2A and 3A, Movie S1). Rather, the known 
pluripotency and EPI markers SOX2 and OCT4, like NANOG, were expressed 
throughout the ICM (PUBLICATION I, Figure 3B). These results were recently 
confirmed by Bessonnard et al. (Bessonnard et al., 2014) and put GATA6 at 
the top of the hierarchy that regulates PrE formation and thereby the second 
cell fate decision.  
It has indeed been suggested that Gata6 might be upstream of some of 
the consecutive PrE markers Sox17, Gata4 and Pdgfra. Accordingly, GATA 
binding motifs can be found in enhancer elements of Pdgfrα and Gata4 
(Niakan et al., 2010; Wang and Song, 1996). Moreover, in a recent study 
performing ChIP-Seq for GATA6 in XEN cells and induced XEN cells, 
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Wamaitha and colleagues showed enrichment of GATA6 near PrE specific 
genes, like Gata4, Sox17 and Pdgfra (Wamaitha et al., 2015). They also 
demonstrated that extraembryonic endoderm specific genes (like Gata4 and 
Sox17) displayed more than ten fold upregulation shortly after activation of 
Gata6 in ES cells. 
It seems, however, that GATA6 alone is not sufficient to activate this 
cascade. Interestingly, in Nanog null mutant embryos, which display an ICM 
solely comprising GATA6 positive PrE biased cells, it has been shown that 
these cells stall in PrE differentiation and cannot activate subsequent PrE 
markers like Sox17 or Gata4 (Frankenberg et al., 2011). Thus, Nanog is non-
cell-autonomously required for PrE formation. Indeed, in the absence of 
Nanog, ICM cells do not express FGF4, which normally fulfills this non-cell-
autonomous role by activating the FGF/ERK signaling pathway in neighboring 
cells and reinforcing their PrE identity (Frankenberg et al., 2011). It is 
therefore likely that GATA6 and FGF signaling are simultaneously required to 
activate secondary PrE genes. To understand if this is indeed the case, it 
would be interesting to ectopically express Gata6 in Fgf4 null mutant 
embryos. This would determine if maintained expression of Gata6 is sufficient 
for PrE formation. Interestingly, this was recently demonstrated in Fgf4 null 
mutant ES cells, which successfully convert to XEN like cells upon 
overexpression of Gata6, including upregulation of Sox17 and Gata4, 
suggesting that GATA6 is indeed sufficient to activate these PrE genes 
(Wamaitha et al., 2015). However, regulation of this process might differ in 
XEN cells compared to the PrE.  Furthermore, Wamaitha et al. showed that 
Gata6 overexpression is sufficient to also reprogram neural cells to XEN cells. 
This underlines the role of GATA6 and points to it being upstream of all 
essential PrE specifying factors. 
REGULATION OF GATA6 EXPRESSION 
Additionally to activation of PrE markers and repression of Nanog (see 
Introduction p. 19, 21), FGF signaling has also been suggested to activate 
Gata6. However, in the Fgf4 null mutant Gata6 expression was observed 
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initially, but its expression was not maintained beyond the 32-cell stage  
(Kang et al., 2013). FGF signaling therefore seems to play an additional role 
in the maintenance of Gata6 rather than its activation.  
Alternatively, it has been speculated that GATA6 could maintain its 
own expression since canonical GATA binding motifs can be found in the 
Gata6 sequence (Frankenberg et al., 2011). Preliminary data using a 
Gata6H2B-Venus knock-in reporter allele (generated by Dr. Christian Schröter in 
Prof. Alfonso Martinez-Arias’ lab at the University of Cambridge, UK) shows 
Venus expression throughout the ICM, even in the absence of GATA6 protein. 
These data imply that the regulatory machinery necessary for Gata6 
maintenance is not dependent on GATA6 protein (Additional results related to 
Publication I, Figure 7, p. 55). However, since NANOG is expressed in these 
cells, this also suggests that NANOG does not transcriptionally repress 
Gata6, and that instead Gata6 repression is dependent on GATA6 or one of 
its downstream targets. Nevertheless, this does not exclude the possibility of 
post-transcriptional or post-translational regulation of GATA6 through 
NANOG.  
A potential GATA factor reinforcing Gata6 expression could potentially 
also be GATA4, as Gata4 overexpression in ES cells is sufficient to stimulate 
Gata6 upregulation (Fujikura et al., 2002). It was shown that ERK 
phosphorylates and activates GATA4 directly in cardiomyocytes (Liang et al., 
2001). This could be a mechanism for FGF signaling to indirectly regulate 
Gata6 expression through GATA4. Furthermore, SOX17 binds to regulatory 
regions of Gata6 and Gata4 in XEN cells (Niakan et al., 2010). The activation 
of certain successive PrE markers after Gata6 could set positive feedback 
loops, thereby progressively securing commitment to a PrE fate. 
Strong evidence also suggests that Gata6 expression is regulated by 
NANOG. Inactivation of Nanog in cells of the ICM induces Gata6 expression 
(Frankenberg et al., 2011) and in ES cells NANOG directly binds the Gata6 
promoter and represses gene expression (Frankenberg et al., 2011; Mitsui et 
al., 2003; Singh et al., 2007). A study using sodium vanadate to activate 
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FGFR/ERK signaling in ES cells further showed that while treated cells 
repressed Nanog and upregulated Gata6, additional ectopic Nanog 
expression in these cells was sufficient to inhibit Gata6 upregulation 
(Hamazaki et al., 2006). These findings highly suggest a repressive role of 
NANOG for Gata6. This suggests that in the absence of NANOG, Gata6 
would be upregulated. In the future it would be interesting to examine if 
GATA6 is increased in Nanog null mutant blastocysts. The absence of FGF4 
in these embryos however, could mask a potential effect of lack of NANOG, 
since FGF/ERK signaling has also been suggested to upregulate Gata6 
(Chazaud et al., 2006; Frankenberg et al., 2011).  
This multilayered interdependence of factors regulating gene 
expression in the ICM makes it extremely difficult to find clear answers. A 
solution to finally elucidate if FGF4 or NANOG or potentially both are the main 
regulators of Gata6 in the ICM, could accrue from single cell protein level 
analysis of a Nanog;Fgf4 allelic series. 
REGULATION OF NANOG EXPRESSION 
It is still popular belief in the field that Gata6 and Nanog repress each 
other and that this mutual repression governs the initiation of the second cell 
fate decision. While there is strong evidence supporting Gata6 repression 
through NANOG, as discussed above, not much has been actually shown to 
prove direct repression of Nanog through GATA6 other than their mutually 
exclusive expression in the ICM. Indeed, while all ICM cells in the Gata6 null 
mutant express NANOG (Publication I, Figure 2A), immunohistochemistry and 
subsequent measurement of fluorescence intensity levels showed no 
upregulation of NANOG levels in Gata6 null embryos in comparison with 
wildtype embryos (Publication I, Figure 2B). These results show that Nanog 
expression is indeed maintained in the absence of Gata6 but in contrast to 
popular belief they also indicate that Nanog might not be directly repressed by 
GATA6. This means another factor has to be in place to downregulate Nanog 
in the ICM even in the absence of Gata6.  
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Nanog, similarly to Gata6, is thought to regulate its own expression, as 
observed in ES cells (Boyer et al., 2005; Fidalgo et al., 2012; Navarro et al., 
2012). Imaging of a transcriptional BAC Nanog:H2B-GFP reporter 
(Xenopoulos et al., 2015) on a Nanog null mutant (Mitsui et al., 2003) 
background, shows unperturbed GFP expression. This observation suggests 
Nanog expression does not require NANOG protein. However, this also 
shows that Nanog repression is dependent on NANOG protein or one of its 
downstream targets but independent of GATA6 protein, which is expressed in 
all cells of Nanog null mutant ICMs. 
Indeed, an ideal candidate for Nanog regulation has already been 
identified. Work in ES cells revealed that FGF signaling transcriptionally 
represses Nanog (Santostefano et al., 2012). This repression seems to occur 
specifically through the FGF/ERK pathway in these cells and likely in the 
embryo. Members of the FGF/ERK signaling pathway are reciprocally 
expressed in the ICM, with EPI cells mainly expressing Fgf4 and PrE cells 
expressing its putative receptor Fgfr2 (Guo et al., 2010; Ohnishi et al., 2014). 
Furthermore, null mutant embryos for FGF/ERK signaling components display 
all-EPI ICMs with ectopic expression of Nanog (Arman et al., 1998; Chazaud 
et al., 2006; Feldman et al., 1995; Kang et al., 2013). This evidence points to 
direct inhibition of Nanog in PrE cells through ERK signaling.  
INTEGRATION OF GATA6, NANOG AND FGF SIGNALING 
Taken together, the FGF/ERK pathway has been implicated in 
repression of Nanog, as well as the activation of not only Gata6, but also 
subsequent factors of the PrE program in the ICM. Indeed, treatment of 
embryos with exogenous FGF4 leads to the downregulation of Nanog in all 
ICM cells, as well as the upregulation of PrE markers (Nichols et al., 2009; 
Yamanaka et al., 2010). To assess the effect of FGF signaling on Gata6 null 
mutant embryos, we treated them with saturated levels of FGF4 and 
performed immunohistochemistry for NANOG and PrE markers. As expected, 
wildtype embryos displayed complete absence of NANOG and ectopic 
expression of PrE markers in all ICM cells. In contrast, forced activation of 
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FGF signaling was not sufficient to activate any PrE markers in Gata6 null 
mutant embryos. Surprisingly however, NANOG was still present in all cells of 
the ICM in these embryos (Publication I, Figure 5A-D). This means that in the 
absence of Gata6, FGF signaling is not sufficient to downregulate Nanog and 
therefore reveals that the FGF signaling mediated repression of Nanog is 
Gata6 dependent. This unexpected finding sheds more light on the 
mechanism in which the master regulators GATA6, NANOG and FGF4 
cooperate to govern the segregation of PrE and EPI. This newly discovered 
dependency between GATA6 and FGF signaling can potentially explain the 
lack of evidence for direct Nanog repression through GATA6 in spite of 
observations pointing to an apparent mutual repression of the two factors. In 
this new light it is likely that Nanog repression through Gata6 is indeed 
occurring, but indirectly via FGF signaling rather than directly and in parallel to 
FGF signaling as assumed before. To conclusively determine if Gata6 can or 
cannot directly repress Nanog it would be interesting to ectopically express 
Gata6 in Fgf4 null mutant embryos and establish if Nanog is being 
downregulated in this context or not. 
 Very recently Nanog was shown to be downregulated upon ectopic 
expression of Gata6 in Fgf4 null mutant ES cells (Wamaitha et al., 2015). This 
result points to GATA6 being sufficient to downregulate Nanog in an ES cell 
context. However, the possibility remains that this regulation takes place 
differently in vivo than in vitro. XEN cells mostly represent a derivative of the 
PrE, the parietal endoderm (Brown et al., 2010; Kunath, 2005), in which 
additional genes are activated and gene regulation might differ substantially 
from that of immature PrE cells. The same experiments have to be performed 
in the embryo to interpret these results in an in vivo context. In one possible 
scenario ERK could be lowering the relative threshold needed for Gata6 to 
overcome Nanog in vivo. Ectopic expression of Gata6 could exceed this 
threshold on its own in vitro. 
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POSSIBLE MECHANISMS FOR GATA6/NANOG/FGF INTERPLAY 
To further investigate the position of Gata6 in the FGF signaling 
pathway, we treated embryos with a potent ERK inhibitor, which as expected 
led to all ICM cells expressing dramatically elevated NANOG levels and 
complete downregulation of PrE markers in wildtype embryos. Interestingly, 
the same observation was made in Gata6 null mutant embryos (Publication I, 
Figure 5A-D). Therefore, since ERK can still directly affect Nanog expression, 
GATA6 has to act upstream of ERK. It is likely that GATA6 acts on the level of 
either the FGF receptor or Grb2, since those are the most specific to the PrE 
and show correlating expression with Gata6 (Guo et al., 2010; Ohnishi et al., 
2014). A recently published mathematical model supports a scenario where 
GATA6 acts upstream of Fgfr2 (Bessonnard et al., 2014). The ideal approach 
to further test this hypothesis would be chromatin immunoprecipitation (ChIP) 
of GATA6 in PrE cells, as well as luciferase assays using promoter regions of 
the candidate FGF signaling components. Unfortunately, it is nearly 
impossible to harvest sufficient material from blastocyst stage embryos for 
biochemical assays of this kind. Alternatively, ChIP has recently been 
performed in XEN cells, where GATA6 enrichment was indeed found 
upstream of Fgfr2 (Wamaitha et al., 2015). Unfortunately, this only provides 
partial evidence since XEN cells may not entirely recapitulate the in vivo state. 
Yet another approach to narrow down possible targets would be treatment of 
Gata6 null mutant embryos with inhibitors for different components of the FGF 
signaling pathway, especially with inhibitors targeting FGF receptors or GRB2. 
These experiments are however further complicated by the diversity of FGF 
receptors (see Introduction p. 14) in combination with the lack of specificity of 
many of the available inhibitors. 
If FGFR2 is indeed the predominant receptor relaying FGF/ERK 
signaling in the ICM then Gata6 cannot be genetically upstream of Fgfr2. If 
this were the case, it would completely abolish FGF signaling in the absence 
of Gata6 and cause upregulation of Nanog in the ICM. Instead, NANOG levels 
were not elevated in Gata6 null mutant ICMs (Publication I, Figure 2B), which 
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means marginal ERK signaling levels have to be active even in the EPI and in 
Gata6 null mutants, which both display absence of GATA6. This suggests that 
FGF/ERK signaling plays a cell-autonomous role in EPI cells to maintain 
NANOG at physiological levels, presumably to ensure the ability of these cells 
to readily respond to differentiation cues after implantation (Chambers et al., 
2003; Hatano et al., 2005; Mitsui et al., 2003; Shin et al., 2011; Suzuki et al., 
2006; Vallier et al., 2009). Regulative FGF signaling in ES and EPI cells would 
also explain why Nanog levels are very heterogeneous in these cells and 
become dramatically upregulated upon treatment with ERK inhibitors. Active 
FGF signaling in the absence of Gata6 could instead point to GATA6 acting 
on FGFR2 in a post-transcriptional or post-translational manner, for example 
by stabilizing the protein. 
Alternatively, another receptor or receptor isoform could be in play. It is 
generally assumed that FGFR2 is the predominant receptor that plays an 
active role during EPI and PrE segregation since its knockout leads to peri-
implantation lethality (Arman et al., 1998), and resembles the Fgf4 or Grb2 
null mutants. Fgfr2 deletion has been attempted by several groups and while 
Arman et al. report peri-implantation lethality (Arman et al., 1998), Xu et al. 
and Yu et al. both report lethality between E10.5 and E11.5 (Yu 2003, Xu 
1998) , which would attribute a far lesser role to Fgfr2 than previously thought. 
Indeed, as mentioned before (see Introduction p. 15), Fgfr1 is also expressed 
in the ICM, but does not acquire reciprocal expression in PrE and EPI cells as 
Fgfr2 does but is expressed similarly in both cell types (Ohnishi et al., 2014). 
Unfortunately, it is yet unknown which isoforms of the two receptors are 
expressed. Both FGFR1 and FGFR2 have several isoforms, which show 
differential specificity for FGF4 binding (Ornitz et al., 1996). FGFR1b and 2b 
both display low FGF4 binding, while FGFR1c and 2c show high specificity 
(Ornitz et al., 1996). The continuous expression of Fgfr1 in EPI cells could 
account for the continued marginally active FGF signaling in these cells if the 
1b isoform is expressed.  
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Figure 8: Model for the segregation of EPI and PrE. GATA6 acts upstream of Fgfr2, 
enhancing FGF/ERK signaling in PrE biased cells. Signaling through FGFR2 in concert with 
FGFR1 is sufficient to repress Nanog, which in turn releases Gata6 repression. This feedback 
loop reinforces the PrE fate in addition to activation of the PrE specific transcription factors 
Gata4 and Sox17 through GATA6. GATA4 may reinforce Gata6 expression. In EPI biased 
cells weaker signaling through only FGFR1 allows for moderation of NANOG levels rather 
than repression. Both NANOG and GATA6 are able to repress their own expression. Mutual 
repression of GATA6 and NANOG likely takes place indirectly. In TE cells GATA6 and CDX2 
repress Nanog. Refer to text for further information. Green: TE. Blue: PrE. Red: EPI. Arrows: 
positive regulation. Blocked arrows: repression. Grey arrows: speculated interactions. Dashed 
arrows: indirect interaction.  
 
Alternatively or in addition, the receptors could rely on cooperative 
activation. Preliminary data suggests that while both Fgfr1 and Fgfr2 null 
mutant embryos show postimplantation lethality, only embryos depleted for 
both genes phenocopy the Fgf4 null mutant (Ms. Minjung Kang – 
Hadjantonakis Lab, personal communication of unpublished data). This 
suggests that FGFR1 and FGFR2 cooperate to relay FGF/ERK signaling in 
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the ICM. In that case FGFR1 would be active in both cell types, possibly only 
moderately downregulating Nanog because both receptors are needed for full 
activity. Since their expression is highly correlated, Gata6 is likely upstream of 
only Fgfr2, which would lead to additional downregulation of Nanog in Gata6 
expressing cells, i.e. PrE cells. Indeed, ChIP in XEN cells has shown 
enrichment of GATA6 upstream the Fgfr2 gene, but not Fgfr1 (Wamaitha et 
al., 2015). Testing this hypothesis in vivo is similarly problematic as before 
(see p. 134) and either specific inhibitors for the different receptors have to be 
found or novel genetic approaches utilized. Double null mutants for either 
receptor and Gata6 would give additional insights. Alternatively, ectopic 
expression of either receptor on a Gata6 null mutant background could give 
answers in a more straightforward fashion. If GATA6 indeed acts upstream of 
one of the two receptors, forced expression of the receptor would result in a 
rescue of the Gata6 mutant cells’ response to FGF signaling. 
Interestingly, Wamaitha and colleagues recently found that FGF 
signaling does not seem necessary for reprogramming of ES cells to XEN 
cells through overexpression of Gata6, which involves downregulation of 
Nanog (Wamaitha et al., 2015). This is yet another discrepancy between in 
vitro and in vivo results and underlines the scrutiny that should be applied 
when interpreting such data. 
FURTHER ROLES OF GATA6 
We have shown that deletion of Gata6 results in embryos lacking the 
PrE lineage and that downregulation of Nanog through FGF signaling in the 
ICM is dependent on GATA6 (Publication I)). We concluded that Gata6 is the 
first single transcription factor deletion resulting in a complete failure of PrE 
formation and maturation. However, another transcription factor deletion has 
recently been shown to result in ablation of the PrE. The pluripotency marker 
Oct4, which becomes restricted to EPI cells in the late blastocyst, also seems 
to be necessary for PrE formation, as its deletion in embryos leads to a failure 
in PrE specification (Frum et al., 2013; Le Bin et al., 2014). Moreover, Nanog 
was not repressed upon treatment with FGF4 in these embryos (Frum et al., 
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2013), similarly to Gata6 null mutant embryos. The authors concluded a 
function for Oct4 in PrE formation. However, their work also showed that Oct4 
null mutant embryos initially express Gata6 but fail to maintain it beyond the 
mid blastocyst stage. This means GATA6 is lost during the window of FGF 
treatment and its absence could readily explain the cell’s lack of response to 
FGF signaling, as we have shown that the FGF signaling mediated 
downregulation of Nanog is Gata6 dependent. Ectopic expression of Gata6 in 
Oct4 null mutant embryos, with the expectation to rescue the cell’s response 
to FGF treatment, would be necessary to confirm this hypothesis. Similarly, 
Oct4 was shown to be dispensable for reprogramming of ES cells to a XEN 
like state through ectopic expression of Gata6, which involved upregulation of 
PrE markers like Sox17 and Gata4 (Wamaitha et al., 2015). 
In other respects, Gata6 also seems involved in TE specification. We 
found ectopic Nanog expression in the TE of Gata6 null mutant embryos 
(Publication I, Figure 2C), suggesting that GATA6 is involved in repression of 
Nanog in the TE under wildtype conditions. In this case, Nanog repression 
through GATA6 functions differently in the TE than in the ICM. As discussed 
above, in the absence of Gata6, ICM cells fail to respond to FGF signaling 
which is responsible for Nanog repression in these cells. In contrast, in the TE 
FGF signaling fulfills a mitogenic role (see Introduction p. 9) and Fgf4 null 
mutant embryos have fewer TE cells (Kang et al., 2013). Taking into account 
that TE size was not affected in Gata6 null mutant embryos, it can be 
concluded that FGF signaling in the TE lineage is intact even in the absence 
of GATA6. Ectopic expression of Nanog in these cells therefore points to 
GATA6 regulating Nanog independently of FGF signaling in the TE. This 
presumably takes place in cooperation with CDX2, which also has been 
shown to repress Nanog in TE cells (see Introduction p. 9). 
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REGULATION OF ICM CELL PLASTICITY THROUGH THE 
GATA6/NANOG/FGF NETWORK 
By the time of implantation the ratio of EPI and PrE inside the ICM is 
surprisingly consistent. As can be seen in Figure 8, for CD1 mice this ratio 
lays at around 40% EPI and 60% PrE (Publication I, Figure 4B; Additional 
results related to Publication I, Figure 8, p. 55) and therefore seems tightly 
regulated. Several mechanisms could contribute to this regulation. It has been 
shown that a subpopulation of ICM cells remains interconvertible between EPI 
and PrE for an extended period. These cells stay plastic, not merely during 
the process of initial cell fate specification, but up until the late blastocyst 
stage when the two cell types are seemingly committed (Grabarek et al., 
2012). This becomes especially evident when cells are pushed towards either 
lineage by treatment with FGF4 or ERK inhibitor (Yamanaka et al., 2010). 
These studies showed that a change in an ICM cell’s environment is able to 
direct it towards either lineage until the late blastocyst stage.  
Plusa and colleagues also demonstrated that this extended plasticity is 
necessary during blastocyst development. By following the expression of the 
PrE specific reporter PdgfraH2B-GFP they showed that cells that do not reach 
their appropriate position through sorting in the late blastocyst could change 
their fate to match their neighbors’ (Plusa et al., 2008). It is understood that 
FGF signaling is involved in this plasticity (Yamanaka et al., 2010) but how 
cells retain or loose plasticity remains unknown. It seems likely that the cells’ 
inherent ability to respond to FGF signaling, rather than a change in its 
environment, is responsible for this feature. When treating embryos with 
exogenous FGF4 during different time frames, we also noted that cells 
reacted variably, with later treatments causing less cells to downregulate 
Nanog and adopt a PrE fate (Publication I, Figure 6). These observations 
confirmed the gradual loss of plasticity inside the ICM, which seems to be 
accompanied by reduced ability to respond to FGF signaling. 
As we also demonstrated that the presence of GATA6 was necessary 
for cells in the ICM to respond to FGF signaling. It could therefore be 
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speculated that cells retain their ability to respond to FGF signaling until they 
are fully committed to an EPI fate and GATA6 is absent. Subsequently those 
cells would be protected from a forced fate switch inside the FGF4 rich, sorted 
EPI compartment of the implanting blastocyst. Work by Grabarek and 
colleagues, which showed that PrE cells remain plastic longer than EPI cells, 
which seemed more sheltered, supports this hypothesis (Grabarek et al., 
2012). 
CONCLUSION AND PERSPECTIVES 
The present work has given many new insights into the mechanisms 
that govern the second cell fate decision and the establishment as well as 
maintenance of pluripotency. Foremost, GATA6 has been shown to be a 
major regulator of the second cell fate decision and it was integrated into the 
regulatory network governing this process, by revealing that the FGF-
mediated downregulation of Nanog is GATA6 dependent. This discovery 
elucidates one step of the complex interactions in the interdependent network 
of GATA6, NANOG and FGF. In the future it will be interesting to find how 
GATA6 acts on the FGF signaling pathway in this context, which might give 
insight into the same kind of interaction in other fields, as in gastric cancer for 
instance, where both FGFR2 as well as GATA6 have been suggested as 
targets (Deng et al., 2012).  
It was further shown that GATA6 acts in a dosage dependent manner 
and a study using a Gata6;Nanog allelic series, currently taking place, will 
reveal if the relative dosages of GATA6 and NANOG are imperative for the 
lineage decision between PrE and EPI. A dosage dependent lineage decision 
would also support the hypothesis that the emergence of the two lineages is 
stochastic, since expression noise could lead to one factor stochastically 
reaching a dosage threshold and initiating differentiation. More experiments, 
especially live imaging of reporters for both markers will be necessary to 
understand this process. 
This work has also provided efficient protocols for the derivation of ES 
and XEN cells, which can serve as models for EPI and PrE respectively. For 
3.  Discussion 
 146 
instance, it was shown that ES cells could be derived from AID null mutant 
embryos, though with reduced efficiency. Furthermore iPS cells generated 
from fibroblasts lacking AID exhibited unstable pluripotency states. Both 
results suggest the involvement of DNA demethylation in the establishment 
and maintenance of pluripotency, but also point to AID possibly cooperating 
with other factors, e.g. TET proteins to fulfill this function. It will be interesting 
to gain further insight into this level of regulation of lineage decisions in the 
embryo. 
This work has provided answers as well as newly opened questions.  
Future studies will elucidate how transcription factors, signaling pathways and 
epigenetic regulation cooperate to allow the proper allocation of PrE and EPI. 
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